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Section 1: INTRODUCTION 
Since 1975, nearly 3 million refugees have resettled in the 
United States.  Numerous other individuals have sought 
political asylum.  They share the experience of fleeing 
persecution and relocating to a new country. 
 
The Federal Refugee Act of 1980 created a uniform system of 
services for refugees resettled in the United States. The Act 
entitled all newly arriving refugees to a comprehensive health 
assessment, to be initiated as soon as possible after arrival. In 
Massachusetts, the Department of Public Health (MDPH), 
through an Interdepartmental Service Agreement with the 
Office for Refugees and Immigrants (ORI), is responsible for 
the health assessment of refugees.  Within MDPH, the health 
assessment program is administered by the Division of Global 
Populations and Infectious Disease Prevention in the Bureau 
of Infectious Disease. 
 
The MDPH Division of Global Populations and Infectious 
Disease Prevention implemented the Refugee Health 
Assessment Program (RHAP) in 1995.  Funding support 
comes from federal Refugee Medical Assistance through the 
Massachusetts Office for Refugees and Immigrants.  
 
The objective of the RHAP is to offer comprehensive initial and 
follow-up screening for all newly arriving refugees.  Health 
care facilities contracted by MDPH through the RHAP must 
provide linguistically and culturally appropriate services and be 
staffed by sensitive professionals able to address cross-
cultural health issues.  RHAP removes financial and 
administrative barriers that could prevent new arrivals from 
receiving early medical and diagnostic services.  It provides 
the initial access to primary care for newly arrived refugees.  
 
Historically, Massachusetts has been among the middle tier of 
states in terms of refugee resettlement caseload.  In recent 
years, excepting the two years following September 11, 2001, 
the new refugee arrivals have numbered between 1,500 and 
2,500 annually.  While in 1980’s and 1990’s, Massachusetts 
refugees were arriving primarily from the former Soviet Union 
and Vietnam, more recently, refugee groups have come from a 
many countries.  These have included Bhutan, Burma, Iraq,  
Somalia, Sudan, Liberia, Cuba and Haiti.  During 2012-2013, 
the largest numbers of arrivals have been from Bhutan, Iraq, 
Somalia, Burma, and from other African nations of Eritrea, 
Democratic Republic of Congo, and Sudan. Diversity in the 
arriving refugee population has necessitated the development 
of programs that can respond effectively in a timely way with 
quality services.  
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Refugees arriving in the United States often have difficulty 
gaining access to services, particularly in the health care 
system. The process of integrating into a new society, often as 
an ethnic or racial minority, is stressful and filled with 
uncertainty, and so often leads to insecurity.  Losing social 
supports that refugees had in their countries of origin – and 
sometimes in refugee camps – after fleeing their countries 
make resettlement tremendously challenging. 
 
Every refugee group is unique in terms of history, health 
beliefs and practices, and epidemiologic profile.  Qualified 
clinicians performing health assessments require knowledge 
and understanding beyond traditional western medical 
expertise.  While the RHAP is constructed to be a traditional 
Western-oriented medical screening, individual clinicians and 
sites must implement the RHAP in a culturally and linguistically 
appropriate manner. 
 
This manual is intended as a clinical reference document for 
the delivery of health care to refugees in the context of the 
Massachusetts RHAP.  While literature about refugee 
medicine is abundant, the need for a single reference specific 
to RHAP prompted the development of this manual.  Since a 
goal of the RHAP is to facilitate high quality services, a manual 
is necessary to provide detailed information about the various 
components of the refugee health assessment. 
 
This manual is not a definitive reference on the topics covered 
and is not meant to substitute for texts or journal articles. The 
reader should still make use of more comprehensive reviews 
of particular diseases or issues.  The manual is intended to 
serve as a convenient guide for refugee health assessments.   
While relevant for any clinician performing medical screening 
of newly arrived immigrants and refugees, because it is 
specific to the components of the Massachusetts RHAP, this 
manual should only be viewed cautiously as a template for the 
health screening of new immigrant patients whose needs (and 
insurance coverage) may differ from those of refugees. 
 
The manual is organized into five sections, as follows: 
 
Section 1: Introduction 
 
Section 2: Refugee Health Assessment Program 
Logistics, which has background information 
on resettlement agencies, the overseas 
processing and medical examination of 
refugees, interpreter services, and the role 
functions of community health workers. 
 
 2
Updated October 2013                       MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE 
Section 1: INTRODUCTION 
Section 3: The Refugee Health Assessment Clinical 
Program, which has information relevant to the 
clinician performing refugee health 
assessments.  Each area of the health 
assessment is reviewed, with background 
information and program requirements. This 
section contains a new chapter on HIV and 
additional information about malaria; nutritional 
deficiencies such as iron and vitamin D; lead 
poisoning; and a section on the RHS 15, a 
refugee mental health screening tool. 
 
Section 4: References and Resources, which contains 
journal citations relevant to the health 
assessment and the general health issues of 
refugees. 
 
Section 5: On-line Resources, which contains hyperlinks 
to useful web resources. 
 
Section 6: Appendices, which contain a protocol 
summary, malaria reference documents, the 
RHS-15 form, useful terms, and staff contact 
information. 
 
The manual is designed to be downloaded and used 
electronically as there are hyperlinks to reference materials 
throughout the document.  Updated information will be sent via 
e-mail from the Division of Global Populations and Infectious 
Disease Prevention and can be incorporated.  In addition, 
refugee health assessment providers will receive regular 
updates from the Massachusetts Immunization Program. 
 
Feedback on the use of the manual, as well as suggestions for 
additional content, are welcomed.  Please send your 
suggestions: 
 
Refugee Health Assessment Program 
Division of Global Populations and Infectious Disease 
Prevention  
Bureau of Infectious Disease 
Massachusetts Department of Public Health  
305 South Street  
Jamaica Plain, MA  02130.  
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PROGRAM   The following program abbreviations are used frequently 
ABBREVIATIONS  in the manual: 
 
 
CDC  Centers for Disease Control and Prevention 
 
IOM International Organization for Migration 
 
MAA Mutual Assistance Association 
 
MDPH  Massachusetts Department of Public Health  
 
ORI Massachusetts Office for Refugees and 
Immigrants 
 
ORR  U.S. Office of Refugee Resettlement 
 
RA  Resettlement Agency 
 
RHAP  Refugee Health Assessment Program 
 
USCIS U.S. Citizenship and Immigration Service    
(part of the former Immigration and Nationality 
Service or INS) 
 
VFC  Vaccines for Children Program 
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2.1 ELIGIBLE POPULATIONS 
 
Individuals eligible for federal refugee benefits and services 
are defined by the Office of Refugee Resettlement (ORR) and 
include: 
? Refugees 
? Asylees 
? Cuban/Haitian Entrants 
? Certain Amerasians 
? Victims of a Severe Form of Human Trafficking 
? Iraqi and Afghan Special Immigrants 
 
To be eligible for RHAP, a person must have one of these 
statuses and be able to initiate RHAP services within 90 days 
of United States entry or during the period of eligibility for 
Refugee Medical Assistance.  Eligibility determination and 
documentation, as well as referrals for RHAP services, are 
managed by resettlement agencies. 
 
 
With Medicaid expansion under the Affordable Care 
Act, refugees who would have been previously 
covered under Refugee Medical Assistance will be 
eligible for MassCare; thus few will be eligible for 
RHAP after the first 90 days in the United States. 
 
 
See Section 2.8 for additional information on asylees, entrants, 
victims of trafficking and special immigrants. 
 
 
2.2 MASSACHUSETTS OFFICE FOR REFUGEES AND 
IMMIGRANTS (ORI) 
 
In Massachusetts, the Office for Refugees and Immigrants 
(ORI) coordinates the Massachusetts Refugee Resettlement 
Program and oversees federally-funded case management, 
employment, English language programs, and other services 
that promote economic self-sufficiency.  Most case 
management services are delivered by resettlement agencies. 
 
ORI describes their goal as “To promote the full participation of 
refugees and immigrants as self-sufficient individuals and 
families in the economic, social, and civic life of 
Massachusetts.”     
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The Refugee Health Assessment Program (RHAP) is a 
federally-funded program that is administered by the 
Massachusetts Department of Public Health (MDPH) through 
an Interdepartmental Service Agreement with ORI. 
 
 
2.3 RESETTLEMENT AGENCIES 
 
Resettlement agencies deliver Reception and Placement 
(R&P) services for refugees as part of cooperative agreements 
with the U.S. Department of State.   
 
Resettlement agency staff, volunteers or family sponsors meet 
arriving refugees in Massachusetts.  Among other services, 
resettlement agencies schedule health assessment 
appointments at RHAP sites.  Resettlement agencies provide 
the site with the refugee’s name, date of birth, alien number 
(A#), language, country of origin, address, and telephone 
number.  Once given an appointment date and time, the 
agency staff contacts the refugee to let him/her know of the 
appointment. Resettlement agency staff may bring refugees to 
the RHAP appointments and may follow up with persons who 
fail to keep appointments.  
 
The following are local affiliates that resettle refugees in 
Massachusetts.  Information is current as of October 2013:  
 
Metro Boston      
 
Catholic Charities Archdiocese of Boston  
275 West Broadway  
South Boston, MA  02127 
Tel:      617-464-8150    
 
International Institute of Boston  
One Milk Street  
Boston, MA  02109 
Tel:     617-695-9990 
 
Refugee and Immigrant Assistance Center
31 Heath Street 
Jamaica Plain, MA 02130 
Tel:  617-238-2430 
 
Refugee Immigration Ministry
142 Pleasant Street 
Malden, MA 02148 
Tel: 781-322-1011   
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MetroWest    
 
Jewish Family Service of Metrowest  
475 Franklin Street  
Framingham, MA  01702 
Tel:     508-875-3100 
 
North Shore/Merrimack Valley             
 
International Institute of Lowell
155 Merrimack Street 
Lowell, MA 01852 
Tel: 978-459-9031 
 
Central    
 
Catholic Charities of Worcester   
10 Hammond Street   
Worcester, MA  01610 
Tel:     508-798-0191 
 
Lutheran Social Services  
Unaccompanied Refugee Minor Program  
10 East Worcester Street 
Worcester, MA 01604 
                                     Tel:       774-243-3900 
 
Lutheran Social Services
51 Union Street 
Worcester, MA 01609 
Tel: 508-754-1121 
 
Refugee and Immigrant Assistance Center
340 Main Street  
Worcester, MA 01608 
Tel: 508-756-7557 
  
West                                 
 
Jewish Family Service of Western Massachusetts  
15 Lenox Street 
Springfield, MA  01108 
Tel:     413-737-2601 
 
Lutheran Social Services
593 Main Street 
West Springfield, MA 01089 
Tel:     413-787-0725 
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2.4 Division of Global Populations and Infectious Disease 
Prevention, MDPH 
 
The Division of Global Populations and Infectious Disease 
Prevention is located within the MDPH Bureau of Infectious 
Disease.  The Division, which was established in 2013, has 
incorporated the legacy Refugee and Immigrant Health 
Program and the Tuberculosis Program. The Division staff 
works closely with other Bureau of Infectious Disease 
programs (HIV/AIDS, Epidemiology and Immunization, STD 
Prevention) and programs in other MDPH bureaus. 
 
Centrally-based Division staff is responsible for overall 
coordination of RHAP, new arrival information, data collection 
and analysis, and medical consultation.  The Division’s 
regional coordinators are based in MDPH offices in Boston, 
Tewksbury, and Northampton and can facilitate outreach 
services for newly arrived refugees.  If questions arise, 
providers should not hesitate to contact the RHAP coordinator 
or regional coordinator for assistance.  See Appendix 6.5 for 
contact information for each of the Division of Global 
Population and Infectious Disease Prevention offices.     
 
ARRIVAL   Refugees generally enter the United States through ports  
NOTIFICATION of entry that are staffed with quarantine officers (Quarantine 
Stations).  Officers of the United States Public Health Service, 
Centers for Disease Control and Prevention (CDC), Division of 
Global Migration and Quarantine may inspect arriving refugees 
and review medical documents at entry. CDC notification to 
the final destination state – the Division of Global Populations 
and Infectious Disease Prevention in Massachusetts – is 
managed electronically through the Electronic Disease 
Notification (EDN) system. The notification record includes the 
overseas medical examination records and the pre-departure 
medical screening information. 
 
RHAP sites that provide more than 50 refugee health 
assessments annually should have access to an electronic 
copy of overseas medical records prior to a patient’s 
appointment through the MDPH  web-based disease 
surveillance and case management system known as MAVEN.  
MDPH uses MAVEN to track newly-arriving refugees and to 
capture data related to outreach, case management, and 
health assessments.  Overseas medical records are uploaded 
from the CDC shortly after a refugee’s arrival in 
Massachusetts and attached to the person’s record in PDF 
format.   
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When a Resettlement Agency notifies MDPH of a refugee’s 
RHAP appointment, the individual’s record in MAVEN is 
released to the RHAP site.   
 
Note that delays in notification from CDC are not uncommon.  
In other cases, the overseas medical records are not available 
to MDPH through the CDC system (see below).   
 
MDPH faxes of overseas records to RHAP sites that do not 
have access to MAVEN.  RHAP sites can contact the MDPH 
RHAP coordinator to request additional information or training 
on the MAVEN system.    
 
COMMUNITY HEALTH The Division of Global Populations and Infectious Disease 
WORKERS (CHWs) Prevention has a CHW component staffed by trained 
 bilingual, bicultural individuals who offer bridging services 
   between their communities and the health care delivery  
system.  Following notification from the CDC that a family or 
an individual has arrived in Massachusetts and reporting of the 
resettlement address by the resettlement agency, a CHW will 
visit the family and provide an orientation to the RHAP and a 
brief introduction to the United States health care system, with 
a focus on primary care. 
 
Outreach and follow-up is provided for refugees and their 
families to monitor the diagnosis and treatment of tuberculosis 
and other communicable diseases, increase understanding of 
and adherence to medical recommendations, and provide 
basic information on the local health care resources available 
to refugees.  In addition, the Division of Global Populations 
and Infectious Disease Prevention CHWs may assist with 
adherence to treatments initiated during the refugee health 
assessment and provide education about primary care.  The 
primary care appointment documented on the Refugee Health 
Assessment Program form is a critical piece of information for 
CHWs. 
 
 
2.5 MUTUAL ASSISTANCE ASSOCIATIONS 
 
Mutual Assistance Associations (MAAs) in Massachusetts are 
grassroots organizations, formed by leaders in a refugee or 
immigrant community to address their specific needs.  For 
example, they provide community outreach and education to 
new arrivals.  They are interested in helping communities 
understand and adjust to the United States system—from 
health care, to monthly bills, to the school system, to civic 
engagement.  Many area MAAs have joined in the MAA 
Coalition of Massachusetts to support one another and use the 
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resources of the group to better serve their respective 
communities.   
 
Some MAAs are funded by ORI as part of the Massachusetts 
Refugee Resettlement Program to provide Post-Resettlement 
Community Services. 
 
2.6 INTERPRETER SERVICES 
 
The RHAP requires delivery of culturally and linguistically 
responsive health care services for refugee populations.  The 
program includes reimbursement for interpretation in the 
global fee that is paid for each health assessment.  The 
utilization of a qualified medical interpreter in the health 
assessment is crucial.  It is important that the medical 
interpreter has an understanding of the refugee health 
assessment before they begin to interpret. 
 
RHAP sites have systems to assure engagement of a trained 
medical interpreter, such as: 
 
In-House Interpreter Services: These are generally 
coordinated centrally and appointments for patients are 
scheduled based on the availability of interpreters.  
Recruitment, training, and supervision are also 
centrally coordinated.  Interpreters may be on staff or 
on call. 
 
Bilingual, bicultural staff functioning in dual or 
multiple roles, including interpreting: These health 
care agency staff may be in roles such as outreach, 
medical assistant or medical records, but have been 
trained in medical interpreting. 
 
Telephonic Interpretation: Particularly for low-volume 
languages and relatively new communities, it may be 
beneficial to make use of medical telephonic 
interpretation as an additional resource. 
 
Interpreter Pools: In some geographic areas, a 
central pool coordinates interpreters for a number of 
providers.  The site coordinating the pool recruits, 
trains, and supervises interpreters and as well as 
manages scheduling.  Sites generally pay on an hourly 
basis. 
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An alternative to the medical interpreter model is the utilization 
of fully bilingual clinical and health education staff.   
 
It is not acceptable to use family/friends in the interpreter role. 
 
The Division of Global Populations and Infectious Disease 
Prevention makes every effort to work with providers when 
new populations are resettled in Massachusetts in order to 
identify potential interpreters.  All sites need to have the 
capacity to serve refugees from a wide range of countries and 
ethnicities. 
 
WORKING WITH  As new populations arrive, providers may have opportunity to 
AN INTERPRETER work with many different languages and cultures. Recognizing 
that the presence of an interpreter significantly affects the 
provider-patient relationship, it is important that providers learn 
to work well with interpreters.  There are many resources to 
support providers in creating a good clinical experience for 
patients. 
 
     
RESOURCES  International Medical Interpreters Association
Boston, MA  
 
National Council on Interpreting in Health Care
 
Hablamos Juntos: Language Policy and Practice in Health 
Care 
 
Refugee Health Technical Assistance Center
 
Massachusetts General Hospital: Working With Interpreters   
 
Cross-Cultural Health Care Program
Seattle, WA 
 
Ethnomed 
 
Diversity Rx
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2.7  OVERSEAS PROCESSING 
 
UNITED STATES   The Refugee Act of 1980 establishes the framework for 
ADMISSIONS   the admission and resettlement of refugees in the United  
States.  The Refugee Act defines the term “refugee” to mean: 
 
“(A) any person who is outside any country of such person’s 
nationality, or, in the case of a person having no nationality, is 
outside any country in which such person last habitually resided, and 
who is unable or unwilling to return to, and is unable or unwilling to 
avail himself or herself of the protection of, that country because of 
persecution or a well-founded fear of persecution on account of race, 
religion, nationality, membership in a particular social group, or 
political opinion, or  
 
(B) in such special circumstances as the President after appropriate 
consultation (as defined in section 207(e) of this Act) may specify, 
any person who is within the country of such person’s nationality or,  
in the case of a person having no nationality, is outside any country 
in which such person is habitually residing, and who is persecuted or 
who has a well-founded fear of persecution on account of race, 
religion, nationality, membership in a particular social group, or 
political opinion.  The term “refugee” does not include any person 
who ordered, incited, assisted, or otherwise participated in the 
persecution of any person on account of race, religion, nationality, 
membership in a particular social group, or political opinion.” 
 
An applicant for refugee admission into the United States must 
meet all of the following criteria1: 
 
The applicant must meet the definition of a refugee in the 
Refugee Act. 
• 
• 
• 
• 
                                                          
The applicant must be among the types of refugees 
determined during the consultation process to be of special 
humanitarian concern to the United States. 
The applicant must be admissible under United States law. 
The applicant must not be firmly resettled in any foreign 
country.  (In some situations, the availability of 
resettlement elsewhere may also preclude the processing 
of applicants.) 
 
The President determines processing priorities and the 
refugee admissions ceiling for each fiscal year after 
consultation with Congress.  The admissions document is 
published by the Department of State, Department of Justice 
and Department of Health and Human Services. 
 
Overseas, the Overseas Processing Entity (OPE) coordinates 
processing for the United States.  The United States Citizen 
1 Office of Refugee Resettlement. Report to Congress: FY94 Refugee Resettlement Program.  
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and Immigration Service (USCIS) staff conducts interviews to 
approve or deny refugee applications for admission. 
 
If an individual is approved for refugee status by USCIS, he or 
she must still meet admissibility requirements outlined in 
United States law.  Among these are the medical 
requirements, which are discussed in greater detail below and 
in Section 3.2. 
 
Decisions about placement in the United States are made by 
national resettlement agencies in coordination with their local 
affiliates.  The assurance, which commits a resettlement 
agency to resettling a case, is processed.   Finally, travel 
arrangements are made – generally by the International 
Organization for Migration – to move the refugee to the United 
States.  Refugees are responsible for repayment of travel 
loans that covered the cost of their air fares. 
 
OVERSEAS MEDICAL Overseas health screenings are conducted to ensure that 
EXAMINATIONS  refugees do not have conditions that would exclude them from 
entering the United States.  These medical exclusions include 
certain communicable diseases and mental health conditions 
associated with violence.  Refugees with communicable 
diseases that preclude their entry into the country may be 
delayed until appropriate treatment is initiated and they are no 
longer infectious.  Following treatment, refugees will be 
allowed to travel to the United States. Waivers may be 
requested for conditions that are grounds for exclusion.  
 
The overseas medical examination is done by a local panel of 
physicians or by physicians working under contract to the 
International Organization for Migration (IOM) and using locally 
available facilities (laboratory, x-rays). The Division of Global 
Migration and Quarantine, CDC, is responsible for oversight of 
all overseas examinations. 
 
An important element of the overseas medical examination is 
the empiric pre-departure treatment of refugees from Sub-
Saharan Africa for parasites and malaria; treatment has been 
extended to Southeast Asia and other departure points. This 
treatment is done in collaboration with the IOM and is 
responsible for the dramatic reduction in helminth infections 
seen among these refugees in the United States. The program 
is further described in the relevant sections of this manual 
pertaining to parasitic infections (Section 3.7). 
 
See Section 3.2 for additional information on the overseas 
medical examination. 
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THE INTERNATIONAL  The IOM is an intergovernmental body, based in Switzerland, 
ORGANIZATION FOR  that manages refugee movements for third country 
MIGRATION (IOM)  resettlement.  In addition, the IOM performs many of 
the overseas health assessments. 
 
The IOM provides each refugee with a white plastic bag that 
contains the individual’s medical records and x-rays.  Currently, 
these records should contain the Department of State medical 
forms, including the DS-2054 form and supplemental vaccine 
form.  Pre-departure treatment and vaccination documentation is 
also contained in the IOM bag.  At times, IOM officials will add 
other supplemental forms to document the complete medical 
history and physical examination.  
 
 
DIVISION OF GLOBAL The Division of Global Migration and Quarantine, Centers for  
MIGRATION and  Disease Control and Prevention, has enhanced the content 
QUARANTINE, CDC  and documentation of the overseas evaluation. The 
enhancements include greater evaluation of children under the 
age of 15 years and more detailed histories and physical 
examinations as well as procedures for evaluating tuberculosis.  
Consequently, overseas refugee documents include the core 
form as well as extended worksheets for use in documenting 
further care of patients with findings that indicate need for follow-
up care in the United States as well as immunizations. 
 
RESOURCES  US. Department of State
Bureau of Population, Refugees and Migration 
 
Division of Global Migration and Quarantine, CDC
Atlanta, GA 
 
International Organization for Migration
Geneva, Switzerland 
 
 
2.8  POPULATIONS WITH STATUS OTHER THAN 
‘REFUGEE’ 
 
ASYLEES   Asylum applications are adjudicated by immigration courts or  
USCIS.  Since June 2000, asylees have been eligible for 
refugee benefits and services, including refugee health 
assessments, beginning on the date asylum is granted. 
Consequently, RHAP providers have seen primary recipients 
of political asylum and family members with derivative visas 
referred for evaluation. Often the family members are coming 
to reunite with the primary asylum recipient and are arriving 
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directly from their country of origin overseas. (“Derivative” 
asylees are described further below). 
 
The process by which asylees access refugee services varies.  
The asylum approval notice may include the ORR website 
where asylees can find information about refugee benefits and 
services.  Through these resources, an asylee is linked with a 
local resettlement agency or state refugee office.  In addition, 
resettlement agencies have conducted outreach to asylees to 
increase awareness and utilization of services.  
 
As is true of refugees, a political asylee is on the path to 
citizenship.  The next milestone is the application for 
permanent residence.  This usually takes place one year after 
receipt of asylum, or for a newly arrived refugee, one year 
after arrival.  The asylee will need a full medical examination at 
that time and documentation of age-appropriate vaccination in 
compliance with government health guidelines (ACIP vaccine 
schedules).  The RHAP affords an excellent opportunity for the 
asylee to have his/her vaccine status reviewed and to initiate 
any necessary vaccines. 
 
Derivative Asylees If an asylee’s immediate family 
members are not in the United States at the time of the 
application for asylum, they may enter later through the visa 
process.  These family members are referred to as “derivative 
asylees” because their immigration status derives from the 
individual with the approved asylum application.  Derivative 
asylees are newly arrived in the United States at the time of 
referral for health assessment.  Unlike the primary asylum 
recipient, the derivative asylee will likely have completed an 
overseas visa medical examination prior to entry. 
 
CUBAN and HAITIAN A Cuban/Haitian "entrant" is a Cuban or Haitian national who  
ENTRANTS   has been granted parole status or is an asylum applicant who  
has not received a final, non-appealable, legally enforceable 
order of removal, deportation, or exclusion. 
 
Cuban or Haitian entrants are the only clients eligible for 
RHAP while they are in removal proceedings, paroled or 
awaiting an asylum determination. 
 
CDC generally does not notify the Division of Global 
Populations and Infectious Disease Prevention of Cuban and 
Haitian Entrants except those that enter the United States 
through a Quarantine Station (i.e., Miami). 
 
VICTIMS OF   Victims of a severe form of human trafficking are eligible for 
TRAFFICKING  RHAP and other refugee services.  “Severe forms of  
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trafficking in persons” means: 
? sex trafficking in which a commercial sex act is induced by 
force, fraud, or coercion, or in which the person induced to 
perform such act has not attained 18 years of age; or 
? the recruitment, harboring, transportation, provision, or 
obtaining of a person for labor or services, through the use 
of force, fraud, or coercion for the purpose of subjection to 
involuntary servitude, peonage, debt bondage, or slavery. 
 
The Department of Health and Human Services certifies 
victims of severe forms of human trafficking.  The date of entry 
that is used for eligibility purposes for trafficking victims is the 
date of certification (or the date ORR issues the letter for child 
victims under the age of 18). 
 
Victims of trafficking have been in the United States prior to 
certification.  The length of time varies.   
 
SPECIAL   Special immigrant visas are granted to Afghan and Iraqi 
IMMIGRANTS  nationals under section 101(a)(27) of the Immigration and  
Nationality Act (INA).  These individuals are eligible for RHAP. 
 
 
PROGRAM   The health assessment is highly recommended for asylees 
REQUIREMENTS & and Cuban/Haitian Entrants who have been in the United 
RECOMMENDATIONS States for less than five years, and the Division of Global 
 Populations and Infectious Disease Prevention recommends 
that resettlement agencies strongly encourage these 
individuals to undergo the assessment.   
 
For those asylees and Cuban/Haitian Entrants in the United 
States for five or more years with poor histories of health 
access, the health assessment process may be highly 
beneficial.  RHAP is an option that can be offered based on 
the health needs and health care experiences of the individual. 
 
Because of their unique experiences in the United States, it is 
recommended that all victims of trafficking be referred for 
RHAP services.  Providers should be attuned to the possibility 
of sex trafficking and risk for sexually transmitted diseases. 
 
Afghani and Iraqi special immigrants may be linked with 
resettlement agencies prior to arrival or soon after entry in the 
United States.  These individuals should be assessed as new 
arrivals and will have completed an overseas medical 
examination. 
 
The health assessment for asylees, Cuban/Haitian entrants, 
victims of trafficking and special immigrants will be similar to 
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that undertaken for refugees.  Providers do need to be 
cognizant of issues that may be unique to individuals in these 
admission categories. 
 
RESOURCES  Resources for New Asylees  
Office of Refugee Resettlement  
 
Anti-Trafficking Resource Center
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3.10 HEALTH EDUCATION 
     
 
 
 
 
PURPOSE  To provide introductory information about key health-related 
topics relevant to newly arriving refugees at the time of the 
refugee health assessment 
BACKGROUND  Studies in the United States have shown that designated 
primary care as the point of first contact for illnesses, as well 
as the utilization of preventive care, is associated with fewer 
acute care visits and lower cost.  Refugees arriving in the 
United States often have an array of complex health problems 
varying from acute to untreated chronic.  Linking the patient to 
comprehensive primary care services should be a priority.   
 
Refugee health education is a key component of the health 
assessment as these are the first encounters a refugee has 
with the United States health care system.  Clinicians should 
have a health education plan that spans both visits.  
 
PROGRAM   Educational content of the health assessment should include,  
REQUIREMENTS  but not be limited to, the topics that are elaborated below: 
 
1. Introduction to the health care system of the U.S. 
 
The U.S. Department of Health and Human Services, in the 
eyes of many newcomers, would be the equivalent of a 
ministry of health in other countries.  Unlike the United States 
however, in most other countries, the government is nominally 
responsible for individual health care and the major funder of 
health services.  Refugees should be informed of their 
responsibilities regarding their own health status and utilization 
of care, as well as the commercial, employment-based nature 
of health care financing in the United States.  This should 
include an introduction to MassHealth coverage and Health 
Care Reform, how to use primary care and emergency 
services, and accessing dental care. Refugees are eligible for 
the Affordable Care Act benefits. 
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2. Primary care and health insurance 
 
The concept of primary care and prevention may be new to 
refugees, many of whom come from areas where health 
services focus on treatment of acute conditions.  Clinicians 
should introduce the concept of preventive medicine, primary 
care clinicians, and the function of such a clinician.  
MassHealth requires designation of a managed care provider 
(primary care clinician or HMO).   
 
Reinforce prevention messages in the context of the 
importance of primary health care, such as immunizations and 
early and periodic screening for children and check-ups for 
adults.  Many refugees may never have had routine preventive 
screening or child development assessments.  In particular, 
many refugee women may never have had gynecological and 
other women’s health screening such as pap smears, 
mammography, or explanation of breast self-examination.  
 
3. Access to health services 
 
Providers should orient refugees to the logistics of office-
based health care services in the United States.  Topics may 
include the use of phone systems, scheduling appointments, 
off-hours coverage, missed appointments, and urgent care 
systems. 
 
One of the most significant problems a refugee may encounter 
arriving in the United States is communication.  Advise 
refugees on basic skills needed to contact you or other 
hysicians: p 
• Calling the clinic for questions or to make/change 
appointments 
• Requesting interpreter assistance 
• How to use voice mail and leave messages 
• Typical hours of operation 
 
4. Insurance / MassHealth 
 
Educational content should include a brief introduction to the 
role of insurance in paying for health services and 
pharmaceuticals.  Discussion should emphasize the role of the 
primary care clinician, coverage of many over-the-counter 
medications, dental care, the use of the MassHealth card, and 
how to designate or change the primary care clinician. 
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Clinicians should provide basic information, as outlined below, 
to the refugee patient. 
 
Medicare: Covers health care services for most people aged 
65 years and older who have paid into the system and for 
some disabled people.   
Medicaid/MassHealth: Covers health care services for low-
income people (defined by each state); includes 
pharmaceutical and dental coverage.  Coverage may be broad 
for individual cases, due to requirements to reimburse any 
treatment necessary for conditions diagnosed as part of 
screening for children.  
Private Health Insurance: In Massachusetts, there are many 
different private insurance and managed care companies such 
as Harvard Pilgrim Health Care (HPHC), Blue Cross Blue 
Shield (BCBS), Tufts Health Plan, US Health Care, 
Neighborhood Health Plan, Network Health, Fallon Community 
Health Plan, etc. While each insurance plan is different, 
Massachusetts is one of the leading states in managed care 
enrollment.  Managed care plans usually require the choice of 
a primary care physician from a panel of covered physicians.  
These health plans will cover only designated services of the 
doctor that the patient has chosen and physician-authorized 
referrals.  If the patient sees other, unauthorized doctors, 
he/she may have to pay a bill.  Co-payments should also be 
explained to the refugee. 
 
All new Medicaid and some Medicare enrollees are being put 
into managed care programs such as the Primary Care 
Clinician Program or contracted commercial HMO’s.  All 
refugees should be introduced to the gatekeeper concept of 
managed health care in Massachusetts.   
 
5. Immunizations 
 
An important issue for refugees of all ages is vaccine 
requirements for school attendance and adjustment of 
immigration status.  Children must have documentation to 
meet school entry requirements.  All refugees must have 
written documentation of immunity to most vaccine-
preventable diseases through a full primary series of these 
vaccines to meet immigration adjustment of status 
requirements.  
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According to current regulations governing school attendance 
and immigration status adjustment, clinicians should advise 
refugees of the need to repeat vaccines for which 
documentation is not available and begin this process during 
the health assessment.  As noted earlier, RHAP requires 
clinicians to review vaccine needs of all refugees, initiate 
vaccines per ACIP guidelines, and complete personal vaccine 
records.  Part of this process should include discussion of 
these requirements with refugees as well as follow-up needs, 
vaccine safety and the importance of vaccines in disease 
prevention. 
 
6. Emergency services and 911 
 
Refugees should be provided with information on how to 
access and appropriately use emergency services.  
Discussion should include the need for primary care clinician 
authorization for emergency use whenever possible except for 
life-threatening emergencies.  Instruct refugees about use of 
‘911’ in case of an emergency.  Define emergency vs. non-
emergency situations, and encourage patients to avoid the 
utilization of emergency rooms for non-emergency conditions.  
In addition, providers should be aware that refugees may turn 
to RHAP clinicians for emergency or acute care beyond the 
scope of the RHAP.  Clinicians and staff should not refuse 
care in these situations, but document and bill for services as 
they do for other MassHealth patients.  It is appropriate to refer 
refugee patients to other primary care or emergency services 
when the situation permits such a delay in care. 
 
7. Oral health / dental care 
 
Forty-five percent of all refugees, and nearly 2/3 of all refugee 
children, regardless of country of origin or age, have significant 
oral health abnormalities.  Clinicians are expected to assess 
oral health history including personal oral hygiene practices 
and professional care history.  Education should emphasize 
personal hygiene, prevention of early childhood (i.e. baby 
bottle) caries, use of fluoridated water (specifically MWRA tap 
water) and toothpaste, brushing including use of traditional 
stick brush, flossing, and regular dental care. With MassHealth 
providing limited coverage of services for adults, education 
regarding personal oral hygiene practices is very important.  
Regardless of their age, clinicians should advise all refugees 
to seek dental consultation as soon as possible and offer 
referrals to clinics that accept MassHealth. 
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8. Give clear instructions on medications 
 
Many refugees may be used to being able to purchase 
medications like antibiotics easily without prescriptions.  A 
brief introduction to the following should be attempted, 
specially if you are prescribing medication for the patient: e 
• Over the counter medications vs. doctor-prescribed 
medications 
• To continue medication as prescribed by the doctor for the 
full course prescribed 
• Not to take additional medicines without checking with the 
doctor first 
• Insurance coverage of medications (keep in mind that 
MassHealth and other Medicaid HMO plans  cover a wide 
array of over-the-counter medications) 
• To discard unused prescription medications after an acute 
illness  
• Not to share prescription medication 
 
9. Provide general health education 
 
If appropriate in the context of the clinical encounter, clinicians 
should consider discussing any relevant topics, such as those 
below:  
• Mental health:  depression, homesickness, substance 
abuse, psychological trauma; coping with emotional stress 
• Safety:  accident prevention, mandatory child seats in cars, 
lead paint, supervision of children 
• Nutritional problems:  changing diets, loss of appetite, 
overweight/obesity 
• Domestic violence: reduction, prevention, Massachusetts 
law 
• Child neglect/child abuse: children protection laws, 
corporal punishment, female genital cutting  
 
Complete paperwork All school-aged refugee children will need Massachusetts  
school health forms completed.  Use any standardized form 
available, as the health assessment precedes school 
registration for most families.  Clinicians without such forms at 
their site should contact the Division of Global Populations and 
Infectious Disease Prevention (617 983 6590) for copies.  
 
Pregnant or lactating women and children up to age 5 years 
should be given a WIC medical form (and instructions on how 
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to enroll in the WIC program, if they have not already done 
so). 
 
All refugees should be given a personal vaccine record booklet 
that documents vaccines from abroad as well as those given 
at the RHAP.  All refugees should be given a copy of their 
RHAP form and advised to bring it to their first primary care 
appointment.  
 
Documentation  Health education content must be documented in the  
patient record as well as the RHAP form. 
 
 
 
RESOURCES   Refugee Health Technical Assistance Center (RHTAC) 
 
Refugee Health Information Network (RHIN) 
 
Healthy Roads Media
 
U.S. Committee for Refugees and Immigrants
Healthy Refugees Toolkit – enter language or topic in search 
box 
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3.12 TARGETED TESTING  
 
 
PURPOSE To provide flexible protocols for the diagnosis of common 
conditions, particularly infectious diseases and conditions 
affecting refugees that might require urgent attention  
 
BACKGROUND The Refugee Health Assessment is a unique clinical encounter 
as it is typically the first encounter a refugee has with the 
United States health care system.  While RHAP has a 
standardized core protocol, refugees may present with broader 
needs than are addressed in this protocol.  
 
Targeted tests allow some flexibility for clinicians to diagnosis  
acute infections and other common but urgent conditions 
about which additional screening data might affect clinical 
decision making during the RHAP, e.g. help the clinician 
decide whether the patient should be referred to a sub-
specialist or can wait for follow-up at the primary care 
appointment.  Protocol updates in 2013 also permit the RHAP 
clinician to conduct limited diagnostic testing for some chronic 
conditions as a way to facilitate the transition into primary care. 
[For information on RHAP pharmaceutical coverage, see also 
Section 3.14.] 
 
PROGRAM  Beyond the core RHAP protocol, targeted tests allow clinicians  
REQUIREMENTS to meet the health care needs of newly arriving refugees.  
Providers must follow protocols for testing and treatment.  The 
targeted tests are for diagnosing: 
 
• Sexually transmitted diseases (gonorrhea, syphilis, 
Chlamydia) 
• Parasitic infections (Strongyloides, Schistosoma, 
Plasmodium [malaria], filariasis, eosinophilia, roundworms) 
• HIV 
• Other infections (streptococcal tonsilopharyngitis, urinary 
tract infections, hepatitides) 
• Pregnancy (urine HCG) 
• Endocrine disorders (thyroid disease, diabetes mellitus) 
• Cardiovascular disorders (comprehensive metabolic panel, 
lipid panel)  
• Blood lead level 
• Nutritional issues (Vitamin B12) 
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• Metabolic disorders (newborn screening profile for <6 
months of age) 
Clinicians are expected to follow specific guidelines listed 
below when ordering targeted tests.  Questions regarding the 
targeted protocols should be addressed to the RHAP Medical 
Director at 617-983-6593. 
 
 
 
Clinicians must document the specific indications for the 
test in the patient’s medical record.  Substitution of 
pharmaceuticals must also follow RHAP guidelines and 
be documented in the record. 
 
 
 
Targeted Testing   When ordering tests, clinicians are expected to document 
Protocols   in the patient’s medical record the specific criteria used to 
 justify the testing.  RHAP annual site visits may include 
assessment of adherence with targeted testing protocol 
criteria.  Clinicians may not order any targeted test for patients 
who do not meet specific criteria.  Targeted tests are not to be 
used for screening of patients originating from particular 
regions but should be ordered only as indicated for individual 
patients’ specific medical needs. 
 
 
Procedure 
Code 
Description Criteria 
Sexually transmitted diseases: clinicians are expected to comply with DPH regulations 
regarding reportable diseases (from 105 CMR: 300). 
86592 Syphilis test, 
qualitative, e.g. RPR 
Painless chancre/s, characteristic rash involving 
palms or soles, condyloma latum, gummatous 
changes, symptoms of neurosyphilis, aortitis, 
non-specific signs or symptoms suggestive of 
syphilis, or contact with a person known to have 
syphilis; presence of risk factors, including 
inconsistent use of barrier contraception, new or 
> one sex partner in past 3 months, new partner 
since last tested, or infected with other STD 
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87491 Chlamydia, amplified 
DNA probe (urine 
specimen only, by 
ligase chain reaction) 
Penile discharge, pyuria, unusual vaginal 
discharge, pelvic or abdominal pain suggestive of 
PID, contact with a person infected with 
Chlamydia; men with urinalysis positive for 
leukocyte esterase or > 10 PMNs in spun 
sediment of first voided urine; presence of risk 
factors, including inconsistent use of barrier 
contraception, new or > one sex partner in past 3 
months, new partner since last tested, or infected 
with other STD 
87591 Gonococcus, amplified 
DNA probe (urine 
specimen only, by 
ligase chain reaction) 
As above. 
Parasitic diseases 
Note: Clinicians who are unfamiliar with the diagnosis and treatment of tropical or parasitic 
diseases should consider obtaining consultation from an infectious disease specialist before 
ordering supplemental tests. Clinicians are expected to comply with DPH regulations regarding 
reportable diseases (from 105 CMR:300). 
82784 
 
Total Ig, or IgG or IgM 
 
For testing of patients from malaria-endemic 
regions with suspected tropical splenomegaly 
syndrome only   
86682 Strongyloides titers 
(unspecified helminth 
antibodies) 
Unexplained eosinophilia on peripheral blood 
counts 
86682 Schistosoma titers 
(unspecified helminth 
antibodies) 
Unexplained eosinophilia on peripheral blood 
counts, hematuria, or hepatosplenomegaly in a 
patient from endemic regions 
86682 Filaria titers 
(unspecified helminth 
antibodies) 
Unexplained eosinophilia on peripheral blood 
counts or suspicious skin lesions in a patient 
from endemic regions 
86750 Malaria (plasmodium) 
antibody titers 
For testing of patients from malaria-endemic 
regions with suspected tropical splenomegaly 
syndrome only.  Should not be used for the 
diagnosis of acute malaria. 
87177 Ova and parasites; 
direct smears, 
concentration, and 
identification 
Clinicians may order up to 3 stool O & P tests for 
patients with no pre-departure treatment,  
unexplained eosinophilia, persistent abdominal 
pain, specific known contact with individuals with 
parasitic diseases and presence of 
gastrointestinal symptoms or poor growth 
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87207 Malaria smears (thin 
and thick); special stain 
for inclusion bodies or 
intracellular parasites 
(may be used for other 
parasites, e.g. kala 
azar, leishmania, 
filaria) 
Fevers, eosinophilia, lymphadenopathy, 
hepatosplenomegaly, or other signs or symptoms 
of parasitic disease, particularly malaria, in 
patients from specific, endemic regions 
Other infectious diseases 
86803/4 Anti-HCV Antibody with 
confirmatory testing 
For testing of patients who are positive for 
HBsAg, have elevated transaminases, or are 
suspected of having chronic hepatitis only 
86704 Anti-HBV Core 
Antibody 
For testing of patients who are positive for 
HBsAg or to determine if immunity (positive Anti-
HBs Ab test) is due to past immunization or 
infection only 
86708 Anti-HAV Total 
Antibody 
For testing of patients who are positive for 
HBsAg, have elevated transaminases, or are 
suspected of having chronic hepatitis only 
87350 HBeAg For testing of patients who are positive for 
HBsAg only 
87536 (HIV1) 
87539 (HIV2) 
86361 
HIV viral load and CD4 
count 
Optional testing for refugees with HIV positive 
screening 
87880 Streptococcus screen, 
direct (“Rapid Strep”) 
Sore throat, fever, tonsilopharyngeal exudate, or 
scarletiniform rash 
87081 Streptococcus (throat) 
culture, bacterial 
screening for single 
organisms 
Sore throat, fever, tonsilopharyngeal exudate, or 
scarletiniform rash 
87086 Urine culture, bacterial; 
quantitative colony 
count 
Dysuria; pyuria; hematuria; urinary retention, 
urgency, or frequency; flank pain; suprapubic 
pain; or unexplained fever in young children 
87186 Sensitivity studies, 
antibiotic; microtiter, 
MIC, any number of 
antibiotics 
For use with positive urine cultures only 
Endocrine diseases 
82948 Glucose; blood reagent 
strip 
Glucosuria, history of diabetes mellitus, or signs 
or symptoms suggestive of diabetes mellitus 
such as polyuria, polydipsia, weight loss, chronic 
ulcers, etc… 
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83036 Hemoglobin A1c The USPSTF recommends screening for type 2 
diabetes in asymptomatic adults with sustained 
blood pressure (either treated or untreated) 
greater than 135/80 mm Hg. Also test those with 
glucosuria, history of hyperglycemia or  diabetes 
mellitus, or signs or symptoms suggestive of 
diabetes mellitus such as polyuria, polydipsia, 
weight loss, chronic ulcers, etc 
84443 Thyroid Stimulating 
Hormone 
Signs or symptoms suggestive of thyroid 
disease, goiter 
Cardiovascular diseases 
80061 Lipid panel The USPSTF strongly recommends screening for 
lipid disorder all men aged 35 and older and men 
aged 20 to 35 if they are at increased risk for 
coronary heart disease. It is strongly 
recommended for women aged 45 and older if 
they are at increased risk for coronary heart 
disease and for women aged 20 to 45 solely 
based on risk for coronary heart disease. 
Other 
81025 Urine pregnancy test, 
by visual color 
comparison methods 
Signs or symptoms of pregnancy, amenorrhea, 
oligomenorrhea or for vaccine clearance 
83655 Blood lead level CDC recommends testing of all refugee children 
through 16 years of age; testing may be ordered 
for all refugees in this age group. 
80053 Comprehensive 
metabolic panel 
History of chronic kidney disease, hypertension, 
diabetes mellitus or sign and symptoms such as 
headaches, chest pain, jaundice. Elevated blood 
pressure on examination. Abnormal urinalysis 
with proteinuria, urobilinogen, hemturia, or 
positive Hepatitis B screening 
82607 Vitamin B12 
(cyanocobalamine) 
level 
Signs or symptoms of B12 deficiency including 
macrocytosis and presence of neuromuscular or 
neuropsychiatric abnormalities 
None Newborn Screening 
Profile 
A newborn metabolic screening may be ordered 
for infants under 6 months of age. 
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3.12  PHARMACEUTICALS 
 
PURPOSE To provide for the initial treatment of parasitic infections and 
other defined conditions, particularly infectious diseases and 
conditions affecting refugees that might require urgent 
attention 
 
BACKGROUND Treatment for certain acute conditions that are diagnosed 
during the health assessment can be reimbursed by RHAP.  In 
general, these are parasitic infections or conditions that 
require prompt treatment.  Incorporating medications into 
RHAP facilitates the process of providing pre-filled 
prescriptions.  Additional defined medications can be pre-filled 
as well.  For those RHAP patients with Medicaid cards, 
pharmacies have the option of billing Medicaid directly and 
there are no restrictions on formulary.  
Urgent medical needs that cannot be addressed during health 
assessment should be managed outside of the health 
assessment context.  Similarly, non-urgent conditions may be 
treated later in the context of primary or specialist care. 
A full listing of pharmaceuticals that will be reimbursed by our 
program are listed in this section. 
 
PROGRAM   Pharmaceutical coverage allows treatment of common 
REQUIREMENTS   parasitic infections, additional acute conditions diagnosed  
clinically, and iron deficiency. 
 
    
 
Clinicians must document the specific indications for 
treatment in the patient’s medical record.  Substitution of 
pharmaceuticals must also follow RHAP guidelines and 
be documented in the record. 
 
 
 
Treatment of Parasites Clinical sites are required to obtain and provide anti-parasitic 
medication to RHAP patients to treat pathologic intestinal 
parasites. Prescribe through a pharmacy affiliated with your 
program to ensure that the patient is not billed for anti-parasitic 
medications.  It is recommended that single dose medications 
be taken at the RHAP clinic visit whenever possible.  
Presumptive treatment is also covered through RHAP.  See 
Section 3.6 on Parasites for detailed information. 
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The following list summarizes the anti-parasitic medications 
covered by RHAP: 
Albendazole/Albenza 
Iodoquinol/Yodoxin 
Ivermectin/Stromectol 
Mebendazole/Vermox 
Metronidazole/Flagyl 
Nitazoxanide/Alinia  
Paromomycin/Humatin 
Praziquantel/Biltricide 
Thiabendazole/Mintezol 
Anti-Malarials 
 
Notes on Treatment of Parasites: 
 
o Treatment for acute malaria can be covered if the 
clinician opts to treat malaria on an outpatient basis. 
 
o Presumptive treatment of malaria can also be covered. 
 
o Patients with Ascaris as well as another parasite should 
always be treated for Ascaris first due to the risk of 
migration of the worm. 
 
o Albendazole is only available as a film-coated tablet and 
may not be suitable for use in young children. 
 
o Paromomycin is not absorbed and may be useful for 
treatment of amebiasis and giardiasis during pregnancy. 
 
o Clinicians may consider empiric treatment of refugees 
with negative O & P tests in the following situations: 
 
1. Multiple family members with similar intestinal 
parasites.  For example, if two family members have 
trichuriasis, the clinician may consider treating the 
patient with mebendazole or albendazole. 
 
2. A patient (from a country with endemic parasitoses) 
with a high-risk medical condition which predisposes to 
complications from parasitoses.  For example, a patient 
with asthma or rheumatic disease who may be likely to 
be placed on steroids, or a patient with HIV infection.  
In these instances, the clinician should consider 
empiric treatment with albendazole, 400 mg bid for 3 
days. 
 
 
o For treatment of malaria, please refer to Section 3.6. 
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Pharmaceuticals 107
RECOMMENDED AND REIMBURSED DRUGS FOR MAJOR PARASITES* 
 
Parasite 
Drug (generic/trade) 
In Order of 
Preference: 
Adult Dosage Pediatric Dosage 
Mebendazole/Vermox 500 mg once or 100mg bid x 3d. Same 
Ascaris  
Albendazole/Albenza 400 mg once Same 
Praziquantel/Biltricide 25 mg/kg q 6° x 3 doses  Same 
Clonorchis 
Albendazole/Albenza 10 mg/kg x 7 days Same 
Paromomycin/Humatin 25-35 mg/kg/day ÷ tid x 7 days Same 
E. histolytica1
Iodoquinol 650 mg tid x 20 days 30-40 mg/kg/day ÷ tid x 20 days (max. 2 gm) 
Metronidazole/Flagyl 250 mg tid x 5 days 15 mg/kg/day ÷ tid x 5 d. 
Giardia 
Nitazoxanide/Alinia Ages 12 years and older: 500 mg bid x 3 days 
1-3 yrs: 100 mg bid x 3 d. 
4-11 yrs: 200 mg bid x 3 d. 
Mebendazole/Vermox 500 mg once or 100mg bid x 3d. Same 
Hookworm 
Albendazole/Albenza 400 mg once Same 
Hymenolepis Praziquantel/Biltricide 25 mg/kg x 1 dose Same 
Lice Permethrin 1% cream rinse/ Nix  Apply x 1; repeat after 2 wks prn Same 
Scabies Permethrin 5% lotion/ Elimite Apply qhs and rinse in AM once Same 
Schistosoma Praziquantel/Biltricide 20 mg/kg bid-tid x 1 day2 Same 
Ivermectin/Stromectol3 200 µg/kg/day x 1-2 days Same 
Strongyloides 
Thiabendazole/Mintezol 25 mg/kg bid x 7 days  
Tape worms4 Praziquantel/Biltricide 5-10 mg/kg x 1 dose Same 
Albendazole/Albenza 400 mg bid x 5 days Same Toxocara 
canis Mebendazole/Vermox 100-200 mg bid x 5 days Same 
Mebendazole/Vermox 500mg once or 100mg bid x 3d. Same 
Trichuris 
Albendazole/Albenza 400 mg once5 Same 
 
*The Medical Letter on Drugs and Therapeutics. August 2004 On-line edition:1-12.   
 
MALARIA TREATMENT 
 
The Centers for Disease Control offer 24-hour consultation at 770-488-7788 during weekday 
business hours and by page at 770-488-7100 after hours and on weekends and holidays.  
Treatment guidelines are available at: 
http://www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm
                                                 
1 Asymptomatic carriage only.  Obtain consultation for symptomatic case treatment. 
2 TID dosing for S. Japonicum and mekongi. 
3 Ivermectin not FDA approved for use in disseminated strongylodiasis. 
4 iphyllobothrium latum, Taenia saginata/solium, and Dipylidum only.  Consult reference for others.  D  
5 In heavy infection, may need to treat with 400 mg bid x 3 days. 
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FORMULATIONS: 
 
• Albendazole/Albenza: 200 mg film-coated tablets 
• Iodoquinol/Yodoxin: 210 and 650 mg tablets    
• Ivermectin/Stromectol:  3 mg unscored and 6 mg scored tablets 
• Mebendazole/Vermox:  100 mg chewable tablets 
• Metronidazole/Flagyl: 250 & 500 mg tablets, 100 mg/5cc suspension (specially prepared) 
• Nitazoxanide/Alinia: 500 mg tablets; 100 mg/5cc suspension 
• Paromomycin/Humatin: 250 mg capsules 
• Permethrin/Elimite/Nix: 5% cream (60gm) /1% cream rinse (59cc) 
• Praziquantel/Biltricide:  600 mg triscored tablets, 150 mg/section 
• Thiabendazole/Mintezol: 500 mg chewable tablets, 500mg/5cc suspension 
 
MAJOR SIDE EFFECTS*: 
Drug Common Rare 
Albendazole Abd. pain, reversible alopecia, 
transaminase elevation, Ascaris migration  
Leukopenia, rash, renal toxicity 
Iodoquinol Rash, acne, goiter, nausea, anal pruritus, 
diarrhea, cramps 
Optic neuritis/atrophy, loss of vision, 
peripheral neuropathy, iodine 
sensitivity 
Ivermectin Mazzotti-type reaction in onchocerciasis: 
fever, pruritus, lymphadenopathy, HA, 
arthralgia 
Hypotension, edema, tachycardia, 
possible ophtho changes 
Mebendazole diarrhea, abd. pain, Ascaris migration leukopenia, alopecia, hepatotoxicity, 
agranulocytosis, hypospermia 
Metronidazole nausea, dry mouth, metallic taste, 
headache, GI disturbance, insomnia, 
vertigo, tinnitus, weakness, stomatitis, 
dark urine, disulfirim-like rxn., paresthesia, 
rash, urethritis 
seizures, encephalopathy, 
pseudomemb.colitis, ataxia, 
leukopenia, pancreatitis, periph. 
Neuropathy 
Nitazoxanide Abdominal pain, diarrhea, headache, nausea 
Paromomycin GI disturbance, eighth nerve toxicity, nephrotoxicity if IV, vertigo, pancreatitis (No 
rare SE’s listed). 
Permethrin Burning, stinging, numbness, increased pruritus, edema, erythema, rash (No rare 
SE’s listed). 
Praziquantel malaise, headache, dizziness, sedation, GI 
upset, fever, sweating, nausea, eosinophilia, 
fatigue 
Pruritus, rash 
Thiabendazole Nausea, vomiting, vertigo, headache, 
drowsiness, pruritus, leukopenia, crystalluria, 
rash, hallucinations and psych. rxns, 
visual/olfactory disturbance, e. multiforme 
Shock, tinnitus, intrahepatic 
cholestasis, seizures, 
angioneurotic edema, Stevens-
Johnson Syndrome 
 
*This table is not meant to be a definitive list of side effects and contraindications.  Clinicians 
are responsible for familiarizing themselves with prescribed anti-parasitic drugs. 
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Treatment of Other   In addition to anti-parasitic medications, RHAP also covers 
Conditions    pharmaceuticals for the treatment of acute conditions.   
 
The following list summarizes the additional medications 
covered by RHAP: 
Amoxicillin 
Azithromycin 
Benzithine Penicillin G 
Ceftriaxone 
Clotrimazole 
Erythromycin ES 
Griseofulvin V (microsize) 
Neomycin/PolymixinB/Hydrocortisone 
Penicillin VK 
Permethrin 1% 
Permethrin 5% 
Trimethoprim-Sulfamethoxazole 
Iron, at treatment doses (any formulation) 
 
 
Clinicians must adhere to the pharmaceutical guidelines listed.  
Dosing, if not delineated, is expected to be according to the 
standard regimen for the drug.   
 
For drug substitutions, clinicians must seek prior approval from 
RIHP medical director; however, clinicians may substitute 
without RIHP authorization for refugee patients who have 
received their MassHealth cards.  In this case, affiliated 
pharmacies must seek reimbursement for substituted drugs 
from MassHealth, not RIHP.   
 
 
Diagnosis Children Adolescents/Adults 
Iron Deficiency 
• • Elemental iron 4-6 mg/kg/day 
(any formulation) x 3 months 
Elemental iron 65mg (= 325mg 
FeSO4) bid – tid x 3 months 
Acute Otitis Media 
• 
• 
• 
• 
• 
• 
• 
Amoxicillin 250mg/5cc 
suspension 
Under 2 years: ~20 – 25 
mg/kg dose po tid for 10 days 
2 years and over: 7 days 
Use azithromycin if PCN 
allergy 
Amoxicillin 500mg tabs 
5 - 7 day course  
Use azithromycin if PCN 
allergy 
Acute Otitis 
Externa 
• • Same Neomycin/Polymixin B/ 
Hydrocortisone otic 
suspension 
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Diagnosis Children Adolescents/Adults 
Streptococcal 
Pharyngitis 
• 
• 
• 
• 
• 
• 
• 
• 
Penicillin VK  250mg/5cc 
suspension 
BID dosing preferred 
10 day course 
Use erythromycin ES if PCN 
allergy 
Penicillin VK 500mg tabs 
BID dosing preferred 
10 day course 
Use erythromycin ES if PCN 
allergy 
Urinary Tract 
Infection 
• 
• 
• 
• 
• 
• 
• 
• 
TMP/SMX suspension  
7 – 10 day course 
Use Amox. if sulfa allergy 
May substitute other drug 
without RIHP approval only if 
indicated by bacterial 
sensitivities or allergies† 
TMP/SMX 80/160mg tabs 
3 day course 
Use Amox. if sulfa allergy 
May substitute other drug 
without RIHP approval only if 
indicated by bacterial 
sensitivities or allergies† 
Gonococcal 
urethritis/cervicitis 
• N/A • Single dose ceftriaxone (125 
mg IM) 
Chlamydia 
urethritis/cervicitis  
• N/A • Single dose azithromycin (1 
gm po) 
Syphilis 
• N/A • Benzathine Penicillin G 2.4 
million units IM once; MDPH 
recommends a second dose 
for Tx of early latent syphilis.  
In addition, a third dose should 
be considered for latent 
syphilis of unknown duration.  
Doses should be one week 
apart. 
Tinea Corporis • • Clotrimazole cream Clotrimazole cream 
Tinea Capitis 
• 
• 
• 
• 
Griseofulvin V microsize 
125mg/5cc suspension 
4 weeks course only (patient 
should f/u with PCP for refill 
covered by MassHealth) 
Griseofulvin V ultramicrosize 
125/250mg tabs 
4 weeks course only (patient 
should f/u with PCP for refill 
covered by MassHealth) 
Lice • • Permethrin 1% cream rinse Permethrin 1% cream rinse 
Scabies • • Permethrin 5% lotion Permethrin 5% lotion 
 
†RIHP may request documentation of need for substitution. 
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3.4 MENTAL HEALTH 
 
 
 
 
 
 
PURPOSE   To screen and identify refugees in need of mental health 
treatment, provide education about mental health issues, 
discuss expected stress responses, improve adjustment and 
provide information about or linkage with mental health 
resources 
 
 
BACKGROUND  Clinical depression is a disorder that affects millions of people 
worldwide. Refugee experiences, long distance journeys and 
resettlement in a new country are life-changing events that can 
predispose refugees to mental health issues. It is estimated 
that the prevalence of major depression, anxiety, panic attacks 
and post-traumatic stress disorder (PTSD) is very high in 
many refugee populations. In studies with representative 
samples using self-rated scales, the prevalence of PTSD 
ranged from 9-86%.1,2,3 Risk factors that may predispose 
refugees and asylum seekers to psychiatric symptoms and 
disorders include: exposure to war, state-sponsored violence 
and oppression, including torture, internment in refugee 
camps, human trafficking, physical displacement outside one's 
home country, loss of family members and prolonged 
separation, the stress of adapting to a new culture, low 
socioeconomic status, and unemployment.4,5
 
    The overall prevalence of major mental illness among 
refugees is likely similar to that in western populations.  Upon 
arrival, a small number of refugees with major mental illness 
may present with symptoms such as suicidal or homicidal 
ideation or severe limitations in ability to function and may 
require immediate attention. This group may include refugees 
with schizophrenia, bipolar disorder, major depression, 
                                                          
1 Carlson,EB & Rosser-Hogan,R. Mental health status of Cambodian refugees ten years after leaving their homes. American 
Journal of Orthopsychiatry, 1993; 63: 223–231 
2 Hauff E, Vaglum P.  Vietnamese boat refugees: The influence of war and flight traumatization on 
mental health on arrival in the country of resettlement. Acta Psychiatr Scand. 1993; 88:162-168. 
3Mollica RF, Donelan K, Tor S, Lavelle J, Elias C, Frankel M, Blendon RJ. The effect of trauma and confinement on functional 
health and mental health status of Cambodians living in Thailand-Cambodia border camps. JAMA. 1993 Aug 4;270(5):581-6. 
4 Mollica RF, Wyshak G, Lavelle J. The psychosocial impact of war trauma and torture on Southeast Asian refugees. Am J 
Psychiatr 1987;144:1567-72. 
5 Porter M, Haslam N. Predisplacement and postdisplacement factors associated with mental health of refugees and internally 
displaced persons: a meta-analysis. JAMA 2005; 294(5): 602-612. 
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traumatic brain injury or PTSD (post-traumatic stress disorder), 
and need immediate psychiatric evaluation and treatment.   
 
A majority of refugees may not be in need of clinical mental 
health services, but should have access to a basic mental 
health screening since all of them have suffered directly or 
indirectly as a result of crisis, trauma or loss. The Refugee 
Health Screener – 15 (RHS-15) is a tool developed to detect 
the range of emotional distress common across refugee 
groups. 
 
PROGRAM    In order to screen refugees for mental health, the RHAP 
 REQUIREMENTS  requires the following of providers: 
  
1. For patients 14 years of age and older: 
 
⇒ Administer the RHS-15 questionnaire to assess for 
risk for PTSD, anxiety or depression, during either 
of the RHAP encounters. 
⇒ Questions: total available points from 1 (no 
emotional distress) to 56 (maximal distress)  
⇒ Distress Thermometer points from 0 (no 
distress) to 10 (maximal distress) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Implementation of the RHS-15 may present challenges 
for clinical sites. The questionnaire can be self-
administered or administered by a nurse, midlevel, 
physician, medical assistant or other appropriate clinic 
staff person.  Sites are encouraged to experiment with 
workflows to determine how best to integrate the 
questionnaire into RHAP clinical encounters.  
Sites are strongly encouraged to view the archived 
RHTAC webinar about implementing the RHS-15 by 
clicking on this hyperlink: Part 2
2. Interpret the test results: 
Screening is POSITIVE if: 
1. Total score of items 1 to 14 is ≥ 12 AND/OR 
2. Distress Thermometer is ≥ 5 
3. A positive screen does not automatically indicate a need 
for psychiatric services but simply a need for further 
assessment and follow-up. At the discretion of the clinician, 
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refer any patient who screens positive to a mental health 
professional or closely follow in primary care.6 
 
 
As of 2013, the RHS-15 is available in Amharic, Arabic, 
Burmese, Karen, Farsi, French, Nepali, Russian, Somali, 
Cuban Spanish, Swahili, Tigrinya, and English.  
The Division of Global Populations and Infectious Disease 
Prevention, MDPH, can provide copies to RHAP clinical 
sites. 
 
 
 
REPORTING   The RHS-15 is validated for several different population groups. 
AND FOLLOW-UP  Scoring was established based on validation research data. 
Sites should report the symptom score and distress 
thermometer score on the RHAP reporting form. 
 
    If significant positive findings are presented from history, 
physical exam and screening tools by clinician, clinical 
judgment and availability of services will determine whether 
emergency or routine follow-up care is needed and how 
quickly these services need to be accessed. If symptoms of 
depression or PTSD affect daily function, more urgent follow-
up care is recommended. The presence of suicidal or 
homicidal ideation should prompt referral for emergency 
follow-up. When PTSD symptoms are severe, it is optimal for 
the refugee to be referred to an agency with special expertise 
in working with refugee mental health issues.  
 
    When referring a patient for mental health evaluation and 
treatment, the clinician should educate and reassure the 
refugee about privacy by describing what to expect on the 
initial mental health evaluation.  
 
RESOURCES   
Mental Health Screening Guidelines for Refugees, DGMQ, 
CDC  
 
RHS-15 Packet
 
Mental health page of the Refugee Health Technical 
Assistance Center with RHS-15 instructional webinar 
recordings (Part 1 and Part 2) 
 
                                                          
6 CDC Guidelines for Mental Health Screening during the Domestic Medical Examination for NewlyArrived Refugees 
http://www.cdc.gov/immigrantrefugeehealth/guidelines/domestic/mental-health-screening-guidelines.html 
Mental Health 3.4.3
Updated October 2013                       MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE 
Section 3: CLINICAL PROGRAM 
3.1 DEMOGRAPHIC INFORMATION 
 
 
 
 
 
PURPOSE     To ensure that demographic data are collected and  
recorded correctly 
 
PROGRAM    The following information is to be completed on the RHAP  
REQUIREMENTS  form: 
 
     NAME:    
• Record clearly – family (last) name and given names. 
 
MAVEN ID: 
• [Optional] For RHAP sites using the state’s MAVEN 
system, enter the refugee’s MAVEN ID number. 
 
BIRTH DATE:   
• Record as MM/DD/YYYY.  (Note: Some records from 
overseas may be in DD/MM/YY or YY/MM/DD format). 
 
    SEX:  
• Record sex: M or F. 
 
ARRIVAL DATE: 
• Record the date of entry into the United States. 
• Note that some refugees are “secondary migrants” in 
Massachusetts, meaning s/he settled in another state in 
the United States (even for as little as one day) before 
moving to Massachusetts. The arrival notification and 
overseas paperwork would be with the original 
resettlement state. 
• For persons granted asylum in the United States (asylees), 
the “arrival date” is considered the date that the individual 
was granted asylum. 
 
ASYLEE DESIGNATION: 
• Check this box if the individual has political asylum 
(either United States-granted or a derivative arrival 
from overseas). 
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ALIEN NUMBER: 
• Record alien number. 
 
ADDRESS:   
• Record current address. (May need to be updated). 
 
TELEPHONE:  
• Record a current phone number. 
 
NATIONALITY:  
• Record the country of nationality, even if born elsewhere. 
For example, a Somali refugee born in Kenya would be 
designated here as “Somali.” Do not list religion or 
language preferences here. 
 
RESETTLEMENT AGENCY:  
• Record the name of the agency that scheduled the 
appointment.  If none, record the referral source (generally 
MDPH). 
 
MDPH staff often relies on the information on the RHAP form 
when arranging contact with a family.  Because refugee 
families may move after their first few weeks in the United 
States, RHAP providers should confirm address information at 
each RHAP visit.   
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3.2 REVIEW OF THE OVERSEAS MEDICAL EXAMINATION 
 
 
 
 
 
 
PURPOSE    To review findings from the overseas visa medical 
examination (as reported on Form DS-2054 for the Overseas 
Medical Examination of Applicants for U.S. Visas and 
additional accompanying documents) and follow up on 
identified conditions. 
 
BACKGROUND  Overseas health screenings are conducted to ensure that 
refugees do not have conditions that would exclude them from 
entering the United States.  These medical exclusions include 
certain communicable diseases and mental health conditions 
associated with violence.  Refugees with communicable 
diseases that preclude their entry into the country may be 
delayed until appropriate treatment is initiated and they are no 
longer infectious.  Following treatment, refugees will be 
allowed to immigrate to the United States. Waivers may be 
requested for conditions that are grounds for exclusion (Class 
A conditions).  Medical conditions are categorized as Class A 
or Class B; however, the lack of a Class A or Class B condition 
does not mean the individual is without medical needs. 
 
Note on asylees: While individuals granted asylum in the 
United States will not have undergone an overseas health 
evaluation, many will have had some kind of medical or 
psychological evaluation in support of their legal case. 
Similarly to reviewing the DS-2054 overseas health screening 
form, RHAP clinicians should ask the asylee if they have any 
documentation of the findings from these assessments, often 
done in private settings.  In most cases, such evaluations are 
not going to include screening tests as are conducted during 
refugee health assessment.   
 
Asylees arriving from overseas (derivative asylees or follow-to-
join asylees) generally do complete an overseas medical 
examination but records are seldom forwarded to the state 
health department.  RHAP providers should ask asylee 
patients for copies of these overseas records, if they are 
available. 
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Class A  Class A conditions are defined as those conditions that 
preclude a refugee from entering the United States.  Class A 
conditions require approved waivers for United States entry 
and immediate follow-up upon arrival.  These conditions 
include communicable diseases of public health significance, 
mental illnesses associated with violent behavior, and drug 
addiction. 
  
 Class B  Class B conditions are defined as significant health 
problems: physical or mental abnormalities, diseases, or 
disabilities serious in degree or permanent in nature 
amounting to a substantial departure from normal well-being.  
Class B conditions require follow-up soon after arrival in the 
United States. Often these are clinical diagnoses and 
subjective in nature.  As a result, overseas panel physicians 
vary in their interpretation of what constitutes a non-
mycobacterial “Other” Class B condition. 
 
The following table summarizes the classifications of various 
diseases: 
 
Overseas Classifications 
 
Class A 
 
Chancroid, Gonorrhea, Granuloma inguinale, 
Lymphogranuloma venereum, Syphilis 
 
 Tuberculosis, active, infectious 
 Hansen’s disease, infectious (leprosy) 
 
 Mental illness with violent behavior 
 
 Drug addiction 
 
Class B Tuberculosis classification is per the Cultures 
and Directly Observed Therapy TB Technical 
Instructions (TI)  
B1 TB, Pulmonary  
B1 TB, Extrapulmonary  
B2 TB, LTBI Evaluation  
B3 TB, Contact Evaluation 
 
 Hansen’s disease, not infectious 
 
 Other significant physical disease, defect, or 
disability 
 
 
The overseas medical examination is done by a physician 
working under contract to the International Organization for 
Migration or by a local panel physician designated by the U.S. 
Department of State and using locally available facilities 
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(laboratory, x-rays).  The Division of Global Migration and 
Quarantine (DGMQ), CDC, is responsible for oversight of all 
overseas examinations. 
   
Protocol  The summary protocol for the overseas visa medical examination is   
    as follows: 
 
• Medical history and physical examination. 
 
• TB evaluation is done according to the Cultures and 
Directly Observed Therapy (DOT) Tuberculosis Technical 
Instructions (CDOT TB TIs) in all countries as of October 1, 
2013:  
• Medical history, physical exam and chest x-ray 
for age ≥15 years 
o Three sputum specimens for smear and 
culture for M. tuberculosis if the refugee 
has a chest x-ray with findings 
suggestive of TB, has signs and 
symptoms of tuberculosis, or has HIV 
infection. If culture positive, drug 
susceptibility testing and treatment by 
Directly Observed Therapy 
• Tuberculin skin test (TST) or an IGRA for age 
2-14 years of age if living in countries with a 
WHO-estimated TB incidence rate of ≥20 cases 
per 100,000 population 
o Chest x-ray if TST >10mm or IGRA 
positive; as above if chest x-ray has 
findings suggestive of TB 
TB Classifications are noted in the table above. 
 
• Serologic test for syphilis for all refugees age ≥15 years.  
Applicants under the age of 15 must be tested if there is 
reason to suspect infection with syphilis or if there is a 
history of syphilis.  Untreated syphilis is Class A; after 
completing treatment, the person is re-classified to Class 
B.  Most refugees complete treatment for syphilis prior to 
departure for the United States; a waiver can be requested 
if treatment is incomplete.   
 
• Other STDs (chancroid, gonorrhea, granuloma inguinale, 
and lymphogranuloma venereum) are treated prior to 
departure if identified. 
 
• Physical exam for signs of Hansen’s disease.  Refugees 
with multibacillary or paucibacillary Hansen’s disease are 
are considered to be Class A.  After seven days of 
treatment, they are reclassified to Class B and are eligible 
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for travel to the United States.  Generally, treatment must 
be continued in the United States. 
 
• Since 2010, refugees are not routinely tested for HIV prior 
to arrival in the United States.   
 
A determination is made regarding whether or not a refugee 
has a mental disorder. Physicians rely on a medical history 
provided by the patient and his/her relatives and any 
documentation such as medical and hospitalization records. 
 
Results are recorded on the overseas visa medical 
examination form (DS-2054) and worksheets. 
 
The quality of the overseas visa medical examination varies 
and depends on such factors as the site of the examination, 
the panel of physicians, and the length of time for which the 
examination process has been in place at a given location.  
The visa medical examination is valid for 3-12 months prior to 
departure. Recent years have seen consolidation of overseas 
exams done through the International Organization for 
Migration with oversight by the CDC and improved quality and 
consistency. 
 
  
The International  The IOM is an intergovernmental body, based in Switzerland, 
 Organization for  that manages refugee movements for third country 
 Migration (IOM) resettlement.  In addition, IOM performs the refugee overseas  
 health assessments in Sub-Saharan Africa, Southeast Asia 
and countries of the former Soviet Union.  The IOM provides 
each refugee with a white plastic bag that contains the 
individual’s medical records and x-rays.  Currently, the IOM 
bag should contain the DS-2054 form and supplemental 
vaccine form.  At times, IOM officials will add other 
supplemental forms to document the medical history based on  
the situation a refugee is coming from.  Recent examples 
include documentation of varicella vaccination in the case of 
an outbreak and pre-embarkation treatment for malaria or 
parasitic infections.   
 
Division of   The Division of Global Migration and Quarantine (DGMQ), 
Global Migration  CDC is responsible for the Technical Instructions and  
and Quarantine,  oversight of the overseas evaluation.  Updates are posted on 
CDC   the CDC website.  Refugee overseas documents now include  
the core form as well as extended worksheets to document 
findings that indicate need for follow-up care in the United 
States.   
 
For a detailed guide to the overseas examination, refer to the 
CDC website.  
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RHAP clinicians should keep in mind that the focus of the 
overseas visa medical examination is not to identify all the 
health conditions a refugee might have, but primarily to ensure 
that an individual does not have an excludable condition. 
Changes in health and disease exposures can occur in a 
refugee camp between the overseas medical and a refugee’s 
arrival in the United States.  
 
 
Refugees may not understand why they have to see a 
doctor now if they have recently seen one overseas and 
‘passed’ the medical examination. Explain that health 
status can change in the interval between exams. Also, 
the RHAP is for the benefit of the refugee and is more 
comprehensive than the overseas exam.  This is a good 
time to start introducing the concept of preventive care. 
 
 
PROGRAM    1.   Review overseas medical forms (DS-2054 Medical 
REQUIREMENTS         Examination; DS-3025 Vaccination; DS-3026 Medical  
History; DS-3030 Chest x-ray and TB Classification) and 
Pre-Departure Medical Screening findings. Review 
contents of the IOM Bag, if available. 
 
2. Record and evaluate Class A/B medical conditions 
identified during the overseas medical examination and 
documented on the DS-2054. 
 
 
All persons with a Class A/B TB condition require referral 
to a state-supported TB clinic. 
 
 
3. Confirm, or reject, overseas diagnoses.  If further 
evaluation is needed to confirm any diagnosis, refer the 
patient for evaluation as appropriate. 
 
4. Document receipt of pre-departure treatments (e.g., 
albendazole, ivermectin, praziquantel, and ACT) by 
checking the appropriate box. 
 
5. Assess immunization records carefully.  Doses received 
and dates should be analyzed.   Record valid doses in the 
IMMUNIZATIONS Section of the RHAP form.  Be sure to 
record the doses in the proper cells of the immunization 
table. 
 
6. Evaluate other medical records.  
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Access to overseas  Sites providing more than 50 refugee health assessments 
records prior to the first annually should have access to an electronic copy of overseas  
health assessment  medical records prior to a patient’s appointment through the 
appointment    MDPH  web-based disease surveillance and case  
management system known as MAVEN.  MDPH uses MAVEN 
to track newly-arriving refugees and to capture data related to 
outreach, case management, and health assessments.  
Overseas medical records are uploaded from the CDC shortly 
after a refugee’s arrival in Massachusetts and attached to the 
person’s record in PDF format.   
 
When a Resettlement Agency notifies MDPH of a refugee’s 
RHAP appointment, the individual’s record in MAVEN is 
released to the RHAP site.   
 
Note that delays in notification from CDC are not uncommon.  
In other cases, the overseas medical records are not available 
to MDPH through the CDC system (see below).   
 
MDPH faxes of overseas records to RHAP sites that do not 
have access to MAVEN.  RHAP sites can contact the MDPH 
RHAP coordinator to request additional information or training 
on the MAVEN system.    
 
What if overseas records  This may be due to one of the following situations: 
are not available? 
? Records not transmitted through the CDC notification 
system: There may be delays in processing of refugee 
documents. Ask the RHAP coordinator for assistance. 
Records for other RHAP-eligible individuals (derivative 
asylees, parolees) often do not come through the CDC 
notification system. Ask your patient if he/she has records 
available to bring in. In some cases, records are taken at 
the airport.  Persons granted asylum in the United States 
did not have an overseas medical examination.  
 
? No records available: Individuals such as asylees and some 
Cuban or Haitian parolees may not have completed 
screening prior to RHAP.  In these cases, on the RHAP 
form, the provider should check off that the DS-2054 was 
not reviewed.  The situation involving lack of immunization 
documentation is addressed in Section 3.8 of this manual. 
 
RESOURCES  Division of Global Migration and Quarantine
Centers for Disease Control and Prevention 
Atlanta, GA 
404-639-8100 
 
International Organization for Migration
Geneva, Switzerland 
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3.3 MEDICAL HISTORY AND PHYSICAL EXAMINATION 
 
 
PURPOSE   To perform a complete, detailed history and physical 
examination for all refugees to ensure diagnosis and treatment 
of conditions not previously detected as well as those treated 
previously but ineffectively. 
 
BACKGROUND  Refugees have diverse experiences with medical care prior to 
arrival in the United States.  During the recent years many of 
the newly-arrived refugees have received health services in 
urban settings either in home country or in the country of first 
asylum.  According to the UNHCR, about fifty percent of 
refugees live in urban areas and one third in camps. Some 
refugees may have received little or no medical care in the 
past.  While the RHAP is a screening program, clinicians 
should be cognizant that their assessment may be the first full 
medical evaluation for some of refugee patients.  Clinicians 
should therefore perform a general history and physical exam.  
It is recognized, however, that an extended history may not be 
necessary.  Instead, clinicians should focus on historical 
elements which may be particular for refugees.  These include, 
for example, migration history and history of trauma.  
 
     Clinicians should also recognize that the RHAP encounter may 
be a new cultural experience for refugees and will leave a 
profound first impression about health care in the United 
States.  As such, sensitivity toward the patient’s gender, 
culture, and similar issues is very important. 
 
Because of societal marginalization of applicants for asylum, 
many asylees will not have a regular source of medical care.  
As is done for refugees, RHAP clinicians should assess the 
asylee patient for access to and utilization of primary care.  
The primary care physician will be able to follow up on 
neglected health needs as well as those newly identified 
during the RHAP.  Some asylum recipients may already be 
well established in primary care, and resettlement agencies 
and RHAP clinicians will need to decide if a health assessment 
is appropriate for an individual asylee and his/her family.  
Under United States immigration law, asylum seekers must file 
their applications with the USCIS within one year from the date 
of last entry to the United States. Further, asylum applicants 
are not eligible for employment authorization until 180 days 
after the filing date of the asylum application. Consequently, 
current asylum recipients may have had fewer opportunities to 
engage in primary care before the RHAP.   
In some ways, the health status of asylees (especially those 
with derivative visas arriving from overseas) may resemble 
Medical History and Physical Exam 3.3.1
Updated October 2013                  MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE 
Section 3: CLINICAL PROGRAM 
 
that of refugees.  Asylees, like refugees, come to the United 
States often after having experienced significant psychological 
and physical trauma, particularly individual torture and rape 
victimization.  At the time of the health assessment, shortly 
after arrival, most refugees are not experiencing symptoms of 
acute psychological distress.  In contrast, psychological issues 
among asylees may be central in the struggles of their daily 
lives and compounded by the day-to-day challenges asylum 
applicants face.     
Like refugees, it is expected that asylees will have high 
prevalences of latent tuberculosis infection, dental caries, 
eosinophilia (as an indicator of parasitic infections), anemia, 
chronic diseases such as diabetes and hypertension, and 
underimmunization.  Some will also come from countries with 
endemic hepatitis B, HIV or parasitoses.  While some 
parasitoses are typically self-limited, others such as 
schistosomiasis and strongyloidiasis may present particular 
long-term health risks to the patient.  Parasitic infections may 
persist for years through transmission within refugee 
communities if not properly identified and treated. As is the 
case with refugees, asylee derivatives must complete a 
medical examination overseas. However, it is less likely that 
asylee derivatives receive pre-departure presumptive therapy 
for intestinal parasite or malaria.   
 
PROGRAM    In brief, the RHAP requires the following of providers: 
REQUIREMENTS    
1. Conduct a full, age-appropriate medical history and 
physical examination for all refugees. 
⇒ The history should be appropriate for the refugee 
experience and emphasize issues such as migration 
and trauma histories and overseas findings. 
⇒ History of adolescents and adults should include 
assessment of use of tobacco and alcohol, and other 
drugs as appropriate. 
⇒ Examination should be developmentally and age-
specific and include vital signs and anthropometric 
measurements. 
 
THE MEDICAL   The aim of taking the medical history is to record any  
HISTORY   significant past or current medical condition or disability, as  
well as preventive care such as immunizations and dental 
work, and document any relevant family history.  During this 
process, it may be possible to detect an obvious speech or 
hearing problem and to assess the patient’s mental status.  
Clinicians should try to be concise about the sequence of 
historical events as they may provide clues to the refugee 
patient’s risk for certain medical conditions, particularly 
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infectious diseases, psychological problems, and 
growth/nutritional abnormalities. 
 
1. BIOGRAPHICAL DATA  
? Brief family tree as appropriate 
? Migration history, including stays in refugee camps 
 
2. PRESENT HEALTH STATUS 
? Chief complaint, if any  
 
3. CURRENT HEALTH DATA 
? Current medications: Type 
Dosage 
Problems 
? Allergies:  Drugs, food, etc… 
? Last examination: Physical 
         Dental 
         Vision 
         Hearing 
         ECG 
         Chest X-ray 
         Pap smear 
? Immunization Status: Update, Due 
 
4.   PAST HEALTH STATUS 
 
Summarize and record chronological data as completely as 
possible.  The following list provides some examples for each 
category. 
 
? Child devel. milestones Speech, gross motor, fine motor,  
Socioemotional  
 
? Childhood illnesses Measles, rubella, mumps,  
pertussis, scarlet fever, chicken 
pox, strep. throat. Note: patient 
reports of a vaccine preventable 
disease other than chicken pox 
should never be used as proof of 
immunity. 
 
? Serious or chronic Malaria, chronic hepatitis,  
illnesses    hypertension, diabetes, 
tuberculosis, asthma,  kidney or 
cardiac problems, seizures, 
obesity, etc. 
 
? Serious physical trauma  Head injuries, fractures, burns,  
          trauma, torture 
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? Hospitalizations  Length of stay, and place 
 
? Transfusions  Dates, indications 
 
? Surgery   Year/age and place; female  
genital cutting, ritual scarring or 
branding 
  
? Dental care  Prophylaxis, restorative work,  
use of fluoride in water and 
toothpaste, brushing, use of 
traditional stick brush, flossing 
 
? Emotional stress/  Symptoms, diagnoses, 
  mental illness  treatments, loss of family, 
exposure to war/other violence 
(see #6 below) 
 
? Obstetrical hx  Number of pregnancies, births,  
still-births, abortions, 
complications 
 
5.  REVIEW OF SYSTEMS  
 
6.   PSYCHOSOCIAL AND TRAUMA HISTORIES 
 
Refugees are at very high risk for depression, anxiety, post-
traumatic stress disorder, and substance use.  Assess the 
patient’s feelings about him/herself, and ability to cope with 
resettlement: stress, losses, isolation, depression, insomnia, 
anorexia, drug/alcohol/smoking use and abuse, nightmares, 
flashbacks.   
 
In children, non-specific somatic or behavioral symptoms may 
indicate problems such as depression, adjustment disorder, or 
post-traumatic stress disorder.  These symptoms may include 
withdrawal, acting out, new fears, anorexia, somatic 
complaints, nightmares and sleep disturbances, separation 
fears, enuresis, or developmental regression. 
 
See Section 3.4 for more discussion of mental health and 
required use of the RHS-15 screening instrument.  
 
The RHS-15 and an instructional webinar recording (Part 1 
and Part 2) are available from the Refugee Health Technical 
Assistance Center. While the RHS-15 is validated for use in 
multiple refugee populations for assessment of adolescents 
and adults, most standardized questionnaires for children are 
not validated for refugee populations. Out of necessity, 
clinicians may consider using other questionnaires to assess 
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mental health status of younger refugees if concerned about 
possible emotional or behavioral abnormalities. Examples of 
brief questionnaires for children that are commonly used in 
primary care settings include the Pediatric Symptom Checklist 
(free) and the Parents’ Evaluation of Developmental Status 
(PEDS, licensed).  
 
 
THE PHYSICAL   The overseas medical evaluation is geared toward 
EXAMINATION  identifying excludable conditions in refugees.  It is not a 
AND REVIEW OF   comprehensive physical for preventive medical care. 
SYSTEMS   Consequently, the RHAP starts the process of 
comprehensive care with an emphasis on primary care and 
preventive medicine.  The physical exam should thus be 
general, not focused.  
 
During the examination, providers should be considerate of 
refugees’ cultural and religious beliefs and accommodate them 
as possible.  For example, an Islamic woman may not wish to 
be examined by a male physician.  The gender of the 
interpreters should similarly be considered, such that those of 
opposite gender from the patient may need to stand behind a 
curtain or screen, and that in some instances the patient may 
not wish to speak freely in front of an interpreter of different 
gender. 
 
General Fatigue, weakness, fever, sweats, 
frequent colds, infections or illnesses, 
ability to carry out activities of daily 
living, mobility, apparent anxiety, 
general hygiene, dress 
 
Nutritional Type of diet, hx of weight gain or losses, 
growth charts for children, body habitus 
 
Skin Skin lesions (wounds, sores, ulcers), 
tumors or masses, pruritus, edema, 
cyanosis, jaundice, nevi, 
hyper/hypopigmentation, scars (esp. 
consistent with torture, such as cigarette 
or electrical burn scars), pallor, tattoos, 
clinical signs of Hansen’s disease 
 
Head Headache, syncope, dizziness, hx or sx 
of trauma 
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Eyes Corneal opacity, cataracts, pterygium, 
nystagmus, jaundice, trauma;  
Visual acuity to be documented with the 
Snellen E chart 
 
Ears/mouth Otoscopy, inspection of mouth and 
throat, tooth loss, caries, ulcers, trauma 
 
Neck Node enlargement, masses, thyroid, 
stiffness 
 
Breast  Pain or tenderness, nipple discharge, 
lumps 
 
Cardiovascular Chest pain, palpitations, dyspnea on 
exertion, orthopnea  
Exam: murmurs, rubs, gallops, pulses, 
perfusion, edema, blood pressure, heart 
rate 
 
Respiratory Chronic cough, sputum production, 
night coughing, dyspnea on exertion; 
Exam: Presence of rhonchi, rales, 
wheezes, rubs, clubbing of extremities; 
TB symptoms: night fever, cough, 
weight loss, night sweats, hemoptysis 
 
Hematolymphatic Anemia, bleeding, fatigue, lymph node 
enlargement 
 
Gastrointestinal Abdominal pain, nausea, vomiting, 
diarrhea, constipation, jaundice, change 
in bowel habits, ascites 
Record recent dietary and travel history 
in the presence of diarrhea and other 
symptoms 
Exam: check for hepatosplenomegaly 
and masses 
 
Urinary Dysuria, pyuria, hematuria, 
incontinence, enuresis, 
polyuria/polydypsia 
 
Genital STD history, discharges, pain, pruritus, 
burning 
Female: LMP, menarche/menopause, 
bleeding, female genital cutting 
Male: scrotal lumps, testicular self-
examination 
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Musculoskeletal Muscles, extremities, gait, bones and 
joints, gross disfigurement, sx of trauma
Movement: gait, any limitation of 
movement or coordination, tremor, body 
symmetry 
 
Nervous System History of seizure, stroke, or speech 
problems, head trauma 
Evaluate cranial nerves, cerebellar 
function, sensorium, strength,   
reflexes, tone 
 
Endocrine Thyroid, diabetes 
  
 
 
Write abnormal findings in the COMMENTS/REFERRALS 
section of the RHAP form.  Because space is limited, do 
not record normal findings or non-specific symptoms that 
do not strongly suggest a probable diagnosis. 
 
 
NOTE ON    When performing a history and physical examination on 
CHILDREN   refugee children, it is important to remember that they will 
have the same levels of fear and anxiety encountered in U.S.-
born children of the same ages.  Attention should be paid to 
reassuring and calming the child as best as possible during 
the exam.  In addition, as refugee children are at high risk for 
developmental delay and behavioral issues, whenever 
possible, the provider should incorporate an assessment of the 
child’s developmental stage using standardized historical and 
exam milestones such as can be found in the Denver 
Developmental Screening Test* and the PEDS.  Lastly, it is 
known that refugee children have high prevalences of 
malnutrition and growth retardation.  Providers should use 
standardized growth charts* and refer families to WIC and 
other nutritional support programs for which they are eligible. 
 
*See DDST and NCHS growth charts.   
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3.5 TUBERCULOSIS 
 
 
 
 
PURPOSE   To ensure effective prevention and control of tuberculosis (TB)  
among newly arrived refugees in Massachusetts 
 
BACKGROUND TB is a major worldwide public health issue.  One-third of the 
world’s population is infected with Mycobacterium tuberculosis 
and TB is a leading infectious cause of death worldwide. For 
2011, the World Health Organization estimated 8.7 million new 
cases of active TB (125 per 100,000 population), with an 
estimated 13% co-infected with HIV. There were 1.4 million 
deaths from TB.  Refugees are at particularly high risk of 
exposure to tuberculosis.  In addition, progress in the 
response to multi-drug resistant strains of TB is slow.1   
 
For decades, TB rates declined steadily in United States but 
several complex social and medical factors caused TB 
morbidity to increase during the late 1980s into the mid 1990s, 
after which the decline of TB resumed. In 2012, 215 cases 
(case rate 3.2 per 100,000 population) of active TB disease 
were reported to and verified by the Massachusetts 
Department of Public Health, Division of TB Prevention and 
Control. Although the TB case rate increased in 2012, 
Massachusetts has had a decreasing trend in case rate from 
4.0 to 3.2 since 2008, representing a 19% decrease overall. 
Case rates in the United States have declined more steeply 
and, in 2012, the state and national rates aligned at 3.2. 
 
Non-U.S. born persons (defined as persons born outside the 
United States and its territories) remain the group at highest 
risk for TB disease in Massachusetts.  In 2012, 186 (87%) TB 
cases occurred in persons born outside the U.S.  Over the 
years, non-US born persons have accounted for an increasing 
proportion of the TB cases in Massachusetts from 35% in 
1984 to 87% in 2012. While the proportion of cases occurring 
among the non-U.S. born has increased the absolute number 
of such cases has been relatively stable since 2002.  
 
Transmission of TB is person-to-person through the air by 
droplet nuclei particles 1-5μm in diameter that contain M. 
                                                 
1 http://www.who.int/tb/publications/global_report/en/ 
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tuberculosis.  Droplet nuclei are produced when an individual 
with pulmonary or laryngeal TB coughs, sneezes, speaks or 
sings. 
 
Latent TB infection (LTBI) occurs when an individual is 
harboring M. tuberculosis in a latent (dormant) form contained 
by the immune system, but does not have systemic or local 
manifestations of tuberculosis disease.  Such individuals will 
usually have a positive TB test (tuberculin skin test [TST] or 
interferon gamma release assay [IGRA]). 
 
Disease occurs when there is an active process of bacterial 
replication and invasion of an organ or organs in an individual 
who is harboring M. tuberculosis.  The most common 
radiologic findings in pulmonary tuberculosis are upper lobe 
(often cavitary) lesions, increased density in the lung 
parenchyma (a "pneumonia") that may occur anywhere, and/or 
regional (hilar or mediastinal) lymph node enlargement.  Other 
findings can include other lymphadenopathy (particularly in the 
neck), pleural effusion, and lesions at other body sites. 
 
The tuberculin skin test (TST) is the only acceptable skin 
test for the diagnosis of LTBI. The test requires intradermal 
injection of 5 TU of PPD, a complex mixture of M. tuberculosis 
proteins by a trained provider, followed by measurement of 
induration at the skin test site after 48-72 hours.  An essential 
aspect of TST testing is that the induration also is measured 
by a trained health care worker (not a parent or relative). 
 
Interferon-gamma release assays (IGRAs) are approved 
blood tests for the diagnosis of LTBI. Two tests generally are 
available, the QuantiFERON®-TB Gold In-Tube test, and the 
T-SPOT.TB test. In most situations an IGRA may be used in 
place of, or in conjunction with, the TST to diagnose LTBI in 
children 5 years of age or older (see below). 
 
In accordance with the current American Thoracic Society 
(ATS) and Centers for Disease Control and Prevention (CDC) 
guidelines, Targeted Tuberculin Testing and Treatment of 
Latent Tuberculosis Infection, refugees are at high risk for 
developing TB disease and would benefit from treatment of 
latent TB infection, if detected.2
 
 
                                                 
2 American Thoracic Society. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit 
Care Med. 161:S221-S247. 
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PROGRAM    In brief, the RHAP requires the following of providers: 
REQUIREMENTS  
1. Review overseas medical examination forms for TB 
evaluations.  Review all immunization records for the 
date of the most recent live viral vaccination (MMR or 
varicella). 
 
Children and contacts evaluated overseas using the 
2007 Technical Instructions will have TST results 
documented on their overseas records. 
 
 
2. Test for TB using IGRA or TST at first visit, with IGRA 
being the preferred test for eligible individuals (see 
below for exceptions). Providers are responsible for 
IGRA or TST testing of RHAP patients to identify M. 
tuberculosis infection. 
 
Exceptions (no TB test required): 
? A positive TST or IGRA is documented on the 
overseas medical forms.  IGRA may be used to 
"confirm” a positive TST from overseas. 
? There is a clear, documented history of treatment for 
clinical TB disease on the overseas medical 
examination form. 
 
Exception to TB test at first RHAP visit: 
? Fewer than 28 days have elapsed since the most 
recent live viral vaccination. Schedule TB testing 
for the second visit or earlier if feasible.  
 
No exception to TB test: 
? Refugees with an overseas diagnosis of TB of any 
class based solely on an overseas chest x-ray 
should have IGRA or TST done.   
? Refugees with a documented negative TST 
overseas should have IGRA or TST repeated during 
the RHAP. 
 
Any deferral should be recorded on the RHAP form in 
the COMMENTS/REFERRALS Section.   
 
a) Administer TB test (IGRA or TST) if no exceptions 
 
IGRAs currently approved by the FDA for use in the 
United States include the Quantiferon TB Gold In-Tube 
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test (QFT-GIT) and T-SPOT. These tests measure the 
patient’s immune response after stimulation of white 
blood cells in a test tube or on a plate with 2-3 
relatively TB specific antigens. The interpretations are 
based on the amount of IFN-g that is released or on 
the number of cells that release IFN-g. 
 
Persons for whom IGRA tests are not 
recommended, should have a TST: 
a. Children < 5 years old 
b. Persons with the following medical conditions: 
diabetes mellitus, chronic renal failure, 
hematologic malignancy (e.g., leukemia) and 
other specific malignancies (carcinoma of the 
head or neck and lung). 
c. Health care workers and others who will 
undergo sequential or periodic testing 
TST should receive 0.1 ml of 5 tuberculin units (TU) 
PPD injected intradermally via the Mantoux technique 
and read by qualified personnel at 48-72 hours.   
 
Record the date the TST is planted, the date read, and 
diameter of induration in millimeters at the TST 
injection site across the forearm (perpendicular to the 
long axis) on the RHAP form.  Record the absence of 
induration as 0mm.  Erythema should not be 
measured.  Only one dimension (perpendicular to the 
long axis of the forearm) should be measured and 
recorded.   
 
 
When reading a TST, measure induration (not erythema) 
perpendicular to the long axis of the forearm (i.e. across 
the arm). 
 
 
 
3. Interpret the test results: 
 
IGRAs have a standard qualitative test interpretation 
that should be reported in the RHAP form: 
a. Positive - suggests that M. tuberculosis 
infection is likely 
b. Negative - suggests that infection is unlikely 
Tuberculosis 3.5.4
Updated October 2013                  MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE 
Section 3: CLINICAL PROGRAM 
c. Indeterminate or Borderline - indicates an 
uncertain likelihood of M. tuberculosis infection 
or test failure. Repeat IGRA or TST is needed. 
TST: The following are guidelines for interpreting TST 
results for newly arrived refugees. 
 
> 5 mm induration is considered positive for: 
• Persons who have had recent close contact 
with a known or suspected case of infectious 
TB 
• Persons with overseas chest x-rays consistent 
with active or previous TB 
• Persons with clinical evidence of TB 
• Persons with HIV infection or other 
immunosuppressive conditions 
 
> 10 mm induration is considered positive for: 
• Persons who, if infected, are at increased risk 
for progression to active TB because of specific 
clinical conditions3 
• Persons from TB endemic regions (i.e., Africa, 
Asia, Central America, South America, Mexico, 
Caribbean, Eastern Europe, Middle East). 
• Persons exposed to individuals who are HIV-
infected, homeless, users of illicit drugs, 
medically indigent city dwellers, residents of 
nursing homes, incarcerated or institutionalized 
persons, and migrant farm workers 
 
4. Refer all persons with positive TB test results and 
those with any overseas diagnosis or treatment of TB 
for TB evaluation. This evaluation must be performed 
at a state TB Clinic or approved alternative. 
a) Refer for TB evaluation as appropriate 
 
The role of the provider during the health assessment 
is to determine whether or not a patient (regardless of 
age or gender) should be referred for TB evaluation at 
a state TB clinic [See list of TB referral clinics] through 
the local health department or an approved alternative 
site. State TB clinics provide comprehensive, expert 
services to Massachusetts residents who require 
evaluation, treatment and follow-up for tuberculosis. 
                                                 
3  Diabetes mellitus, silicosis, gastrectomy/jejunoileal bypass, chronic renal failure, some hematologic disorders (e.g. leukemias 
and lymphomas) other specific malignancies (e.g., carcinoma of the head, or neck and lungs), weight loss of > 10% of ideal 
body weight 
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Refugees meeting any of the following criteria must be 
referred for TB evaluation: 
     
• Clinical evidence of TB disease 
• Abnormal overseas chest x-ray consistent with TB 
(Class A TB/Class B TB) regardless of the TST result 
• Treatment for active or latent TB started overseas 
• Positive IGRA or TST result (regardless of age, gender 
or overseas chest x-ray) either from testing overseas 
or during the RHAP 
 
All cases of suspected active TB must be reported to the 
Massachusetts Department of Public Health.   
To report TB, call: 
 
617-983-6813 
 
Latent TB infection is also reportable. The electronic 
reporting TeleForm is provided to all RHAP sites. 
 
     
Logistics for TB screening and evaluation vary in the state. 
Specific RHAP provider responsibilities are clearly outlined for 
each site in coordination with the Refugee and Immigrant 
Health Program. 
 
Note on BCG   The Massachusetts Department of Public Health, Division of 
Vaccination   Tuberculosis Prevention and Control IGRA guidelines note 
that the antigens used for the IGRA tests are not present in 
BCG vaccines, so false positive results due to prior 
sensitization to BCG do not occur. Thus, IGRA is the preferred 
test for individuals who have received BCG vaccine. 
 
    The Massachusetts Department of Public Health, Division of 
    Tuberculosis Prevention and Control, has an earlier policy 
statement on BCG and PPD.4  The policy states that TST 
reactions should be interpreted without regard to BCG history 
in almost all circumstances.  TST reactions of 10mm or more 
in adults or children who are from high prevalence countries 
are likely to be due to TB infection.   
 
The requirements of the RHAP are consistent with this policy, 
yet place an increased emphasis on acknowledging and 
discussing BCG.  Providers should obtain a BCG history, 
                                                 
4 BCG AND PPD. Policy of the Massachusetts Department of Public Health, Division of Tuberculosis Prevention and Control. 
September 6, 1986.  
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including age at vaccination and number of vaccinations, if 
possible.  Record the most recent BCG vaccination date on 
the health assessment form.   
 
Decisions around treatment for latent TB infection will take into 
account BCG history.  Providers may want to cover the 
following points relative to BCG:5
 
• BCG protects against the most severe forms of TB in 
infants and very young children.  Protection against TB in 
the lungs in both children and adults is not proven. 
• Nearly all countries where BCG is used have high rates of 
TB. 
• IGRAs do not cross-react with BCG, so false-positive tests 
due to sensitization to BCG antigens are unlikely to occur.  
• Positive TST reactions are generally not due to BCG: 
• Not all persons who are vaccinated convert their PPD; 
• The reaction to BCG is usually <10mm; and,  
• The sensitivity (reaction) wanes over time. 
 
TB Clinic Role  The purpose of TB clinics is to assess, evaluate, and  
determine treatment for all refugees with an overseas 
diagnosis of TB, abnormal overseas chest x-ray, or a positive 
IGRA or TST.   
 
Refugees for whom treatment for latent TB infection is 
recommended may be managed at the primary care site 
following initial evaluation at the TB clinic.  In such cases, the 
TB clinic will be available for further consultation. 
 
Treatment guidelines are outlined in the ATS/CDC statements 
on testing6 and treatment.7    
  
CHILDREN   Infants and young children with latent TB infection have, by  
definition, been infected recently. This places them at 
increased risk for progression to disease, especially if under 
the age of 5 years.  Further, infants and young children are 
more likely than older children and adults to develop severe 
forms of TB, e.g., TB meningitis or disseminated TB.  The risk 
for disease appears to decline after 5 years of age.  
 
Treatment for latent TB infection is effective and well-tolerated 
in children.  The recommended regimen for treatment in HIV-
                                                 
5 Centers for Disease Control and Prevention. The role of BCG vaccine in the prevention and control of tuberculosis in the 
United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on 
Immunization Practices. MMWR. 1996;45(RR-4). 
6 American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent 
tuberculosis infection. Am J Respir Crit Care Med. 2000;161:S221-S247. 
7American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Treatment of  
tuberculosis. Am J Respir Crit Care Med. 2003;167:603-662. 
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uninfected children is a 9-month course of isoniazid (INH) self-
administered daily or by directly observed therapy (DOT) 
twice-weekly.8 In the US, INH is available in liquid form only as 
a suspension formulated at 50mg/5ml in a sorbitol-based 
vehicle. Since sorbitol may cause diarrhea, crushed tablets 
suspended in something tasty to the child like pudding 
generally are preferred. 
 
As noted in the section on tuberculin skin testing and BCG, 
TST reactions over 10mm in young children are, under nearly 
all circumstances, interpreted as resulting from TB infection.  
Likewise, the decision to treat a young refugee child with latent 
TB infection is not affected by the history of BCG. 
 
According to current guidelines, IGRA is not recommended for 
children less than 5 years of age. 
 
TB diagnosis in children relies on TB test (IGRA or TST), chest 
radiography, and evaluation for clinical symptoms and signs, 
and often follows discovery of an adult case.  A child with a 
positive TB test, then, is a sentinel event potentially indicating 
an adult with active disease.  However, one may not 
immediately be able to determine if exposed children are 
infected because the development of delayed-type 
hypersensitivity to TB infection may take up to 3 months.  
Clinical symptoms are often nonspecific, and chest 
radiographs are difficult to interpret though they remain the 
most reliable tool for diagnosing tuberculosis in children.  
Because the diagnosis of TB in children is often made on 
clinical grounds, both over- and under-diagnosis are possible.  
Routine laboratory tests are not helpful.  Young children with 
disease rarely produce sputum as they are usually unable to 
expectorate voluntarily, and gastric aspirations result in a 
positive culture only 40 percent of the time.9  Recent attempts 
to induce sputum through inhalation of nebulized hypertonic 
saline and oropharyngeal suctioning have proven successful, 
but the technique is not yet in common practice. 
 
ELDERLY   Providers should get an accurate history of previous TB  
exposure and an accurate medical history, including history of 
TB disease.  There are co-existing medical conditions such as 
previous gastrectomy, diabetes mellitus, or on-going therapy 
with immunosuppressive drugs that may predispose 
reactivation of old infection or development of new foci of 
infection.  Providers should maintain a high index of suspicion 
when assessing the elderly. 
                                                 
8 TS/CDC/IDSA, 2003.  A
9 Khan EA, Starke JR.  Diagnosis of tuberculosis in children: increased need for better methods. Emerging Infectious Diseases. 
1995;1:115-123. 
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Many healthy elders react vigorously to PPD testing, 
especially if infected recently.  However, TB skin test reactivity 
declines with age; therefore, TB reaction may develop slowly 
and not peak until approximately 72 hours.  Furthermore, the 
TST reaction may be negative secondary to decline in delayed 
hypersensitivity with age.10   Two-step testing with a second 
test planted a week or more after an initial negative test with 
minimal or no induration on the first test may often be positive 
because the initial test triggered immune memory.  The 
second test, if positive, indicates true TB infection, most likely 
from many years earlier.  Note that 2-step testing is not a 
routine part of the refugee health assessment. 
 
The ATS/CDC guidelines on treatment of latent TB infection 
consider all persons at high risk for developing TB as 
candidates for treatment, regardless of age.  In addition to 
isoniazid, clinicians have treatment options with a less 
hepatotoxic drug regimen (i.e. Rifampin) that may be used with 
older patients. In select, high risk circumstances, a short 
course, 12 week regimen consisting of once-weekly INH and 
rifapentine administered by DOT may be considered as an 
alternative to daily INH or rifampin ( see: MDPH website 
guideline for 3HP).  
 
Predominant symptoms of TB disease in the elderly include 
unexplained weight loss, fevers, sweats at night, cough (often 
non-productive), and progressive dyspnea.  Treatment tends 
to be successful for pulmonary TB, though drug toxicity is 
higher among the elderly. 
 
PREGNANCY  The clinical presentation of TB in pregnant women is similar to 
that in non-pregnant women and pregnancy does not increase 
the risk of progression to active disease. Providers should 
question pregnant women about symptoms and proceed to 
test with IGRA or TST routinely.  If the TB test is positive, the 
woman should be referred to a TB clinic for evaluation. If the 
patient has symptoms of TB or if she falls into a high risk 
group (e.g. recent TST conversion by CDC critreia, infected 
close contact to an infectious case, immune compromised, 
insulin-dependent diabetes), a clinical evaluation with a chest 
radiograph (single PA view with shielding is sufficient) should 
not be delayed.  If the patient does not have symptoms or is 
not at high risk, the radiograph may be delayed until after the 
12th week of gestation. 
 
 
                                                 
10 American Thoracic Society/Centers for Disease Control and Prevention. Diagnostic standards and classification of 
tuberculosis in adults and children.  Am J Respir Crit Care Med. 2000;161:1376-1395. 
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TST and IGRA testing are considered valid and safe 
throughout pregnancy. 
 
 
A newly arrived pregnant refugee whose IGRA or TST is 
positive, with a normal chest x-ray, is a candidate for treatment 
of latent TB infection. The infant does not require special 
evaluation for TB if the mother is asymptomatic.   
 
A woman who has been diagnosed with active TB during 
pregnancy and has been culture-negative for 3 months before 
delivery poses little risk of infection to the newborn.  The infant 
should be evaluated following birth for signs of disseminated 
tuberculosis placental transmission by a trained pediatric 
specialist and have a TST placed at 3 month intervals but 
does not require further evaluation, unless the TST is positive.  
If the mother has not been culture-negative for three months 
before delivery, the child should be evaluated by a TB 
specialist for possible congenital disease.11   For care of the 
newborn, please refer to the 2012 Red Book: Report of the 
Committee on Infectious Diseases, 29th Edition, or seek 
consultation from an infectious disease specialist. 
 
ISSUES ASSOCIATED  While the understanding of TB by any group of people varies 
WITH TB   considerably and reflects the group culture and socio- 
economic status, the social stigma of TB is nearly universal. 
The belief that a positive TST is caused by BCG is a source of 
much confusion among refugees.  Refugees who are identified 
as infected or diseased may have a difficult time accepting the 
diagnosis, particularly if there are no symptoms.  It may ease a 
refugee’s anxiety to learn that a third of the world’s population 
is TB-infected and that infection could have occurred during 
their stay in an overcrowded refugee camp or during periods of 
unrest in their home country. 
 
An empathetic bond with a refugee who is newly-identified as 
having latent TB infection or TB disease will help encourage 
adherence with preventive and curative protocols.12   Cultural 
and behavioral factors affecting both parties, patients and 
providers, should be taken into account and an appropriate 
network of support and education should be provided to 
medical staff, patients and their families. Education should be 
aimed to empower people to understand the complex nature of 
TB and not just to promote adherence to medication regimens.  
 
                                                 
11 ATS/CDC/IDSA, 2003. 
12 Thorensen CE.  Overview. In: Matarazzo JD, Weiss SM, Herd JA, eds. Behavioral Health: A Handbook of Health 
Enhancement and Disease Prevention. John Wiley and Sons, 1984. 
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Socio-behavioral studies have demonstrated that people in 
developing countries tend to describe TB as a multi-causal 
and multi-factorial disease.13 As the disease can present in 
many ways and is greatly stigmatized around the world, 
symptoms are often attributed to other, more benign causes.  
Weight loss and fatigue can be attributed to hard work and 
lack of sleep.  Also, loss of weight, back pain, intermittent 
headache, coughing, fatigue, or rhinorrhea can be attributed to 
gripe (common cold) or susto (fright illness) in some Latin 
American cultures.  The same symptoms and signs can be 
attributed to piang, or weak lungs, in the Philippines and 
witchcraft in India.  Such cultural attributions should be 
acknowledged by the provider. 
 
 
RESOURCES  Division of TB Prevention & Control
Massachusetts Department of Public Health  
305 South Street, Jamaica Plain, MA 02130 
617-983-6970 
 
Division of TB Elimination
Centers for Disease Control and Prevention 
Atlanta, GA  30333 
404-639-8140 
 
International Union Against TB & Lung Disease
Paris FRANCE 
 
STOP TB Program
World Health Organization   
                                                 
13 Jaramillo E.  Anthropological issues and their impact on tuberculosis control in developing countries.  Paper presented at the 
International Union Against Tuberculosis and Lung Disease (IUATLD), North American Regional Meeting, Chicago, March 1-
2, 1996. 
Tuberculosis 3.5.11
Updated October 2013                  MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE 
Section 3: CLINICAL PROGRAM 
 
Hepatitis B  3.6.1 
 
 
3.6  HEPATITIS B 
 
 
 
 
 
PURPOSE   To reduce the risk of hepatitis B transmission by:  
• Identifying persons with hepatitis B infection 
• Providing risk reduction education and referring individuals 
with hepatitis B infection for follow-up care, and  
• Identifying and vaccinating susceptible contacts, children 
through 18 years of age, and high-risk adults 
 
BACKGROUND  The prevalence of hepatitis B virus (HBV) infection and 
patterns of transmission vary in different parts of the world.1   
Approximately 45% of global population lives in areas in which 
HBV is highly endemic (>8% prevalence of chronic HBV 
infection) and 43% lives in regions with intermediate 
prevalence of chronic HBV infection (2-7% prevalence of 
chronic HBV).  HBV infection is highly or intermediately 
endemic in much of Eastern Europe, Asia, Africa, the Middle 
East and the Pacific Islands.2  In the United States, 
approximately 0.4% of the general population is infected with 
HBV.   
 
Persons with chronic HBV infection are at risk for premature 
death from chronic liver disease (cirrhosis and liver cancer), 
affecting an estimated 25% of those chronically infected during 
childhood and 15% of those chronically infected after 
childhood.3 
 
In 2008, CDC published Recommendations for Identification 
and Public Health Management of Persons with Chronic 
Hepatitis B Virus Infection.4   
                                                          
1 Centers for Disease Control and Prevention. Health Information for International Travel. 2008.  See 
http://wwwn.cdc.gov/travel/yellowBookCh4-HepB.aspx  
2 Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons 
with chronic hepaitis B virus infection. MMWR. 2008;57 (No. RR-8):1-20. 
3 Recommendations of the Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive immunization 
strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. Dec. 8, 2006;55(No. RR-16):1-
33. See http://www.cdc.gov/ncidod/diseases/hepatitis/recs/index.htm  
4 Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons 
with chronic hepaitis B virus infection. MMWR. 2008;57 (No. RR-8):1-20. 
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Hepatitis B  3.6.2 
 
 
 
PROGRAM    In brief, the RHAP requires the following of providers: 
REQUIREMENTS    
1. Test for HBsAg and anti-HBs at the first visit. 
⇒ Serologies must be drawn before hepatitis B 
vaccine is administered. 
2. Initiate hepatitis B vaccination on the first RHAP visit for all 
children, and adults from countries of high or intermediate 
endemnicity or at risk for hepatitis B infection. 
3. Continue hepatitis B vaccination series on the second 
RHAP visit for those individuals whose serologies are 
negative. 
⇒ Initiate hepatitis B vaccination for those adults from 
areas where HBV is highly or intermediately 
endemic, whose serologies are negative and for 
whom vaccination was not begun at the first visit. 
4. Evaluate family and household members’ lab results and 
immunization status when an individual is diagnosed with 
hepatitis B infection, as household contacts are at risk of 
transmission of hepatitis B virus. If family or household 
member is found to be HBsAg positive and less than 5 
years of age, notify the MDPH Perinatal Program 
(617.983.6849). 
5. Document the need for follow-up HBV evaluation of HBV-
positive individuals as part of the primary care referral. 
6. Report positive HBsAg results to the Massachusetts 
Department of Public Health (fax lab report to 
617.983.6813) or local health department. Note if the 
individual is pregnant. If pregnant, notify the MDPH 
Perinatal Hepatitis B Program (617.983.6849). 
 
Testing for HBsAg and anti-HBs must be done at the first visit.  
Testing for IgM anti-HBc is limited for diagnosis of acute HBV 
infection in persons with clinical evidence of acute hepatitis or 
an epidemiologic link to a person with HBV infection.  
Vaccination should be initiated as described later in this 
section but should not precede the blood draw for serologies.     
 
The laboratories should use an FDA-licensed or FDA-
approved HBsAg test and should perform testing according to 
the manufacturer’s labeling, including testing of initially 
reactive specimens with a licensed, neutralizing confirmatory 
test.5 
 
                                                          
5 Ibid. 
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Hepatitis B  3.6.3 
 
 
EVALUATING   Serologic markers of HBV vary depending on whether the 
FINDINGS    patient is infected and the infection is acute or chronic. HBsAg can  
be detected as early as 1 or 2 weeks and as late as 11 or 12 weeks 
(usually 30-60 days) after exposure to HBV.  In persons who 
recover, HBsAg is no longer detectable in serum after a period of 
about 3 months.  Anti-HBs IgG becomes detectable during 
convalescence in patients who do not progress to chronic infection.  
The presence of anti-HBs antibodies following acute infection 
generally indicates recovery and immunity from reinfection.6  
Virtually all patients with past HBV infection will have core 
antibodies (anti HBc) as well, although this does not indicate 
immunity. 
 
During the second RHAP visit, review the lab results with your 
patient.  Determine if the patient is immune, a [likely] HBV 
carrier, or susceptible to infection.  Although chronic infection 
is confirmed by additional hepatitis B tests (see below), in the 
context of RHAP an individual with a positive HBsAg result is 
considered likely to be a carrier.  Proceed to educate, 
vaccinate, and refer to primary care as appropriate.   
 
 
When an individual with hepatitis B virus infection is 
identified, it is important to review other family and 
household members’ lab results and immunization status, 
as household contacts are at risk of transmission of 
hepatitis B virus. 
 
RHAP clinicians should note follow-up recommendations 
for family and household contacts as part of the primary 
care referral. 
 
 
  
REPORTING  Report hepatitis B. Note if the individual is pregnant or less  
than 5 years of age and report to the MDPH Perinatal 
Hepatitis B program (617 983-6849). 
 
 
RHAP providers must report certain diseases to either 
state or local public health officials.  Reporting on the 
RHAP form is NOT sufficient.  For more information on 
reportable conditions, go to the Mass.gov website 
regarding surveillance requirements.  
(105 CMR 300.00). 
  
 
                                                          
6 Recommendations of the Immunization Practices Advisory Committee. MMWR. Dec. 8, 2006;55(No. RR-16):1-33. 
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Hepatitis B  3.6.4 
 
 
 
INTERPRETING  The following charts summarize interpretation of individual  
RESULTS   and panel hepatitis B serologic tests. 
 
Interpretation of Individual Positive HBV Tests 
Serologic Test Interpretation Follow-up Needed 
HBsAg 
Hepatitis surface 
antigen positive 
Infectious.  If 
positive for more 
than 6 months, 
patient is a chronic 
carrier. 
Vaccinate family and/or 
close contacts.  Further 
serologies and LFT’s in 
follow-up care.  
Educate re: 
transmission and refer 
to physician 
experienced in 
management of chronic 
liver disease.  
IgM anti-HBc 
Hepatitis B IgM core 
antibody positive 
Recent infection 
Test for IgG anti-HBs  
Vaccinate contacts 
IgG anti-HBs 
(aka: anti-HBs or 
HBsAb) 
Hepatitis B surface 
antibody positive 
Immune by past 
infection or 
immunization 
Finish vaccine series if 
in process (i.e., 1 or 2 
doses received prior to 
test). Otherwise, no 
follow-up needed. 
IgG anti-HBc 
(aka: anti-HBc) 
Hepatitis B total core 
antibody positive 
Past infection.  Does 
not necessarily 
indicate immunity. 
Test for IgG anti-HBs 
HBeAg 
Hepatitis B e-
antigen positive 
Highly infectious 
Test for clearance, 
other serologies, LFT’s, 
and IgG anti-HBs 
 
Interpretation of Serologic Test Results 
Serologic Marker Interpretation 
HBsAg 
Total 
anti-
HBc 
IgM 
anti-
HBc 
Anti-
HBs 
 
- - - - Never infected and no evidence of 
immunization 
+ + - - Chronic infection 
+ + + - Acute infection 
- + - + Recovered from past infection and 
immune 
- +/- - + Immune (immunization or natural) 
 
The laboratory criteria for a diagnosis of acute HBV infection 
are a positive hepatitis B surface antigen result (HBsAg) AND 
Immunoglobulin M (IgM) antibody to hepatitis B core antigen (IgM 
anti-HBc) positive (if done).7  Positive HBeAg correlates with 
higher titers of HBV and infectiousness.   
                                                          
7 http://wwwn.cdc.gov/nndss/document/2012_Case%20Definitions.pdf 
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Hepatitis B  3.6.5 
 
 
 
The laboratory criteria for chronic hepatitis B are:  
? Immunoglobulin M (IgM) antibody to hepatitis B core 
antigen (IgM anti-HBc) negative AND a positive result on 
one of the following tests: hepatitis B surface antigen 
(HBsAg), hepatitis B e antigen (HBeAg), or nucleic acid 
test for hepatitis B virus DNA (including qualitative, 
quantitative and genotype testing) OR 
?  HBsAg positive or nucleic acid test for HBV DNA positive 
(including qualitative, quantitative and genotype testing) or 
HBeAg positive two times at least 6 months apart (Any 
combination of these tests performed 6 months apart is 
acceptable).8  
 
A chronic carrier should be considered infectious.  In the case 
of acute hepatitis B, prophylaxis is required for sexual 
contacts.  Hepatitis B immune globulin (HBIG) 0.06 ml/kg IM 
and hepatitis B vaccine can effectively prevent infection after 
exposure to the virus.   
 
EDUCATION FOR   HBV transmission occurs via percutaneous or mucosal 
HEPATITIS B   routes; infective blood or body fluids can be introduced 
CARRIERS   transplacentally or at birth, through sexual contact, by 
contaminated needles, and in some instances by casual 
household contact.  HBV is not transmitted via the fecal-oral 
route. 
 
Teach your patient about risk reduction measures: 
 
• Cover all cuts and open sores with a bandage. 
• Throw away used personal items such as tissues, 
menstrual pads, or tampons in paper bags. 
• Wash hands well after touching blood or body 
fluids. 
• Use condoms to protect non-immune sexual 
partners. 
• Clean up blood spills.  Clean the area with a bleach 
solution (1 part bleach and 9 parts water). 
• Do not share toothbrushes, razors, needles for ear 
piercing, earrings, nail files, clippers, scissors, or 
anything that may come in contact with blood or 
body fluids. 
• Do not donate blood, plasma, body organs, other 
tissues, or semen. 
 
Chronic carriers should be advised to have liver tests 
monitored regularly to determine whether disease is 
progressing (chronic active hepatitis) or treatment is needed.  
                                                          
8 Ibid. 
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Hepatitis B  3.6.6 
 
 
As part of the referral to primary care, note the need for follow-
up by a physician experienced in the management of chronic 
liver disease. 
 
If a sexual partner of a HBV carrier is not immune, discuss the 
use of condoms for sexual contact.  HBV carriers should also 
be encouraged to inform medical and dental care providers 
about their HBV status both to encourage proper infectious 
disease precautions and to ensure appropriate follow-up 
evaluation. 
 
VACCINATION  Current recommendations from MDPH call for the 
vaccination of all children through age 18 years and high risk 
adults.  The following are some adult high risk categories: 
 
• Refugees from hepatitis B endemic regions, such 
as Sub-Saharan Africa, Asia, the Middle East, 
Eastern Europe and Haiti 
• Household contacts and sexual partners of HBV 
carriers 
• Sexually active heterosexuals with multiple partners 
in the past 6 months or past STD 
• Sexually active men who have sex with men (MSM) 
• Residents of chronic or long-term care facilities 
 
 
To avoid missed opportunities for vaccination of all 
children and adult high-risk individuals, these individuals 
should receive the first dose of HBV vaccine at the first 
RHAP visit. Serologic testing must precede or be done 
concurrent to the vaccine dose; i.e., at the same visit as 
vaccination. If serologies show immunity, no further 
doses are needed. 
 
It is important to remember that individuals who received 
one or two doses of vaccine overseas may test positive 
for anti-HBs antibodies. These individuals should finish 
the full three-dose vaccine series. 
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Hepatitis B  3.6.7 
 
 
RESOURCES  Massachusetts Immunization Program 
Massachusetts Department of Public Health  
617-983-6800 
 
    Hepatitis B Coalition / Immunization Action Coalition 
St Paul, MN 55104  
612-647-9009  
 
Hepatitis Branch, CDC 
888-443-7232 
 
American Liver Foundation 
800-465-4837 
 
Asian Liver Center 
Stanford University School of Medicine 
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3.6 PARASITIC INFECTIONS 
 
PARASITIC INFECTIONS (Stool O & P): Record treatment in the “Medications Prescribed” section. 
____ None Identified  __ Ascaris  ___ Giardia  ___Strongyloides  Giardia FAb:              __Neg __Pos 
___Blastocystis   ___ H.nana  ___Trichuris     Cryptosporidium FAb: __Neg __Pos 
___E.histolytica   ___Hookworm  ___Other 
_______________________________________ 
 
 
PURPOSE   To identify and treat intestinal parasite infections  
 
 
BACKGROUND  The worldwide prevalence of parasitoses is staggering. It is  
estimated that one quarter of the world’s population may be 
infected by soil-transmitted nematodes such as round worms, 
hookworm, and whipworm.15 Over one billion persons 
worldwide are estimated to be carriers of Ascaris.  
Approximately 480 million people, or 12% of world population, 
are infected with Entamoeba histolytica.16  At least 500 million 
carry Trichuris (whipworm).  At present, 200 to 300 million 
people are infected with one or more of Schistosoma species, 
and it is estimated that more than 20 million persons 
throughout the world are infected with H. nana.17 Giardia 
lamblia infects between 2 – 8% of the developing world’s 
population.18 The enormous morbidity from parasitoses is a 
reflection of the number of people infected.  Consequences of 
parasitic infection include anemia due to blood loss and iron 
deficiency, malnutrition, growth retardation, invasive disease, 
and death.   
 
Parasitic infections are frequently detected in refugees; 
however, the types of organisms found will vary with the 
geographic origin of the refugee. It is important to note, 
however, that most refugees are asymptomatic carriers of 
parasites. Consequently, the imperative for testing and treating 
refugees is to prevent long-term sequelae to the refugee and 
prevent transmission in the U.S. Refugees from tropical 
countries typically have mixed helminth and protozoan 
infections, while refugees from the former socialist countries of 
Eastern Europe and the former Soviet Union typically have 
protozoan infections.  
 
In 2001, the CDC implemented a program of pre-departure 
empiric treatment for refugees in Sub-Sahara Africa. This 
                                                 
15 Chan MS. The global burden of intestinal nematode infections – fifty years on. Parasitol Today. 1997;13:438-448. 
16
 Bruckner D. Amebiasis. Clinical Microbiology Reviews. 1992;5:356-369. 
17 Katz M, Et al. Parasitic Diseases, Second edition. Springger-Verlag, 1989.  p 96. 
18 Gardner TB, Hill DR. Treatment of giardiasis. Clinical Microbiology Reviews. 2001;14:114-128. 
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treatment entails a single 600 mg oral dose of albendazole. 
Since implementation of this program, RIHP has documented 
dramatically decreased prevalences of intestinal parasites 
(particularly helminths) among African refugees.19 Prior to this 
program, the most common pathogens found in refugees 
resettled in Massachusetts were Giardia (45% of pathogenic 
parasites identified), Trichuris (whipworm, 33%), E.histolytica 
(9%), and Ascaris and hookworm (each 5%).  Subsequent to 
the empiric treatment program, overall prevalence of helminth 
infections declined from 24% to 4% among African refugees. 
The odds of having a helminth infection in African refugees 
who have had pre-departure treatment with albendazole is 
now only 15% that of refugees who arrived prior to the 
program implementation. 
 
In 2008, CDC developed new guidelines for overseas 
presumptive treatment of intestinal parasites and domestic 
evaluation.  The overseas recommendations are summarized: 
? All South and Southeast Asian refugees [some exceptions 
noted] should receive presumptive therapy with a single 
dose of albendazole (400 mg, 200 mg for children 12-23 
months) and ivermectin, 200 μg/kg orally once a day for 
two days, prior to departure to the United States. 
? All African refugees who are not at risk of Loa loa infection 
[some exceptions noted] should receive presumptive 
therapy with a single dose of albendazole (400 mg for 
adults and children older than 23 months, 200 mg for 
children 12-23 months) and ivermectin, 200 μg/kg orally 
once a day for two days, and praziquantel, 40 mg/kg 
divided in two doses, prior to departure to the United 
States. 
? All African refugees who are at risk of Loa loa infection 
[some exceptions noted] should receive presumptive 
therapy with a seven-day course of albendazole (400 mg 
orally twice a day) and praziquantel, 40 mg/kg divided in 
two doses, prior to departure to the United States. 
 
The domestic guidance is based on implementation of the 
overseas treatment recommendations. 
 
Finally, malaria is increasingly an important issue among 
refugees resettled in the U.S. Recent literature20,21 has 
documented a high prevalence of malaria among recent 
                                                 
19 Geltman PL, Cochran J, Hedgecock C. Intestinal parasites among African refugees resettled in Massachusetts and the 
impact of an overseas pre-departure treatment program. Am J Trop Med Hyg. 2003;69:657-662. 
20 Maroushek SR, Aguilar EF, Stauffer W, Abd-Alla MD. Malaria among refugee children at arrival in the United States. Pediatr 
Infect Dis J. 2005;24:450-452. 
21 Ndao M, Bandyayera E, Kokoskin E, Gyorkos TW, MacLean JD, Ward BJ. Comparison of blood smear, antigen detection, 
and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in 
Quebec, Canada. Journal of Clinical Microbiology. 2004;42:2694-2700. 
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refugee arrivals from Africa. Among symptomatic cases, the 
triad of fever, splenomegaly, and thrombocytopenia were 
highly specific for malaria. Of note, a fairly high proportion of 
children with malaria were asymptomatic. In the report by 
Maroushek et al., 29% of those with malaria were 
asymptomatic. Because of the predominance of P. falciparum 
in most of Africa, individuals often will develop some immunity 
over time, thus reducing symptoms. This is not the case with 
other forms of malaria that predominate in other parts of the 
world, in particular Southeast Asia.  Pre-departure treatment 
with Fansidar is likely to be ineffective due to high rates of 
resistance to that drug.22  
 
CDC recommended pre-departure presumptive treatment 
against P. falciparum malaria using artemisinin-based 
combination therapy (ACT) with artemether-lumefantrine for 
refugees from sub-Saharan Africa.  The 2008 CDC guidelines 
for overseas and domestic presumptive treatment of malaria 
are available from the Division of Global Migration and 
Quarantine.  
 
PROGRAM    In brief, the RHAP requires the following of providers: 
REQUIREMENTS 
1. Collect a single stool sample from each refugee. 
⇒ For those refugees returning for TST reading in 48-
72 hours, provide the stool collection kit at the first 
visit and request return at the time of the TST 
reading. 
⇒ Order O&P and fluorescent antibody testing for 
Giardia and Cryptosporidium. 
2. Consider presumptive treatment for strongyloides, 
schistosomiasis or malaria per recommendations detailed 
below. 
3. Review positive findings in the context of families; consider 
presumptive treatment of negative individuals. 
4. Provide needed anti-parasitic medication at the second 
visit; earlier if clinically indicated. 
5. Report positive Cryptosporidium, Giardia, E. histolytica and 
other reportable enteric results to the Massachusetts 
Department of Public Health (fax lab report to 
617.983.6813) or local health department. 
 
First visit   Because of the continued risk of protozoan infections, all 
refugees should have a single stool sample screened for ova 
and parasites (O&P) and fluorescent antibody testing for 
Giardia and Cryptosporidium.  Instruct the refugee on actual 
specimen collection and give kits to patients.  Instruct the 
                                                 
22 Centers for Disease Control. Malaria in refugees from Tanzania -- King County, Washington, 2007. MMWR. 2008;57:869-
872. 
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refugee patient to bring back stool in 2-3 days, preferably 
when she/he is coming for the PPD reading.  The stool results 
should be available for the second visit. 
 
Because of reports of high prevalence of asymptomatic 
parasitemia among African refugees, in FY2007, RIHP 
required malaria smears for all refugee arrivals from Sub-
Saharan Africa. This testing failed to detect unsuspected 
cases of malaria and was discontinued for FY2008. Instead, 
clinicians should assess refugees from Sub-Saharan Africa 
and other regions with endemic malaria for signs or symptoms 
suggestive of acute or chronic malaria (e.g. fever, 
splenomegaly, and thrombocytopenia). Consider ordering 
malaria thick and thin blood smears for these patients. RIHP 
encourages clinicians to test refugees liberally as the 
Maroushek study found that no symptom, either alone or in 
combination with another symptom, was predictive of the 
presence or absence of malaria. Results of the malaria smear 
should be reported on the targeted testing form. 
Documentation should include treatment as well.  
 
As always, RIHP requires RHAP clinical sites to obtain and 
provide anti-parasitic medication to refugee patients deemed 
eligible for outpatient treatment of uncomplicated malaria. 
Treatment should not be deferred until the second visit, as 
may be done for asymptomatic intestinal parasites. Guidelines 
for treatment of malaria are in Appendix 6.3 and include 
criteria for determining severity level and eligibility for 
outpatient treatment.  
 
 
 
24-hour malaria consultation is available from the  
Centers for Disease Control and Prevention 
at 770-488-7788 during weekday business hours 
and by page at 770-488-7100 after hours and on 
weekends and holidays. 
 
 
 
Alternatively, clinicians may consult local infectious disease 
specialists with expertise in the treatment of malaria. 
 
 
Empiric Treatment of Because surveillance data suggest a high prevalence of 
Strongyloides and   occult infection with Strongyloides stercoralis and 
Schistosome   Schistosoma species among Somali Bantu and Southern  
Sudanese refugees, the CDC has issued guidance regarding 
presumptive treatment of recently arrived Sudanese and 
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Somali Bantus for strongyloidiasis and schistosomiasis. The 
full text of this guidance can be found on the website of the 
CDC’s Division of Global Migration and Quarantine.  
 
The CDC guidance recommends that in the absence of 
evidence of cysticercosis; history of seizures not evaluated for 
neurocysticercosis; pregnancy; or lactation; the preferred 
treatments are as follows: 
 
Strongyloidiasis:  
 
? Somali Bantu: If > 15 kg, treat with ivermectin 200 
mcg/kg, by mouth, once; if < 15 kg but > 1 year of age, 
treat with albendazole 400 mg, by mouth, two times per 
day, for 7 days. 
? Sudanese: if > 1 year of age, treat with albendazole as 
above. 
 
Schistosomiasis: 
 
? Somali Bantu and Sudanese: If > 4 years of age, treat 
with praziquantel in two doses of 20 mg/kg, by mouth, 
given 6-8 hours apart. 
 
For Sudanese refugees, the CDC guidance recommends 
use of the alternative regimen of albendazole for the 
presumptive treatment of strongyloidiasis because 
Southern Sudan falls within the geographic distribution of 
Loa loa infection. Rarely, individuals with concurrent loiasis 
may develop encephalopathy after taking ivermectin. 
 
RHAP clinicians are encouraged to follow these 
recommendations until the CDC implements a pre-departure 
treatment program overseas. RIHP will reimburse RHAP sites 
for these three medications for new arrivals.  
 
Clinicians may also opt to test newly arrived refugees for 
evidence of these infections. Most academic and commercial 
reference laboratories can perform accurate serologic testing 
for Strongyloides; however the estimated prevalence in these 
populations is high enough for the CDC to recommend 
treatment without testing. Presumptive treatment is 
particularly appropriate for strongyloidiasis because the 
surveillance data are derived from serologic testing that 
indicates an active infection. Occult infection could place a 
refugee at risk of developing disseminated strongyloidiasis 
under certain circumstances.  
 
Unlike for Strongyloides, a positive serologic test for 
Schistosoma is not specific for active infection; therefore, 
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rather than treating patients presumptively, clinicians may 
prefer to test patients with clinical findings suggestive of active 
schistosomiasis (e.g. hematuria or eosinophilia). Testing for 
Schistosoma infection can be unreliable however. Clinicians 
wishing to test for schistosomiasis should arrange for 
specimens to be sent to the CDC through the State Laboratory 
Institute. 
 
Lastly, because these infections are endemic throughout most 
of tropical Sub-Saharan Africa, RIHP recommends 
implementation of this guidance with other refugees from 
Africa, such as Liberians, other West Africans, and majority-
clan ethnic Somalis. RIHP encourages clinicians to 
consider presumptive treatment of all new arrivals from 
Sub-Saharan Africa until pre-departure treatment 
programs are implemented overseas. The choice of 
treatment regimen is at the clinician’s discretion. A list of 
countries with endemic loiasis follows below as a guide for 
clinicians to determine which treatment regimen is appropriate 
based on whether the refugee’s country of origin has a high 
prevalence of loiasis: 
 
Countries Endemic for Loa loa Infection 
Angola, Benin, Cameroon, Central African Republic, (Chad, 
southern half of country), Congo, Democratic Republic of 
Congo (formerly Zaire), Equatorial Guinea, Gabon, Nigeria, 
Sudan (Western and Southwestern parts of Darfur, Bahr El 
Ghazal, and Equatoria Provinces). 
  
Countries with Isolated Cases of Loiasis: 
Ethiopia, Guinea, Ivory Coast, Liberia, Malawi, Sierra Leone, 
Uganda, Zambia 
 
Between visits  Review lab results.  Write and pre-fill prescriptions for 
medications to treat pathological intestinal parasites. Prescribe 
through a pharmacy affiliated with your program to ensure that 
the patient is not billed for antiparasitic medications. 
 
Second visit   Describe the findings to the patient.  If test results are positive 
for a pathological parasite, discuss treatment with your patient.  
Give the pre-filled medication to the patient and describe how 
to take medications.  Single dose medications should be taken 
at the clinic visit whenever possible.  Discuss the need for 
follow-up.  In addition, clinicians have the option of testing up 
to 2 additional O & P’s and serologic testing for helminths and 
filaria for patients with eosinophilia or other clinical findings 
suggestive of parasitoses. 
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EVALUATING  The health assessment program requires examination of 
FINDINGS   stool to detect parasites. If parasites other than those listed 
on the health assessment form are identified, please list by 
name under “Other.” 
 
Decisions concerning management of an individual patient 
require experience with the different clinical characteristics of 
the various parasitic infections.  The usual sites of the parasite 
infection in the host are often apparent, but certain parasites’ 
life cycles will take them to other parts of the human body 
where they may or may not cause symptoms.  The existence 
of a tissue-invasive parasite should be considered in patients 
with peripheral eosinophilia. 
 
The geographic distribution of parasitic infections is varied, 
and knowledge of distributions is of great value to knowing 
what to look for in a patient.  Information such as refugee 
migration, food habits, lack of shoes, lack of potable water, 
quality of sanitation, and history of insect bites are helpful in 
ruling-out or -in parasitic infections.  Tissue invasion may 
produce fever, headache, pain, chills, nausea and vomiting.  
Pressure from growing parasites may give rise to pain.  In the 
brain, parasitic infection might cause various motor and 
sensory abnormalities, including seizures.  Parasites may 
obstruct the intestine, bile ducts, lymph channels, and 
capillaries of the brain and other organs causing serious 
problems.  Extensive anemia may be produced by red cell 
destruction, blood loss, or suppression of hematopoiesis. 
 
 
Clinicians are reminded to comply with the Commonwealth’s 
regulations regarding reporting of certain diseases to either 
local or state public health officials as required by state 
regulations  
(105 CMR 300.00).  
The list of infectious diseases reportable by law as well as other 
resources related to reporting are on the DPH web site. 
 
 
The following is a brief guide to the life cycle, pathology, 
symptomatology, and treatment of parasites most 
commonly seen in refugee populations: 
 
Ascaris Ascaris lumbricoides (Roundworm) 
 
Ascaris is the largest intestinal roundworm in humans (8-12 
inch in length). Infections are common world-wide, but mostly 
in the tropics, in areas with poor sanitation, and wherever 
human feces are used as fertilizer.  Nonspecific 
gastrointestinal symptoms are reported in some patients.  If 
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the infection goes untreated, adult worms can live for as long 
as 12 to 18 months.  Patients with multiple parasites 
including Ascaris should always receive treatment for 
Ascaris first, due to the risk of migration of the worm in 
response to noxious stimuli.23
 
Blastocystis   Blastocystis hominis (Protozoan) 
 
Blastocystis is present in many healthy, asymptomatic 
individuals with stool microscopy showing fewer than three 
trophozoites per high powered field. It is often considered non-
pathogenic. Infrequently, any of the following symptoms may 
occur: mild diarrhea (two to four soft stools per day), 
abdominal pain, nausea, anorexia, fatigue, bloating, cramps, 
or alternating diarrhea and constipation.24  Treatment should 
be reserved for immunocompromised patients who are 
symptomatic and in whom no other pathogen or process is 
found to explain gastrointestinal symptoms. 
 
Clonorchis Clonorchis sinensis  (Fluke) 
 
Clonorchis is commonly known as the Oriental liver fluke.  
Humans get infected by eating uncooked fish containing 
infectious metacercariae and by ingestion of cysts in drinking 
water.   The parasites live in the distal bile ducts and irritate 
them by mechanical force and toxic secretions.  Depending on 
the severity of the infection (may be up to thousands of 
worms), the liver may become enlarged and tender.  The bile 
ducts gradually thicken, becoming dilated and tortuous.  
Adenomatous transformation of the biliary epithelium 
develops.  Light infections, however, may produce only mild 
symptoms or go unrecognized.  As additional worms are 
acquired, indigestion and epigastric discomfort (unrelated to 
meals), weakness, and weight loss become noticeable.  In 
heavy infection, anemia, liver enlargement, slight jaundice, 
edema, ascites, and diarrhea also develop.  In late stages, 
tachycardia, palpitations, vertigo and mental depression may 
ensue.25
 
E. histolytica Entamoeba histolytica (Protozoan) 
 
Entamoeba histolytica occurs in both pathogenic and non-
pathogenic strains.  Pathogenic strains may penetrate the 
epithelial tissue of the colon causing ulceration (amebic 
dysentery).  In some cases, organisms that reach the liver by 
the portal bloodstream produce abscesses (hepatic 
                                                 
23 Red Book 2006. pp 218-219. 
24Red Book 2006. pp 231-232. 
25 Brown, pp 222-225. 
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amebiasis).  The onset of symptoms of amebic liver abscesses 
can be abrupt or insidious.  Fever and localized abdominal 
pain are almost always present.  Right shoulder pain usually 
indicates referred pain from diaphragmatic irritation.  The liver 
is usually tender to palpation.  In a fraction of these cases, 
amoebae may spread to other organs such as the lungs, brain, 
kidney or skin, with a high fatality rate.26
 
Giardia Giardia lamblia (intestinalis)  (Protozoan)   
 
Giardia  is a flagellate protozoan that exists in trophozoite and 
cyst forms; the cyst form is resistant to drying and other 
environmental effects and is infectious. Infection is limited to 
the small intestine and/or biliary tract.  It is transmitted through 
food and water contaminated by sewage, food handlers with 
poor hygiene, and through other fecal-oral routes.  Infection is 
more common in children than in adults, particularly in the 6-
10 year age group.  Patients with clinical illness may develop 
acute watery diarrhea with abdominal pain, or they may 
experience a protracted, intermittent, disease which is 
characterized by passage of foul-smelling diarrhea or soft stool 
associated with flatulence, abdominal distention, and 
anorexia.27
 
Hookworms   Ancylostoma duodenale and Necator americanus
 
Hookworm eggs are passed in the stool and then hatch in 
warm, moist soil, releasing rhabditiform larvae that develop 
within a few days into filariform larvae.  No free-living adult 
forms exist.  Filariform larvae invade the skin and migrate 
through venous blood to the heart and then the lungs, where 
they penetrate into alveoli and migrate via the trachea into the 
gastrointestinal system.  Once the larvae reach the small 
intestine, they mature into adults that attach themselves to the 
duodenal and jejunal mucosa where they suck blood. The 
worms produce an anticoagulant that causes blood to ooze 
around the feeding worm, leading to blood in the stool and on-
going blood loss. Clinical manifestations are complaints of 
hunger and nondescript abdominal pain. Severe cases can 
lead to anemia. Children with significant worm loads may 
experience growth retardation and inanition.28
 
H. nana   Hymenolepis nana (Dwarf tapeworm) 
 
Tapeworms, or cestodes, are hermaphroditic flatworms 
composed of a scolex, or head, that attaches itself to the 
                                                 
26 Red Book 2006. pp 204-206. 
27 Red Book 2006. pp 296-301. 
28 Brown, pp 119-125 and Red Book 2006, pp 374-375. 
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intestinal mucosa where a chain of progressively mature 
segments (proglottids) containing the reproductive parts 
produce ova.  Adults live in the gut lumen of the definitive host.  
These worms have no gut and absorb nutrients across their 
integument. Larval forms encyst in the tissues of intermediate 
hosts.  H. nana uses the human as both definitive and 
intermediate host.  It is transmitted directly from hand to mouth 
and, less frequently, by contaminated food or water, and, 
possibly, by insect intermediate hosts.  The unhygienic habits 
of children favor the prevalence of the parasites in the younger 
age groups.  The worm's habitat is in the upper two-thirds of 
the ileum with a life span of several weeks. 
 
The ability of H. nana to autoinoculate may lead to very heavy 
worm loads (as many as 2000 worms) and to cramping pain, 
diarrhea, nausea and vomiting, and headache.  Intestinal 
erosions may occur.  In children, heavy H. nana infestation 
may be associated with lack of appetite, abdominal pain with 
or without diarrhea, anorexia, vomiting, irritability, and rarely, 
seizures. These neurologic manifestations have been ascribed 
to absorption of toxic substances produced by the worms.29
 
Schistosoma Schistosoma species
 
Schistosomiasis encompasses three distinct phases of clinical 
manifestations and on a worldwide scale is one of the most 
common causes of hematuria.  Individuals exposed to various 
Schistosoma sp. trematodes will initially experience a pruritic 
papular dermatitis after penetratrion of the skin by cercariae.  
With non-human pathogen species, this is referred to as 
“swimmer’s itch,” and can be contracted from fresh and salt 
water.  Human pathogenic species include the following:  
S. mansoni, S. japonicum, S. haematobium, S. mekongi, and 
S. intercalatum. These species rely on the presence of a fresh 
water snail as vector and have various geographic 
distributions.  S. mansoni is found mainly in tropical Africa, 
Latin America, the Caribbean, and the Arabian peninsula.   
S. haematobium is found mainly in Africa and the eastern 
Mediterranean area.  S. mekongi and japonicum are found 
mainly in the Mekong River delta and in parts of China, the 
Philippines, and Indonesia respectively. 
 
After skin penetration, the organism migrates through the 
blood stream via the lungs before ultimately lodging in the 
venous plexus draining the bladder (hematobium) or the colon.  
Following a period of 4-6 weeks, an acute illness 
(characterized by fever, malaise, cough, rash, abdominal pain, 
                                                 
29 Brown H, Neva F. Basic Clinical Parasitology. Appleton-Century-Crofts, 1983.  pp 179-181; and Red Book 2006, pp 646-
648. 
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nausea, diarrhea, lymphadenopathy, and eosinophilia) ensues 
and is termed “Katayama fever.”  With heavy gastrointestinal 
infestations, bloody diarrhea and tender hepatomegaly may 
occur.  Chronic disease reflects the worm burden and fibrosis 
with inflammation at the sites of deposited eggs.  Infected 
individuals may be asymptomatic with light infestations.  
Heavy colon involvement may cause chronic bloody, mucoid 
diarrhea, abdominal pain, hepatosplenomegaly, ascites, and 
esophageal varices (due to portal hypertension).  Bladder 
symptoms related to inflammation and fibrosis may include 
dysuria, terminal hematuria (microscopic or gross), secondary 
UTIs, and pelvic pain.        
 
Infections by S. mansoni and other species affecting the GI 
tract are diagnosed by microscopy of concentrated stool 
specimens.   Infections by S. haematobium are diagnosed by 
microscopy of filtered urine.  Egg excretion peaks at 12-3:00 
PM.  Mucosal biopies may be necessary for diagnosis, and 
serologic testing is available. 
 
Strongyloides  Strongyloides stercoralis (Roundworm) 
 
S. stercoralis is usually excreted in the stool as a rhabditiform 
larva.  The rhabditiform larva molts into an infective filariform 
larva (about 700 µm) after a couple of days in the soil.  The 
filariform larvae may penetrate the human skin and migrate in 
the same manner as the hookworms.  When larvae reach the 
upper part of the small intestine, they develop into adults.   
The rhabditiform larvae also may develop into sexually mature 
free-living males and females in the soil.  This indirect cycle 
appears to be associated with the optimal environmental 
conditions for a free-living existence in tropical countries.  
Autoinfection and maintenance of the disease may occur 
(despite removal of the host from an endemic area) when 
rhabditiform larvae develop into filariform larvae in the gut 
lumen.30  
 
Most patients with strongyloidiasis are asymptomatic.  A heavy 
worm load can lead to epigastric pain, weakness, malaise and 
watery diarrhea, perhaps due to an absorptive defect. Upper 
gastrointestinal radiographic studies may show duodenal and 
jejunal mucosal edema. Ulceration, and even intestinal 
perforation may occur.  The hyperinfection syndrome can be 
an overwhelming systemic disease and is often fatal.  
Extensive migration of larvae can lead to derangement of 
multiple organs, secondary bacterial abscesses in the liver and 
other organs, and development of adult worms in the bronchial 
tree.  Strongyloidiasis can be diagnosed by demonstrating 
                                                 
30 Brown, pp 115-119; and Red Book 2006, pp 629-631. 
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larval forms in the stool or parasites in duodenal aspirates or 
biopsies and is suggested by blood tests that show 
hypereosinophilia of greater than 30% without obvious clinical 
correlation.31
 
Trichuris   Trichuris trichiura (Whipworm) 
 
Prior to the CDC’s overseas empiric treatment program, 
Trichuriasis was the second most common intestinal 
parasitosis diagnosed during the RHAP. The embryonic 
development of Trichuris takes place outside the host.  An 
unhatched, infectious first stage larva is produced in three 
weeks in a warm, moist, and shaded soil environment.  When 
the egg is ingested by humans, the activated larva escapes 
from the weakened egg shell in the upper small intestine and 
penetrates an intestinal villus. Trichuris lives primarily in the 
human cecum, but is also found in the appendix and lower 
ileum.  Clinical manifestations are usually absent in light 
infections; in heavy or chronic infections, abdominal pain and 
tenderness, frequent blood-streaked diarrheal stools, nausea 
and vomiting, weight loss and anemia may occur.32  
 
 
Common Non-Pathogenic Blastocystis hominis (see above) 
Parasites   Dientamoeba fragilis (may treat with Paromomycin if 
symptomatic and no other etiology – see table for 
Entamoeba histolytica treatment) 
Endolimax nana 
Entamoeba coli 
Entamoeba hartmanni 
Iodamoeba butschlii 
 
 
Other Common Parasites Lice and scabies are two common arthropod parasites 
Lice, Scabies often found in refugee populations.  MassHealth covers 
both over-the-counter permethrin and lindane; in addition, if 
prescribed by a RHAP provider, the RHAP will reimburse sites 
and affiliated pharmacies for permethrin for refugees who have 
not yet received their MassHealth cards.  Preferred treatment 
of lice is permethrin 1% cream rinse (“Nix”)33 with removal of 
nits.  Scabies also should be treated but with permethrin 5% 
lotion (“Elimite”)27 in a single overnight application with 
instructions about careful hygiene and simultaneous 
household cleaning.  Symptomatic treatment of pruritus is 
                                                 
31 Jain M, DeMaria A Jr. Parasitic and tropical diseases and advice for travelers. In: Noble J, Gantz N, eds. Primary Care and 
General Medicine, Second Edition.  p 4. 
32 Red Book 2006, pp 674-675. 
33 Use of brand name is for identification purposes only and does not imply product endorsement. 
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essential for relief from the allergic response to scabies 
infection, with anti-histamines and/or topical steroids for up to 
two weeks after permethrin treatment. 
 
 
 
PHARMACOLOGIC  Clinicians at RHAP clinical sites should become familiar 
TREATMENT OF   with the treatment of common, uncomplicated parasitic 
PARASITIC DISEASES infections.  Most common among these are trichuriasis, 
giardiasis, intestinal amoebiasis, and ascariasis.  The following 
tables summarize medications that are reimbursed by RHAP 
for the treatment of intestinal parasites.  In addition to these, 
RHAP will reimburse for permethrin to treat scabies and lice.  
RHAP clinics are expected to have a relationship with a local 
or on-site pharmacy for obtaining anti-parasitic (and other) 
medications for patients in advance of the second visit.  At the 
time of the second visit, clinicians should review dosing with 
patients (via an interpreter) and observe consumption of the 
medication (at least the first dose if part of a multi-dose 
course). 
 
Note: Clinicians may consider empiric treatment of refugees 
with negative O & P tests in the following situations: 
 
• Multiple family members with similar intestinal parasites.  
For example, if two family members have trichuriasis, the 
clinician may consider treating the patient with 
mebendazole or albendazole. 
 
• A patient (from a country with endemic parasitoses) with a 
high-risk medical condition which predisposes to 
complications from parasitoses.  For example, a patient 
with asthma or rheumatic disease who may be likely to be 
placed on steroids.  In these instances, the clinician should 
consider empiric treatment with albendazole, 400 mg po 
bid for 3 days. 
Parasites 60
Updated September 2008             MASSACHUSETTS REFUGEE HEALTH ASSESSMENT GUIDE 
Section 3: CLINICAL PROGRAM 
RECOMMENDED AND REIMBURSED DRUGS FOR MAJOR PARASITES* 
 
Parasite Drug (generic/trade) 
 
In Order of Preference: 
Adult Dosage Pediatric Dosage 
Mebendazole/Vermox 500 mg once or 100mg 
bid x 3d. 
Same Ascaris  
Albendazole/Albenza 400 mg once Same 
Praziquantel/Biltricide 25 mg/kg q 6° x 3 doses  Same Clonorchis 
Albendazole/Albenza 10 mg/kg x 7 days Same 
Paromomycin/Humatin 25-35 mg/kg/day ÷ tid x 7 
days 
Same E. histolytica34
Iodoquinol/Yodoxin 650 mg tid x 20 days 30-40 mg/kg/day ÷ tid x 20 
days (max. 2 gm) 
Metronidazole/Flagyl 250 mg tid x 5 days 15 mg/kg/day ÷ tid x 5 d. Giardia 
Nitazoxanide/Alinia  100 mg bid x 3d. (1-3 yrs) 
200 mg bid x 3d. (4-11 yrs)
Mebendazole/Vermox 500 mg once or 100mg 
bid x 3d. 
Same Hookworm 
Albendazole/Albenza 400 mg once Same 
Hymenolepis Praziquantel/Biltricide 25 mg/kg x 1 dose Same 
Lice Permethrin 1% cream rinse/ 
Nix 
Apply x 1; repeat after 2 
wks prn 
Same 
Scabies Permethrin 5% lotion/Elimite Apply qhs and rinse in 
AM once 
Same 
Schistosoma Praziquantel/Biltricide 20 mg/kg bid-tid x 1 day35 Same 
Ivermectin/Stromectol36 200 µg/kg/day x 1-2 days Same Strongyloides 
Thiabendazole/Mintezol 25 mg/kg bid x 7 days Same 
Tape worms37 Praziquantel/Biltricide 5-10 mg/kg x 1 dose Same 
Albendazole/Albenza 400 mg bid x 5 days Same Toxocara canis 
Mebendazole/Vermox 100-200 mg bid x 5 days Same 
Mebendazole/Vermox 500mg once or 100mg 
bid x 3d. 
Same Trichuris 
Albendazole/Albenza 400 mg once38 Same 
 
*The Medical Letter on Drugs and Therapeutics. August 2004;1-12.   
Note: Nitazoxanide/Alinia is only reimbursed for children under 12 years of age. 
Note: Patients with Ascaris as well as another parasite should always be treated for Ascaris first due 
to the risk of migration of the worm. 
Note: Albendazole is only available as a film-coated tablet and may not be suitable for use in young 
children. 
Note: Paromomycin is not absorbed and may be useful for treatment of amoebiasis and giardiasis 
during pregnancy. 
                                                 
34 Asymptomatic carriage only.  Obtain consultation for symptomatic case treatment. 
35 TID dosing for S. japonicum and S. mekongi. 
36 Ivermectin not FDA approved for use in disseminated strongyloidiasis. 
37 Diphyllobothrium latum, Taenia saginata/solium, and Dipylidum only.  Consult reference for others. 
38 In heavy infection, may need to treat with 400 mg bid x 3 days. 
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FORMULATIONS: 
 
• Albendazole/Albenza: 200 mg film-coated tablets 
• Iodoquinol/Yodoxin:  210 and 650 mg tablets    
• Ivermectin/Stromectol:  3 mg unscored and 6 mg scored tablets 
• Mebendazole/Vermox:  100 mg chewable tablets 
• Metronidazole/Flagyl: 250 & 500 mg tablets, 100 mg/5cc suspension (specially prepared) 
• Nitazoxanide/Alinia:  500 mg tablets, 100mg/5cc suspension 
• Paromomycin/Humatin: 250 mg capsules 
• Permethrin/Elimite/Nix: 5% cream (60gm) /1% cream rinse (59cc) 
• Praziquantel/Biltricide:  600 mg triscored tablets, 150 mg/section 
• Thiabendazole/Mintezol: 500 mg chewable tablets, 500mg/5cc suspension 
 
MAJOR SIDE EFFECTS*: 
 
Drug Common Rare 
Albendazole Abd. pain, reversible alopecia, transaminase 
elevation, Ascaris migration  
Leukopenia, rash, renal toxicity 
Iodoquinol Rash, acne, goiter, nausea, anal pruritus, 
diarrhea, cramps 
Optic neuritis/atrophy, loss of vision, 
peripheral neuropathy, iodine 
sensitivity 
Ivermectin Mazzotti-type reaction in onchocerciasis: fever, 
pruritus, lymphadenopathy, headache, arthralgia 
Hypotension, edema, tachycardia, 
possible ophthalmological changes 
Mebendazole Diarrhea, abdominal pain, Ascaris migration Leukopenia, alopecia, hepatotoxicity, 
agranulocytosis, hypospermia 
Metronidazole Nausea, dry mouth, metallic taste, headache, GI 
disturbance, insomnia, vertigo, tinnitus, weakness, 
stomatitis, dark urine, disulfirim-like rxn., 
paresthesia, rash, urethritis 
Seizures, encephalopathy, 
pseudomembranous colitis, ataxia, 
leukopenia, pancreatitis, peripheral 
neuropathy 
Nitazoxanide Abdominal pain, diarrhea, headache, nausea (No rare side effects listed) 
Paromomycin GI disturbance, eighth nerve toxicity, 
nephrotoxicity if IV administration, vertigo, 
pancreatitis  
(No rare side effects listed) 
Permethrin Burning, stinging, numbness, increased pruritus, 
edema, erythema, rash  
(No rare side effects listed) 
Praziquantel Malaise, headache, dizziness, sedation, GI upset, 
fever, sweating, nausea, eosinophilia, fatigue 
Pruritus, rash 
Thiabendazole Nausea, vomiting, vertigo, headache, drowsiness, 
pruritus, leukopenia, crystalluria, rash, 
hallucinations and psychological reactions, 
visual/olfactory disturbance, erythema multiforme 
Shock, tinnitus, intrahepatic 
cholestasis, seizures, angioneurotic 
edema, Stevens-Johnson Syndrome 
 
*This table is not meant to be a definitive list of side effects and contraindications.  Clinicians are 
responsible for familiarizing themselves with prescribed anti-parasitic drugs. 
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DISEASE SYNDROMES Diarrhea, eosinophilia, fever, mass lesions, respiratory 
IN TRAVELERS AND  infections, and skin lesions are the most common disease 
REFUGEES syndromes in travelers and immigrant (refugee) 
populations.  RHAP’s targeted testing includes common first 
line tests used in the evaluation of eosinophilia.  Included in 
these are up to two stool microscopy tests in addition to the 
one in the core protocol and serologic tests for Schistosoma, 
Strongyloides, and filaria.  Targeted testing is described in 
Section 3.11.  The following tables about the etiologies of 
eosinophilia are from: Jain M, DeMaria, A Jr. Parasitic and 
tropical diseases and advice for travelers. In: Primary Care & 
General Medicine, Second Edition.39
 
 
CAUSES OF SIGNIFICANT Peripheral blood eosinophilia is defined as more than 450 
PERIPHERAL BLOOD  eosinophils per cubic millimeter of blood.  It occurs with 
EOSINOPHILIA  allergic reactions and a number of disease processes but, on a 
worldwide basis, it is a common laboratory finding associated 
with parasitic infection. 
 
Helminthic parasites: 
 
Angiostrongylus cantonesis and A. costaricensis  
Anisakiasis  
Ascaris lumbricoides (invasive larval stage) 
Capillaria phillippinensis 
Echinococcus  
Fasciolopsis buski 
Filariasis  
Animal hookworms 
Hookworms (invasive larval stage) 
Liver flukes  
Paragonimus westermani  
Schistosomiasis 
Strongyloides stercoralis (initial inf. and autoinf.)  
Toxocara species  
Trichinosis 
Tropical eosinophilia 
(Unidentified microfilariae) 
 
Other infections/infestations:  
Pulmonary aspergillosis   
Severe scabies   
Wiscott-Aldrich syndrome 
                                                 
39 Jain, p 35. 
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Allergies:  
Asthma  
Hay fever  
Drug reactions  
 (Eosinophilic myalgia syndrome-tryptophan, toxic oil 
syndrome) 
 
Other: 
Addison’s disease 
Inflammatory bowel disease 
Dermatitis herpetiformis 
Atopic dermatitis 
Toxic/chemical syndrome 
 
Autoimmune and related disorders:  
Hypereosinophilia syndrome (unknown etiology)  
Polyarteritis nodosa  
Necrotizing fasciitis  
Eosinophilic vasculitis  
Pemphigus  
Mucin-secreting adenocarcinomas 
 
Immunodeficiency states: 
Hyperimmunoglobulin E with  
  recurrent infection  
 
Neoplastic diseases: 
Hodgkin’s disease  
Mycosis fungoides 
Chronic myelocytic leukemia 
Eosinophilic leukemia  
    Polycythemia vera 
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EVALUATION OF FEVER The differential diagnosis of fever in a refugee can be 
narrowed by a good history (travel history, food/water 
exposure, insect bites, and animal contacts in particular), a 
physical examination (looking specifically for rash, 
lymphadenopathy and hepatosplenomegaly), and appropriate 
laboratory testing (particularly a CBC to identify anemia and 
eosinophilia).  A differential diagnosis of some selected 
systemic febrile illnesses to consider in refugees is listed 
below. 
 
DIAGNOSIS REGION  VECTORS [ ] and  
CLINICAL CHARACTERISTICS { } 
COMMON 
Acute respiratory infection Worldwide 
Gastroenteritis Worldwide  [Food, water, fecal-oral] 
Enteric fever, incl. typhoid Worldwide  [Food, water, fecal-oral] 
Urinary tract infection Worldwide   
Drug reactions Worldwide  [Antibiotics,prophylactic agents, other] {Rash frequent} 
Malaria Tropics, mainly [Mosquitoes] {Fever, hepatosplenomegaly} 
Arboviruses Asia, Carib., Afr. [Mosquitoes]  
Viral Hepatitis Worldwide  {Fever, malaise, jaundice} 
 Hepatitis A Worldwide  [Food, water, fecal-oral] 
 Hepatitis B Worldwide, esp. Asia,  [Body fluids] {Long incubation}  
  Africa  
 Hepatitis C Worldwide      [Body fluids] 
Tuberculosis Worldwide  [Airborne, milk] {Long incubation} 
STD Worldwide  [Sexual contact] 
 
LESS COMMON 
Filariasis Asia, Afr., S.Amer.   [Biting insects] {Long incubation} 
Measles Worldwide  [Airborne]  
Amebiasis +/- abscess Worldwide, tropics [Food, water, fecal-oral] 
Brucellosis Worldwide  [Milk, cheese, food, animal contact] 
Listeriosis Worldwide  [Foodborne] {Meningitis} 
Leptospirosis Worldwide  [Animals, fresh water] {Jaundice, Meningitis} 
Strongyloidiasis Tropics  [Soil contact]  {Eosinophilia} 
Toxoplasmosis Worldwide  [Undercooked meat, cat feces, congenital] 
 
RARE 
Relapsing fever West Americas, Asia,   [Ticks, lice] 
  N. Afr.    
Hemorrhagic fevers Worldwide  [Arthropod and non-arthropod transmitted] 
Yellow fever Tropics  [Mosquitoes] {Hepatitis} 
Hemorrhagic fever 
     with renal syndrome Europe, Asia [Rodent urine] {Renal impairment} 
Hantavirus  Western N. Amer.  [Rodent urine] {Resp. Distress Syndrome} 
Lassa fever Africa  [Rodent excreta, person to person] {Often severe} 
Other 
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MALARIA40 Malaria, caused by the Plasmodium sp. parasites, is one of 
the most prevalent diseases in the world, with disastrous 
social consequences and a heavy burden on economic 
development. Malaria accounts for 10% to 30% of all hospital 
admissions worldwide.  The total cost of malaria-related health 
care, treatment, and lost economic productivity was estimated 
to be nearly $1 billion for tropical Africa alone. 
 
The deterioration of social and economic conditions, 
dislocation of populations, and armed conflicts in Africa and 
Southeast Asia have exacerbated control of malaria.  With 
disrupted public and clinical health services, malaria control 
efforts are limited, putting underserved rural populations at 
greater risk.  In the absence of adequate health services, 
incomplete treatment and inappropriate use of prophylaxis 
increases drug resistance of the Plasmodia parasites.   
 
Annually, 300 – 500 million cases and 1.5 – 2.7 million deaths 
are estimated to occur. Eighty percent of the cases occur in 
tropical Africa, and malaria is the cause of 15% to 25% of all 
deaths of children under the age of five.  Around 800,000 
children under the age of five die from malaria every year.  
Pregnant women who contract malaria are at risk of 
miscarriage and in utero growth retardation.  Refugees from 
non-endemic areas may also be at risk if they have had to 
migrate through or into an endemic zone. 
 
Refugees from sub-Saharan Africa likely received pre-
departure presumptive treatment for malaria.  If an individual 
from sub-Saharan Africa did not receive treatment before 
travelling to the United States, please consider presumptive 
treatment. 
 
Malaria is an infection caused by protozoa of the genus 
Plasmodium in which the asexual cycle (schizogony) takes 
place in the red blood cells of vertebrates and the sexual cycle 
(sporogony) takes place in mosquitoes. The Anopheles 
mosquito is the arthropod vector for transmission outside the 
human host.  Four Plasmodia species are most common in 
infections of human beings: P. falciparum, P. vivax, P. ovale, 
and P. malariae.  Diagnosis relies on identification of the 
parasite on stained thick blood smears.   
 
Acute illness is characterized by non-specific symptoms such 
as fever, malaise, myalgia, headache, photophobia, diarrhea, 
anorexia and nausea.  Fever may last up to three weeks and 
gradually come in the classic cyclic paroxysms.  Complications 
may include meningoencephalitis, arthralgia/arthritis, orchitis, 
                                                 
40 Red Book 2006; pp. 435-441. 
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shock, and respiratory symptoms (including pulmonary 
edema).  Laboratory findings include anemia, hypoglycemia, 
evidence of acidosis or renal failure, and leukopenia.  
Hepatosplenomegaly, pallor, and jaundice are common 
physical findings.  Perinatal and congenital infections of 
mother and fetus may be severe.  Chronic infection may result 
in tropical splenomegaly syndrome, characterized by 
hemolysis and splenomegaly with elevated titers of 
antiplasmodium antibodies.   
 
The CDC recently has revised its recommended regimen for 
pre-departure presumptive treatment for refugees departing 
from Sub-Saharan Africa (i.e. the region of endemic falciparum 
malaria). The current recommendation is for artemisinin-based 
combination therapy (ACT) with artemether-lumefantrine. 
Malaria pre-departure presumptive therapy is administered 
and documented as directly-observed therapy, and this 
documentation must be carried by the refugee.  To be 
considered valid the presumptive therapy must be completed 
no sooner than 3 days prior to departure.   
 
Special populations including pregnant or lactating women and 
children <5 kilograms require directed treatment after 
diagnostic testing and thus do not receive presumptive 
therapy.  Individuals in these groups who lack signs and 
symptoms of malaria but have laboratory-diagnosed 
Plasmodium falciparum infection are treated with either a 
combination of oral quinine and clindamycin (preferred) or a 
longer course of oral quinine. 
 
Refugees from Sub-Saharan African who have received pre-
departure treatment with a recommended antimalarial drug or 
drug combination do not need further evaluation or treatment 
for malaria once in the U.S. unless they have clinical 
symptoms.   
 
Refugees from Sub-Saharan Africa who have not received the 
recommended presumptive or directed pre-departure 
treatment should either receive presumptive treatment on 
arrival (preferred) or have laboratory screening to detect 
Plasmodium infection.   
 
Given the low prevalence of infection in most other areas from 
which refugees arrive, the prolonged course of treatment, 
potential adverse effects of medication, and the lack of useful 
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laboratory screening tools, the CDC does not currently 
recommend that newly arriving refugees from regions other 
than Sub-Saharan Africa receive presumptive treatment for 
non-falciparum malaria or laboratory diagnostic evaluation on 
arrival to the United States. The CDC will monitor non-
falciparum prevalence rates among future arriving refugee 
populations, and will update their guidance if indicated. 
 
The CDC’s website contains detailed guidance on dosing of 
atovaquine-proguanil for presumptive treatment in the U.S.: 
 
http://www.cdc.gov/ncidod/dq/refugee/rh_guide/malaria/domes
tic.htm#table2
 
Other than presumptive outpatient treatment, any treatment of 
refugees for malaria should be done in consultation with an 
infectious disease specialist.   
 
 
 
 
 
 
 
 
 
 
The Centers for Disease Control offer 24-hour 
consultation at 770-488-7788 during weekday 
business hours and by page at 770-488-7100 after 
hours and on weekends and holidays. 
 
Treatment guidelines are available at: 
http://www.cdc.gov/malaria/diagnosis_treatment/tx_cli
nicians.htm
 
 
 
 
 
 
RESOURCES Division of Parasitic Diseases, NCID
 CDC 
404-488-4050 
 
CDC Malaria Guidelines 
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3.8  IMMUNIZATIONS 
 
 
 
 
 
PURPOSE  To ensure that every child and adult refugee is appropriately 
immunized against vaccine-preventable diseases. 
 
 
BACKGROUND  Outbreaks of vaccine-preventable diseases occur overseas as  
well as in the United States.  Highlighting this risk, the CDC 
has documented outbreaks of vaccine-preventable diseases. 
An estimated 20 million cases of measles occur each year 
worldwide, and cases continue to be imported into the United 
States.  Imported measles cases can result in large outbreaks, 
particularly if introduced into areas with pockets of 
unvaccinated persons.1,2,3  
In 2005 mumps cases in Indiana4 as well as widespread 
mumps outbreak in the Midwest.5  Globally, high infant and 
child mortality from vaccine preventable diseases has led to 
major childhood immunization efforts.   
 
While vaccination programs are incorporated into refugee 
health services, most refugee children and adults come to the 
United States with high risk of under-immunization.  United 
States-bound refugees may receive additional vaccinations 
pre-departure; the schedules as of September 2012 are 
available on-line.   
 
Recommendations for child and adult immunizations change.  
Integration of newer vaccines combined with changes in 
guidelines for older vaccines may present challenges for 
clinical logistics. The extra burden of these vaccination 
changes for both patient and clinic staff are notable; however, 
clinics must overcome such challenges to ensure that refugee 
patients are on the path to being fully immunized according to 
the vaccine schedules of the CDC’s Advisory Committee on 
                                                 
1 Centers for Disase Control and Prevention. Measles – United States, January 1-August 24, 2013. MMWR. 2013;62:741-743. 
2 Centers for Disease Control and Prevention. Measles Outbreak Among Members of a Religious Community – Brooklyn, New 
York March-June 2013. MMWR. 2013;62:752. 
3 Centers for Disease Control and Prevention. Measles Outbreak Outbreak Associated with a Traveler Returing from India – 
North Carolina April-May 2013. MMWR. 2013;62:753 
4 Centers for Disease Control. Import-associated measles outbreak -- Indiana, May--June 2005. MMWR. 2005;54:1073-1075. 
5 Centers for Disease Control. Update: multistate outbreak of mumps -- United States, January 1--May 2, 2006. MMWR. 
2006;55:559-563. 
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Immunization Practices (ACIP) and the MDPH Immunization 
Program. 
 
RIHP always requires clinicians to follow the latest ACIP 
routine and catch-up scheudules for both children and adults 
which can be found on the CDC website.In addition, detailed 
guidance from the ACIP about each vaccine can be found on 
their website. Massachusetts school entry vaccine 
requirements are on the MDPH Immunization Program 
website.    
 
All individuals applying to adjust their immigration status to 
Permanent Resident Alien are required to document 
vaccination in accordance with ACIP recommendations; 
vaccinations are recorded on the USCIS Form I-693 by a Civil 
Surgeon.  The RHAP provider plays an essential role in 
assuring that refugees meet the vaccine requirements. 
 
The recommendations in this manual are current as of October 
2013.  For updates, please see the MDPH Immunization 
Program or CDC websites.   
 
 
 
Note: All Refugee Health Assessment Program sites must 
be enrolled and participate in the Vaccines for Children 
Program/MDPH Immunization Program. 
 
 
 
PROGRAM   In brief, the RHAP requires the following of providers:  
REQUIREMENTS 
1. Evaluate immunization history, review overseas 
documentation including pre-departure documents and 
record valid doses on the RHAP form and/or the electronic 
health record. 
2. Initiate all necessary age-appropriate vaccines per ACIP 
adult and childhood vaccine schedules. Provide each 
refugee with a childhood or adult vaccination booklet, or 
equivalent document, with completed documentation of 
past and RHAP vaccination; update at the second visit. 
3. Order serum IgG levels against Varicella (chicken pox) for 
all refugees aged > 5 years of age. 
⇒ Vaccinate susceptible individuals. Clinicians may 
consider administering a single dose of vaccine 
pending the serology results to facilitate school entry. 
⇒ Blood should be drawn prior to immunization whenever 
possible (for Varicella and Hepatitis B serologies). 
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4. Document immunity to varicella, based on exam, history or 
serologic testing. 
5. Educate refugees of the need to bring the immunization 
documentation to all medical visits including the Civil 
Surgeon evaluation required for change of status 
applications. 
 
 
All RHAP clinicians must follow all adult and childhood 
vaccine schedules and guidelines from the MDPH 
Immunization Program and ACIP. 
 
 
Because the basic RHAP process is two visits separated by 
approximately one month, it is not expected that RHAP 
providers will be able to administer complete vaccine series for 
refugees who need them.  At a minimum, RHAP providers 
should initiate/continue appropriate vaccination at each RHAP 
visit, refer to primary care, and educate the refugee about 
school and USCIS requirements and follow-up timing to 
complete vaccine series. RHAP providers also have the option 
of scheduling pre-RHAP (for children) and post-RHAP (for 
adults) vaccine-only nursing visits to facilitate school entry for 
children or complete a primary vaccine series for adult 
refugees. RHAP reimburses these visits and the cost of 
vaccines procured by the site for immunizing adult refugees.  
 
Evaluation of immunization history through record review 
should determine any need for vaccination to achieve age-
appropriate vaccination levels. The ACIP has clear guidelines 
on evaluation of immunization status for individuals vaccinated 
outside the United States.6  These are summarized below. 
 
Evaluating Findings The role of a provider during the health assessment is, first, to  
assess the immunization status of the patient (including 
serologic testing as described above); second, to proceed to 
vaccinate according to age in order to initiate or complete the 
required primary vaccine series’; and third, to make 
recommendations to primary care for necessary follow-up in 
order to complete recommended vaccination.  All refugees, 
especially parents of school-age children, should be educated 
about the importance of completing primary vaccine series’ 
and immunization requirements for school entry, daycare 
attendance, and future immigration status changes. 
 
                                                 
6 Centers for Disease Control and Prevention.  General recommendations on immunization recommendations of the Advisory 
Committee on Immunization Practices (ACIP). MMWR. 2011;60(No. RR-2):27-29 .  
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With the exception of chicken pox, verbal or written report of a 
history of a disease is not considered adequate proof of 
immunity.  Similarly, incomplete documentation of overseas 
vaccines may not be considered adequate for withholding 
vaccination.  For example, a document with only a year for the 
vaccination date is not acceptable.  Clinicians should not write 
phrases such as “received in home country,” “up to date,” or 
“in time” on the RHAP form or a personal vaccine document.  
These assertions will not be useful for school nurses or Civil 
Surgeon personnel guided by strict regulations.  Instead, 
clinicians must inform refugees of the need for vaccines to 
assure immunity to vaccine-preventable disease and proceed 
with necessary immunizations per ACIP guidelines. 
 
Acceptability of   The acceptability of vaccines received in other countries to meet 
Vaccinations Received  vaccination requirements in the United States depends on three 
Outside the US  factors: Vaccine potency, adequate documentation, and  
 vaccination in accordance with the US immunization schedule. 
 For complete guidance, see pages 27-29 and 49 in ACIP’s 
section on Persons Vaccinated Outside the United States in 
their General Recommendations on Immunization. 
 
1. Vaccine Potency 
  
♦ The majority of vaccines used worldwide are from reliable 
local or international manufacturers, and no potency 
problems have been detected, with the occasional 
exception of tetanus toxoid and OPV vaccines. 
 
2. Adequate Documentation of Receipt of Vaccine 
 
♦ Doses of vaccine with written documentation of the date of 
receipt should be accepted as valid. At a minimum, month 
and year must be a part of the date. Camp vaccination 
cards or Department of State forms are acceptable 
records. Self-reported doses of vaccine without written 
documentation should not be accepted, and patients 
should be considered susceptible.  CDC notes that under 
mass vaccination campaigns conducted overseas for 
outbreak control, documentation may not be provided and 
therefore may not be recorded on the Department of State 
forms.   
♦ Language translations for vaccine names are available at 
Immunization Action Coalition and CDC.   
♦ All adults and children should be started on the age-
appropriate catch-up immunization schedule used in the 
United States.  
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3. Immunization Schedule  
 
Age at vaccination and spacing of vaccine doses must be 
assessed for acceptability.  To be considered valid, the 
doses must meet the minimum age and intervals in the U.S. 
immunization schedules posted on the CDC website. The 
minimum intervals of different vaccine antigens can be found 
in Table 1 of the ACIP’s General Recommendations on 
Immunization. 
 
DTP/DTaP:   
? Age: Any dose of DTP/DTaP vaccine administered at  
> 6 weeks of age can be considered valid.   
? Spacing: The first 3 doses of DTP/DTaP vaccine 
should have been separated by a minimum of 4 weeks.   
? The 4th dose should have been administered no less 
than 6 months after the third dose.  
? The 5th dose should have been adminstered no less 
than 6 months after the 4th dose and at 4 years of age 
or older. 
? A 5th dose is not needed if the 4th dose was 
administered after 4 years of age or older. 
 
HIB:   
? Age: Any dose of Hib vaccine administered at > 6 
weeks of age can be considered valid.   
? Spacing: Doses of Hib vaccine in the primary series 
should have been administered no less than 1 month 
apart.   
? The booster dose of Hib vaccine should be 
administered at least 2 months after the previous dose, 
and should not be administered before age 15 months. 
 
POLIO:  
? Age: Doses of OPV and IPV administered at > 6 weeks 
of age of age can be considered valid.  
This section refers to evaluation of overseas 
vaccination only.  Current ACIP guidelines stipulate 
that in most circumstances, only IPV should be used in 
the United States.  See below for further information. 
 
 Spacing: The timing of vaccine doses varies 
depending on the schedule used: 
  
When interpreting records from oversees, please note 
bivalent OPV does not count as a valid dose towards 
meeting the recommendations/requirements for the 
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U.S. schedule.  Only trivalent doses of OPV or IPV 
should be counted. 
 
 Sequential IPV/OPV: 
At least 4 weeks are needed between doses 1, 2, and 
3, although an interval of 6-8 weeks is preferred.  At 
least 4 weeks are needed between doses 3 and 4, 
although an interval of 6 months is preferred. When 
IPV and OPV are used in combination, 4 doses are 
always needed to complete the primary series.   
 
All OPV: 
At least 4 weeks are needed between doses 1, 2, 3, 
and 4; however, >6 months is preferred between the 
final doses in the series. For children who received all 
OPV, the third dose of OPV could be administered as 
early as 6 months of age.  A minimum of 3 doses is 
needed to complete the primary series, if the final dose 
was administered at age > 4 years. 
 
All IPV: 
At least 4 weeks are needed between doses 1 and 2, 
and > 6 months between doses 3 and 4.  The final 
dose in the IPV series should be administered at age 
>4 years regardless of the number of previous doses. 
A 4th dose IPV is not necessary if the 3rd dose was 
administered at 4 years of age or older and >6 months 
after the previous dose 
 
 Any dose of polio vaccine administered at the above- 
recommended minimum intervals can be considered 
valid.  Persons vaccinated outside the United States 
may need one or more additional doses of IPV to meet 
current immunization guidelines in the United States. 
 
 NOTE: Current ACIP guidelines call for the use of all-
IPV vaccine schedule in the United States.  While most 
refugees will have received OPV overseas, RHAP 
clinicians should only use IPV except in specific 
circumstances described in the ACIP guidelines. See 
ACIP recommendations for polio vaccine. 
 
MEASLES:  
? Age: Any dose of measles vaccine administered at     > 
12 months of age can be interpreted as valid. Children 
vaccinated against measles before their first birthday 
should be revaccinated if they are now >12 months of 
age. The 2nd dose may be given at age 4-6 years, prior 
to school entry, provided > 4 weeks have elapsed 
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since the prior dose. 
? Spacing: Persons born in or after 1957 should have 
documentation of having received two doses of live 
measles vaccine and live mumps vaccine (preferably 
combination measles, mumps and rubella) on or after 
their first birthday or other evidence of immunity.  The 2 
doses of vaccine should be at least 4 weeks apart.  
When interpreting overseas vaccine documentation, 
clinicians must note whether the patient received 
measles vaccine only or the trivalent MMR.   
 
A written or verbal report of a history of measles (as 
well as mumps and rubella) disease is not considered 
adequate documentation of immunity.  While serologic 
confirmation is acceptable, RHAP should administer 
MMR to any refugee in need of immunization with any 
of the three disease components.  Most refugees will 
need a dose of MMR for coverage against rubella 
and/or mumps. Thus MMR may need to be given 
even if a refugee has documentation of previous 
measles vaccination. 
 
NOTE: Administration of measles vaccine (M) or 
measles/rubella vaccine (MR) may be documented on 
overseas records. These records should be carefully 
reviewed and doses appropriately documented to 
assure appropriate follow-up.  
 
HEPATITIS B:  
HBV vaccine is now being used in much of the world. 
Schedules may vary slightly from ACIP guidelines. In 
general, the minimum interval between dose 1 and 
dose 2 is 4 weeks and between dose 2 and 3 is 8 
weeks. The final (third or fourth) dose in the HBV 
vaccine series should be administered no earlier than 
age 24 weeks and at least 16 weeks after the first 
dose. When using combination vaccines that include 
HBV, four doses are recommended. Lastly, 
individuals who have received one or two doses of 
vaccine overseas and then have a positive Anti-
HBs serology test during RHAP still should finish 
the remaining doses of the HBV vaccine series. 
 
VACCINES FOR   RHAP clinicians should follow all routine or catch-up 
CHILDREN   recommendations of the ACIP/MDPH Immunization Program.   
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These recommendations include immunization against 
hepatitis B, polio, diphtheria, tetanus, pertussis, H. influenzae 
type B, measles, mumps, rubella, pneumococcus, and 
varicella as well as the newer recommendations for human 
papilomavirus, rotavirus, hepatitis A, meningococcus, and 
influenza.   
 
 
Review current ACIP/MDPH Immunization Program 
recommendations for routine and catch-up vaccination of 
children and adults and requirements for school 
attendance.
 
 
A note on repeating immunizations: 
Some clinicians may be concerned that it is unnecessary to re-
immunize children (or adults) who do not have documentation 
of prior vaccination. ACIP recommendations state that while 
various approaches are valid, repeating vaccinations is an 
acceptable option that is safe and prevents the need to obtain 
and interpret serologic tests. If avoiding unnecessary 
injections is desired, judicious use of serologic testing might 
help determine which vaccinations are needed; however, since 
for some vaccines, the most readily available serologic tests 
cannot document protection against infection, it is RHAP policy 
that serologic testing be limited to determining immunity to 
Hepatitis B and Varicella. Most refugees will be under-
immunized for most vaccines and lack documentation for 
those they did receive.  Given school and USCIS 
requirements, clinicians should promptly vaccinate refugee 
children with all needed age-appropriate vaccines.   
 
For ascertaining the need for varicella immunization, RHAP 
protocols include a mixed screening strategy to ensure 
immunity in all refugees. Such a screening strategy has been 
shown to be cost-effective for varicella.7  Clinicians should 
assess for a reliable history of chicken pox disease.  If the 
patient has had chicken pox, the clinician should document the 
positive history on the RHAP form.  In addition, if the clinician 
notes signs of chicken pox scars on physical examination, s/he 
should document this on the form.  In these cases, no 
immunization is needed.  Additionally, refugees 5 years of age 
and older will be screened for anti-varicella IgG antibody levels 
                                                 
7 Figueira M, Barnett ED, Christiansen D, McNamara ER. Cost-benefit of serotesting compared with universal immunization for 
varicella in refugee children from six geographic regions. J Travel Med. 2003;10:203-207.  
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at the first visit.  This age was determined based on 
seroprevalance studies as noted above and RHAP 
administrative requirements. Those with serologic evidence of 
immunity do not need immunization while those without 
immunity should receive the vaccine and be instructed on 
follow-up timing if a second dose is needed.  Clinicians may 
also opt to give a single dose of vaccine to school-aged 
children pending the serology result to facilitate school entry. 
Children under age 5 years without a positive history or 
physical exam should receive the vaccine without serologic 
testing. The revised RHAP form contains space for 
documentation of the results of varicella serology. 
 
For measles, all refugees should receive MMR vaccine 
according to ACIP/MDPH Immunization Program schedules. 
Refugees born in or after 1957, who are age 12 months or 
older and without contraindications, should be given the 
first dose of MMR vaccine at the first visit. This dose will 
also cover for immunity to rubella.  For children (and adults 
who meet ACIP criteria), a second dose of MMR at least 4 
weeks after the first dose is recommended to ensure measles 
and mumps immunity. 
 
? Remember, children vaccinated against measles 
before their first birthday should be revaccinated if they 
are now >12 months of age.  The 2nd dose may be 
given at age 4-6 years, prior to school entry, provided 
>4 weeks have elapsed. 
 
Child Vaccine Updates  Recent updates in child and adolescent vaccines are  
summarized as follows: 
 
• Rotavirus vaccine is recommended in either a 2-dose 
schedule at ages 2 and 4 months (Rotarix) or 3-dose 
schedule at ages 2, 4, and 6 months (RotaTeq). The 
first dose should be administered at ages 6 weeks 
through 12 weeks with subsequent doses administered 
at 4--10 week intervals. Rotavirus vaccination should 
not be initiated for infants aged 14 weeks 6 days and 
the maximum age for the final dose is 8 months 0 days  
• The human papillomavirus (HPV) vaccine is 
recommended in a 3-dose schedule with the second 
and third doses administered 1-2 and 6 months after 
the first dose. Routine vaccination with HPV is 
recommended for all adolescents aged 11-12 years; 
the vaccination series can be started as young as age 
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9 years; and a catch-up vaccination is recommended 
for females aged 13-18 years who have not been 
vaccinated previously or who have not completed the 
full vaccine series. Males aged 11-18 may also be 
immunized regardless of individual risk. Either HPV4 
(Gardasil) or HPV2 (Cervarix) can be used for females; 
only HPV4 is approved for males.  
• Hepatitis A vaccine consists of a 2-dose schedule with 
the 2nd dose administered 6-18 months apart.  It is 
recommended for all children 12-23 months of age, but 
it may be completed after 23 months of age if 
necessary. NOTE: In recognition of research that 
has shown high levels of naturally-acquired 
immunity to hepatitis A virus, until it becomes a 
school entry requirement, RHAP will NOT require 
clinicians to administer hepatitis A vaccine during 
the health assessment. 
• Meningococcal vaccination is routinely recommended. 
The MCV4 vaccine should be given to children 11-12 
years of age with a booster dose at 16 years of age. In 
addition, unvaccinated adolescents at any age should 
receive one or two doses as appropriate. Certain high 
risk individuals should also receive a 1 or 2 dose 
primary series of MCV4 (e.g., asplenia, persistent 
compliment component deficiencies, HIV infection, 
military, travel, etc).  Boosters may be indicated if they 
remain at risk and should be given at >3 year intervals  
for children aged 2 through 6 years and at > 5 year 
intervals for persons aged 7 years and older. See the 
ACIP recommendations on meningococcal vaccines for 
more detailed information. 
 
• Tdap. Tdap is routinely recommended for all 
adolescents at 11-12 years and can be administered, 
regardless of the interval since the last tetanus- or 
diphtheria- containing dose (no minimum interval).  
Children aged 7-10 years who are not fully immunized 
with the DTaP vaccine (<5 doses or < 4 doses if the 
4th dose was given on or after the 4th birthday) should 
be given Tdap vaccine as the first dose in the catch-up 
series.  Adolescents 11-18 years of age who have not 
received a Tdap should be given one at their 1st visit.  
In addition, a single dose of Tdap should be given to all 
adolescents who will be close contacts with infants to 
help prevent transmission of pertussis. 
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• Pneumococcal Vaccines.  
o  PCV13: This vaccine series is recommended 
routinely for healthy children through 59 months of 
age. It is recommended for PCV13 naïve children 
with chronic medical conditions through 71 months 
of age (e.g., chronic heart disease, chronic lung 
disease [including asthma if treated with high dose 
steroids], diabetes, immunocompromsing 
conditions, asplenia (including sickle cell), cochlear 
implants; and cerebrospinal fluid (CSF) leaks, etc.).  
In addition, a single dose of PCV13 is 
recommended for children 6 through 18 years of 
age who have never been vaccinated with: 
functional or anatomic asplenia; HIV infection or 
other immunocompromising conditions; cochlear 
implants; and CSF leaks. 
 
o PPSV23: 1 dose is also recommended for children 
>2 years of age with certain chronic medical 
conditions including, asplenia, 
immunicompromising conditions, cochlear implants 
and CSF fluid leaks.  One-time revaccination >5 
years after the 1st dose is indicated for those with: 
functional or anatomic asplenia (including sickle); 
HIV infection or other immunocompromising 
conditions; chronic renal failure or nephrotic 
syndrome.   
 
See the ACIP immunization schedules for guidance 
on risk groups, revaccination and intervals between 
doses of PPSV23 and PCV13. 
 
See also the ACIP recommendations for 
pneumococcal vaccines for more detailed 
information. 
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VACCINES FOR  Td/Tdap: 
ADULTS All adults lacking a completed primary series of diphtheria 
and tetanus toxoid should be vaccinated with three doses of 
Td. The first dose of the series should be Tdap vaccine. 
? The first two doses of a primary series should be 
administered during health assessment visits, after which 
the refugee should receive subsequent doses by a primary 
care provider or at a third visit with the RHAP clinic.   
? There is no need to repeat doses if the schedule for the 
primary series or booster doses is delayed. 
? A single dose of Tdap should be administered to all adults 
who have not previously received one, regardless of the 
time since the last tetanus- or diphtheria- containing dose 
(no minimum interval).   
? Tdap should replace Td for a single dose in the primary 
series for unvaccinated or partially vaccinated adults or for 
a booster dose if they have completed the series. 
? Special note for pregnant women: Tdap should be 
administered during each pregnancy, regardless of the 
time since last dose of Td or Tdap (no minimum interval)  
To maximize antibody transfer to the infant, administer 
Tdap between 27 and 36 weeks gestation, although Tdap 
may be given any time during pregnancy. 
 
To help prevent the transmission of pertussis to infants, all 
adolescent and adults who are close contacts should 
receive a single dose of Tdap. Children < 7 years age 
should be up-to-date on their DTaP series. This is referred 
to as the “cocooning effect” to protect infants until their 
own immunity develops. 
 
? All RHAP clinical staff should receive a booster dose 
of Tdap regardless of interval since the last Td dose. 
 
For adults who have not received the primary series of 
at least 3 doses of DTP or TD/Td/Tdap, vaccinate as 
follows: 
 
Dose Age/Interval Product  
Primary 1 --- Tdap 
Primary 2 4 - 8 weeks after #1 
dose 
Td 
Primary 3 6 - 12 months after 
#2 dose  
Td 
Booster Every 10 years since 
last dose 
Single dose of Tdap if not 
received, and then Td 
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POLIO:  
? Routine vaccination is not recommended for persons over 
age 18 years who reside in the United States except for 
individuals at high risk of exposure to wild-type polio virus 
and unimmunized adults at risk of exposure to OPV.  
Unimmunized adults who require vaccination should 
receive three doses of IPV per the above schedule for Td. 
 
MMR:  
? Adult refugees born in or after 1957 should have 
documentation of having received at least one dose of live 
measles vaccine, as MMR with mumps and rubella, on or 
after their first birthday, or serologic evidence of immunity.  
If not, proceed to vaccinate them with MMR.   
? A second dose of MMR for measles and mumps coverage 
is recommended for adults who: 
? are recently exposed to measles/mumps cases or have 
been in an outbreak setting 
? were previously vaccinated with killed measles vaccine 
? were vaccinated with an unknown vaccine between 
1963 and 1967 
? are students in post-secondary educational institutions 
? work in health care facilities 
? plan to travel internationally 
? Because of the high potential for contact with new 
immigrants or international travelers by refugees, the 
RHAP recommendation is two doses of MMR for 
susceptible adult refugees for whom measles/mumps 
vaccination is indicated. 
? MMR doses may be given at an interval of one month 
apart, with the first two doses of Td/Tdap in the above 
schedule.   
? MMR is contraindicated during pregnancy. Routine 
pregnancy testing before administering live vaccines is not 
recommended. According to the ACIP, reasonable 
practices include: 
? Asking women if they are pregnant or might 
become pregnant in the next 4 weeks; 
? Not vaccinating women who state they are 
pregnant or plan to become pregnant; 
? Explaining the theoretical risk to the fetus if MMR or 
varicella vaccine is administered to a pregnant 
woman; and 
? Counseling women who are vaccinated not to 
become pregnant during the 4 weeks after 
receiving MMR or varicella vaccine. 
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? All RHAP clinical staff should have documented immunity 
to measles, mumps and rubella, or receive 1 dose if MMR 
if born before 1957 or 2 doses of MMR if born in or after 
1957. 
 
HEPATITIS B VIRUS (HBV):  
? Adults should be vaccinated for HBV if they fall into a high-
risk category, come from a country where hepatitis B is 
intermediately or highly endemic (HBsAg prevalence >2%), 
or are a household contact.  The first dose should be given 
whenever possible at the first visit. The need for 
subsequent doses is determined after interpretation of 
results of Anti-HBs and HBsAg serologic tests. Individuals 
who received one or two doses of vaccine overseas and 
then have a positive Anti-HBs antibody test during RHAP 
should still finish the full three-dose vaccine series. 
 
HEPATITIS A VIRUS: 
? Vaccination of adults is based on personal risk criteria. As 
noted for children, most adult refugees will be immune to 
hepatitis A virus from naturally acquired infection.  
 
INFLUENZA: 
? All refugees and RHAP clinical staff without 
contraindications should have a seasonal dose of flu 
vaccine.   
 
PNEUMOCCOCUS: 
? PPV23: 1 dose of PPV23 should be administered to all 
adults 65 years of age or older; younger adults with 
chronic medical conditions including asthma; and those 
who smoke cigarettes. One-time revaccination >5 years 
after the 1st dose is indicated for adults 19 through 64 
years of age with: functional or anatomic asplenia 
(including sickle cell); HIV infection or other 
immunocompromising conditions; chronic renal failure or 
nephrotic syndrome.  No further doses are needed for 
those vaccinated at > 65 years 
 
? PCV13:  A single dose of PCV13 is recommended for 
adults who have never been vaccinated with: functional or 
anatomic asplenia; HIV infection or other 
immunocompromising conditions; cochlear implants; and 
CSF leaks. 
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See the latest ACIP immunization schedules for guidance 
on risk groups, revaccination and intervals between doses 
of PPSV23 and PCV13.
 
See also the ACIP recommendations for pneumococcal 
vaccines for more detailed information. 
 
 VARICELLA-ZOSTER: 
? All adult refugees should be assessed for immunity to 
varicella by history, exam, and serologic testing as 
described above. Susceptible individuals require two 
doses of the varicella vaccine, given at least 4 weeks 
apart. The first dose should be initiated at the second 
RHAP visit. 
? Varicella vaccine is contraindicated during pregnancy. 
When giving MMR and varicella vaccines to women of 
child bearing age, the patient should be advised to avoid 
getting pregnant for one month after vaccination. 
? For all adults 60 years of age and older, zoster vaccine 
should be given to prevent shingles unless the patient has 
specific medical contraindications. Refugees in this age 
group may be immunized for zoster.  Screening for a 
history of varicella or serologic testing is not necessary or 
recommended. Titers consistent with immunity to 
chickenpox may represent waning immunity that is not 
sufficient to prevent zoster. NOTE: because of the 
complexities of Medicare reimbursement, RHAP 
recognizes that clinical sites may not be able to 
provide Zostavax to refugees during the RHAP. RHAP 
sites can be reimbursed for zoster vaccine administered 
during the health assessment. 
? All RHAP clinical staff should have documented immunity 
to varicella.   
 
HUMAN PAPILLOMAVIRUS: 
? Vaccination is recommended for females aged 11-26 years 
who have not been vaccinated previously or who have not 
completed the full vaccine series. Males aged 11-21 
should also be immunized regardless of individual risk. 
Males aged 22-26 years should be immunized based on 
risk.  
 
MENINGOCOCCAL: 
? Vaccination of adults is based on personal risk criteria, 
including first year college students living in dormitories. 
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Certain high risk individuals should also receive a 1 or 2 
dose primary series of MCV4 (e.g., asplenia, persistent 
compliment component deficiencies, HIV infection military, 
travel, etc).  Boosters may be indicated if they remain at 
risk and should be given at > 5 year intervals for persons 
aged 7 years and older.  
? Use MPSV4 vaccine, if patients are 56 years of age or 
older.   
 
See the latest ACIP immunization schedules for guidance on 
risk groups, recommendations for primary series and need for 
boosters.
 
See also the ACIP recommendations on meningococcal 
vaccines for more detailed information. 
  
 
MDPH will reimburse clinics for additional nurse visits 
and vaccine costs as part of RHAP for adults who need to 
complete a primary vaccine series, for example a second 
or third dose of Td, Hepatitis B, HPV or varicella vaccines. 
The purpose of this policy is to facilitate completion of 
age-appropriate immunization of adults in a timely manner 
in anticipation of the refugee applying for adjustment of 
legal status, i.e. a “green card.” For insured refugees, 
clinics should seek reimbursement for visits from the 
patient’s insurance; therefore, clinics will generally not 
need to utilize this reimbursement mechanism for insured 
refugees who continue to receive primary care at their 
site. The policy, however, provides a mechanism for sites 
to seek reimbursement for a vaccine office visit for 
uninsured refugees or refugees who were seen for the 
RHAP but receive primary care elsewhere and do not have 
PCP authorization for the visit. These visits must occur 
within one year of the refugee’s date of entry in the United 
States.   
Further information on this policy is available from the 
RHAP Coordinator at 617-983-6564. 
 
 
Pregnant Women  MMR, varicella, zoster and LAIV are the only routine, live viral  
vaccines given in the U.S. those are contraindicated during 
pregnancy.  All other routine vaccines (and TB skin testing) 
may be given to pregnant women who are at risk of exposure. 
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There is no apparent risk of adverse effects to developing 
fetuses when hepatitis B vaccine is administered to pregnant 
women.  The vaccine contains non-infectious HBsAg particles 
and should cause no risk to the fetus.  Therefore, the vaccine 
series can be administered to women who are at risk and who 
test negative for hepatitis B virus infection. 
 
? Refugee women of reproductive age should be questioned 
about being pregnant or having intentions of getting 
pregnant before administering MMR or varicella vaccine 
and counseled as noted above.  Although a theoretical risk 
of congenital rubella syndrome exists for fetuses of 
pregnant women vaccinated with MMR, no harm to a fetus 
has been documented in women inadvertently vaccinated 
during pregnancy.  Routine pregnancy testing before 
administering live vaccines is not recommended.  
According to the ACIP, reasonable practices include: 
? Asking women if they are pregnant or might 
become pregnant in the next 4 weeks; 
? Not vaccinating women who state they are 
pregnant or plan to become pregnant; 
? Explaining the theoretical risk to the fetus if MMR or 
varicella vaccine is administered to a pregnant 
woman; and 
? Counseling women who are vaccinated not to 
become pregnant during the 4 weeks after 
receiving MMR or varicella vaccine. 
 
Providers assessing pregnant women should administer 
influenza vaccine to all women who will be pregnant during 
influenza season, regardless of stage of pregnancy.  
Administration of influenza vaccine is considered safe at any 
stage of pregnancy.   
 
Tdap should be administered during each pregnancy, 
regardless of the time since last dose of Td or Tdap (no 
minimum interval).  To maximize antibody transfer to the 
infant, administer Tdap between 27 and 36 weeks gestation, 
although Tdap may be given any time during pregnancy.  
Pregnant women who have never received Td or have not 
completed the 3-dose primary series should be vaccinated.  
Tdap should replace one dose of Td, preferably between 27 
weeks and 36 weeks.Women not vaccinated with Tdap during 
pregnancy should receive a dose immediately post partum.   
 
To reduce the likelihood of transmitting pertussis to infants, all 
adolescents and adults who are close contacts of infants, and 
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have not already received a Tdap, should receive a single 
dose.  
   
Immune globulin or a specific immune globulin is indicated for 
pregnant women following exposure to measles, hepatitis A or 
B, tetanus, chickenpox, or rabies. 
 
Lastly, clinicians may also perform urine HCG testing at either 
RHAP visit. 
 
Full recommendations for pregnant and breastfeeding women 
can be found at CDC’s Guidelines for Vaccinating Pregnant 
Women. 
 
Contraindications  History of anaphylactic or anaphylactic-like reactions to 
vaccine components and the presence of moderate or severe 
illness, with or without fever, are contraindications applicable 
to all vaccines.  For the purposes of the RHAP, the patient’s 
immunization series will be considered incomplete and he/she 
should be referred to primary care for consideration of allergen 
desensitization and follow-up on diagnosed illnesses. 
 
TB Testing and   The TB test (interferon gamma release assay [IGRA] or  
Vaccination   tuberculin skin test [TST]), varicella vaccine, and MMR 
vaccine may be given on the same day.  If MMR or varicella  
vaccines have been given recently, postpone the TB test until 
4-6 weeks after administration of the vaccines because such 
vaccination may temporarily suppress tuberculin reactivity and 
affect IGRA test results. 
 
U.S. Citizenship and  All refugees who apply for adjustment of status to permanent  
Immigration Service resident (legal permanent residence, or “green card”) are 
Requirements for  required to have written documentation of vaccination or  
Adjustment of  immunity for all vaccines recommended by the ACIP based on 
Status to Permanent  the age of the individual at the time of medical evaluation (with 
Resident    the exception of HPV and zoster). This documentation is  
verified by a Civil Surgeon, a physician appointed by the 
USCIS District Office to complete medical evaluations of 
adjustment of status applicants.  Refugees are eligible to apply 
for permanent residence one year after arrival in the United 
States.  The immunization requirements apply to all refugees, 
not just children. 
 
The immunization guidelines require all applicants to have 
documentation of immunity to, or primary vaccination against, 
all major vaccine-preventable diseases.  In addition, the 
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USCIS requires seasonal influenza vaccine for eligible 
individuals age 6 months to 18 years and > 50 years.  Single 
booster doses for adults are considered incomplete and may 
cause delay or jeopardize granting of legal permanent 
residence status.  Varicella requirements may be met by 
vaccination, reliable written or oral history of varicella disease, 
or serologic evidence of immunity.  While waivers exist for 
some incomplete vaccine series (such as insufficient time to 
complete a series, or medical contraindication), RHAP 
providers are strongly encouraged to support appropriate and 
complete vaccination of refugee patients.    
 
 
 
RESOURCES Immunization Program
Massachusetts Department of Public Health 
617-983-6800 
 
CDC’s Immunization Program
800-CDC-INFO or 800- 232-4636 
 
Recommendations of the Advisory Committee on 
Immunization Practices
 
Vaccine Adverse Events Reporting System (VAERS)
800-822-7967 
 
Immunization Action Coalition
612-647-9009 
 
CDC Domestic Refugee Health Guidelines: Immunization
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3.9 SCREENING 
 
 
 
 
 
 
 
 
 
PURPOSE    To evaluate and identify abnormalities in vital signs, visual  
   acuity, oral health, hematological indices, and urine chemistry 
   which may indicate underlying disease pathology; to evaluate 
   use of tobacco, alcohol and other drugs 
 
PROGRAM     In brief, the RHAP requires the following of providers: 
REQUIREMENTS    
1. Collect a urine sample from all refugees who are 
continent of urine for urinalysis by dipstick. 
2. Draw blood for all tests at the first visit before vaccines 
are administered. 
3. Order tests for all refugees: 
⇒ Anti-HBs and HBsAg 
⇒ CBC with 5 cell differential 
4. With consent, order testing for HIV antigen and/or 
antibodies for all refugees 14-64 years of age at first visit. 
(4th generation antigen-antibody test is preferred). 
Screening of refugees <14 years and > 64 years of age is 
also encouraged.  
5. Order blood lead level with a venous sample for all 
refugees <14 years of age. 
6. Order serum IgG levels against varicella zoster virus 
(chicken pox) for all refugees 5 years of age and older.  
7. Conduct formal, age-appropriate vision screening, gross 
hearing screening, and oral health/dental screening for all 
refugees. 
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[Note: RHS-15 requirements are discussed in Section 3.4] 
 
Refugees should have an evaluation for abnormalities of vision, 
hearing, and dentition as well as a complete set of vital signs 
and routine laboratory tests of blood and urine.  Vital signs 
should include head circumference in preschool-aged children.  
 
VISUAL ACUITY:   To test visual acuity, use the Snellen E 
chart. For preverbal children, the 
MassVAT flip cards may be used.  
Report 20/50 or worse as abnormal. 
 
HEARING:  An otoscopic examination of the 
external ear, the ear canal, and the 
tympanic membrane should precede 
any auditory test. Test for hearing 
grossly with the whisper test. 
 
If you notice your patient is having 
difficulty understanding you or the 
interpreter (and this is not a language 
barrier) or if you observe that in the 
interpreter's interaction with the patient, 
the interpreter is having difficulty 
understanding the patient (and again, 
this is not a problem with language or 
dialects), consider possible hearing 
impairment and the need for further 
evaluation. 
 
DENTITION:  All refugees should receive a gross oral 
exam to assess for oral health 
problems.  Abnormal findings may 
include missing teeth, caries, significant 
spacing problems, poorly fitting 
dentures, gingivitis, excessive plaque, 
signs of oral cancer, multiple fillings, 
etc… 
 
WEIGHT:   Record weight in pounds
 
HEIGHT:   Record height in inches
 
BP:    Utilize appropriate size cuffs for  
    children.  
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HEAD CIRCUM: Required for children under 3 years old; 
record in centimeters in chart (not 
reported on RHAP form). 
 
CBC:  Required for adults and children, with a 
five-cell white blood cell differential; 
document hemoglobin, mean 
corpuscular volume, white blood cell 
count, percent eosinophils, and platelet 
count on the RHAP form. 
 
  HIV:  Required to be offered for all refugees 
14-64 years of age at first visit. 
Screening of refugees < 14 years and > 
64 years of age is also strongly 
encouraged.  RHAP recommendations 
are adapted and modified slightly from 
CDC guidelines for HIV screening of 
refugees. RHAP encourages sites to 
use 4th generation (as of 2013) HIV 
antigen-antibody testing. 
 
Screening should be repeated 3-6 
months following resettlement for 
refugees who had recent exposure or 
at high risk. 
 
Children <18 months of age who test 
positive for HIV antibodies should 
receive further testing with DNA or 
RNA assays.  Results of positive 
antibody tests in this age group can be 
unreliable because they may detect 
persistent maternal antibody. 
 
LEAD: Blood lead level is required for children 
< 14 years of age. Record results in 
micrograms per deciliter. 
 
URINALYSIS:  Required for all patients, except 
children who are unable to void 
voluntarily.  Record the presence of 
sugar, protein, or blood as (-), (+), or 
(++). 
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TOBACCO: Assess use of tobacco products for all 
patients age 14 years and older.  
Record response as Yes or No.  
 
ALCOHOL: Assess alcohol consumption for all 
patients age 14 years and older. 
Record response as Yes or No.  
 (Note: Providers may need to 
specifically ask about beer as this is not 
always considered when discussing 
alcohol use.)  
 
FULL H & P: Document that a full history and 
physical examination were completed. 
 
MULTIVITAMINS: Provide all refugees with an age-
appropriate multivitamin and iron 
formulation in a quantity roughly 
sufficient to last one month. 
 
VITAMIN D: All refugees should be provided with a 
prescription for vitamin D using 
MassHealth coverage during the 
second health assessment visit (at 
treatment doses). Recent cohorts of 
refugees have been documented to 
have high prevalence of insufficiency or 
deficiency.58
 
 
TESTING AND   HIV testing, diagnosis, and care should be provided within  
REFERALS    specific cultural and societal norms. All HIV-infected  
FOR HIV   individuals should receive culturally sensitive and appropriate 
    counseling in their primary spoken language.  MDPH offers 
    various patient and clinician guides on its information  
    clearinghouse. Appropriate referral (with a warm hand-off) for  
care, treatment and preventive services should be made for 
all individuals confirmed to be HIV-infected. 
 
CONFIDENTIALITY Refugees may not understand their rights to confidentiality in 
AND DISCLOSURE  the United States. Information about refugees newly 
FOR HIV diagnosed with HIV during the health assessment should not 
be released to Resettlement Agencies or other third parties 
without the patient’s expressed permission in writing; 
                                                 
58 Penrose K, Hunter Adams J, Nguyen T, Cochran J, Geltman PL. Vitamin D Deficiency Among Newly Resettled Refugees in 
Massachusetts. J Immigr Minor Health. 2012 Mar 13. 
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however, results may be reported to the Division of Global 
Populations and Infectious Disease Prevention, MDPH, on 
the health assessment form without such written consent. 
(When obtaining verbal consent for testing, clinicians should 
inform  refugees that results of all RHAP testing are reported 
to the Massachusetts Department of Public Health).  
  
As of July 26, 2012, Massachusetts General Law (M.G.L), c. 
111, § 70F permits health care providers to test patients for 
HIV infection following verbal informed consent. Verbal 
informed consent should include an explanation of HIV 
infection and the meanings of positive and negative test 
results, and the patient should be offered an opportunity to 
ask questions. The Department of Public Health also had 
issued a clinical advisory regarding the change in consent 
process.  
  
When a refugee declines an HIV test, this decision should be 
documented in the medical record.  
 
 
MALNUTRITION,  Malnutrition, manifesting as growth abnormalities and  
ANEMIA, AND LEAD  micronutrient deficiencies, is an important and highly 
POISONING AMONG  prevalent problem among child and adult refugees. In 
REFUGEE CHILDREN addition, iron deficiency is known to predispose children to 
having elevated blood lead levels. RHAP data have shown 
that refugee children have significant growth abnormalities 
and rates of anemia59 as well as a double risk of having 
elevated blood lead: both on arrival due to overseas 
exposures and after resettlement in the United States due to 
lead contamination of the home environment (i.e. lead 
paint).60,61 Among some age groups of refugee children, rates 
of anemia may be well over 50%. Growth abnormalities and 
anemia have been particularly prevalent among recently 
arrived refugees from Africa. Recent investigation by the CDC 
has also found that lead poisoning (more common in iron-
deficient children) continues to be prevalent among African62 
and Burmese63 refugee children. 
 
                                                 
59 Geltman PL, Radin M, Zhang Z, Cochran J, Meyers AF. Growth status and related medical conditions among refugee 
children in Massachusetts, 1995 – 1998. Am J Public Health. 2001;91:1800-1805. 
60 Geltman PL, Brown MJ, Cochran J. Lead poisoning among refugee children resettled in Massachusetts, 1995 – 1999. 
Pediatrics. 2001;108:158-162. 
61 Eisenberg KW, van Wijngaarden E, Cochran J, Geltman PL. Increases in blood lead levels among refugee children 
resettled in Massachusetts, 2000-2007. Am J Public Health. 2011;101:48-54. 
62 Kellenberg J, DiPentima R, Maruyama M, et al. Elevated blood lead levels in refugee children – New Hampshire, 2003 – 
2004. MMWR. 2005;54:42-46. 
63 Mitchell T, Jentes E, Ortega L, Scalia Sucosky M, Jefferies T, Bajcevic P, Parr V, Jones W, Brown MJ, Painter J. Lead 
poisoning in United States-bound refugee children: Thailand-Burma border, 2009. Pediatrics. 2012 Feb;129(2):e392-9. 
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Among adults, RHAP data indicate high rates of anemia. In 
particular, recent cohorts of refugee women of child-bearing 
years entering Massachusetts have had rates of anemia as 
high as 57%. In addition, published reports have documented 
many other manifestations of nutritional deficiency among 
adult refugees. One area of concern is vitamin D deficiency. 
In New Zealand, 17% of refugees were deficient, and another 
37% were insufficient. Female gender was strongly 
associated with low vitamin D levels.64  Vitamin B12 
deficiency is addressed in Section 3.12 Targeted Testing.   
 
Because of these issues, RHAP sites are required to obtain 
and provide 30-day supply of multivitamins with iron for 
refugees during the first health assessment visit. 
 
At the first RHAP visit, clinicians should conduct an 
appropriate nutritional assessment, including use of 
anthropometrics and CDC growth charts, and refer 
appropriate children and families to their local WIC program 
and other nutritional support services.  In addition, during the 
second RHAP visit, clinicians should provide new written 
prescriptions for supplements that will be covered by the 
refugee’s MassHealth.  
 
Lastly, in response to CDC guidance on the issue of lead 
poisoning, the RHAP protocol requires lead testing of older 
children and thorough assessment of nutritional status.  
 
• All refugee children should have a thorough nutritional 
assessment. 
• All children should start taking a daily multivitamin with 
iron shortly after arrival in the United States. RHAP 
clinicians should check to be sure that children are taking 
vitamins with iron, assess the need for refills that can be 
covered by MassHealth after a family’s temporary supply 
runs out, or prescribe them if not already being taken.  
• All children should have blood testing for anemia, and 
children < 14 years of age should have testing of blood 
lead levels.  
• Children under 7 years of age should have another lead 
test 3-6 months after the first test, after permanent 
housing placement as recommended by CDC guidelines 
• Consider repeat blood lead testing of older children living 
with lead hazards 
 
                                                 
64 Wishart HD, Reeve AMF, Grant CC. Vitamin D deficiency in a multinational refugee population. Internal Med Journal. 2007 
Dec;37(12):792-7. Epub 2007 May 21. 
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The recommendation for repeat lead testing derives from 
clear evidence that refugee children, particularly those from 
Africa, are developing elevated blood levels after resettlement 
in the United States as a result of lead contamination of their 
home environments.65
 
The Division of Global Populations and Infectious Disease 
Prevention encourages all RHAP provider sites to collaborate 
with resettlement agencies and the Massachusetts Childhood 
Lead Poisoning Prevention Program (CLPPP) to ensure 
repeat testing and follow-up of young refugee children.   
 
More information on lead prevention services, regulations and 
statistics in Massachusetts is available at 
http://www.mass.gov/eohhs/gov/departments/dph/programs/e
nvironmental-health/exposure-topics/lead/. In addition, 
information from the CDC on lead prevention programs is 
available at http://www.cdc.gov/nceh/lead/about/program.htm. 
 
 
 
 
RESOURCES  Massachusetts Childhood Lead Poisoning Prevention  
Program 
Massachusetts Department of Public Health 
617-624-5757 
 
CDC Lead Poisoning Prevention in Newly Arrived Refugee 
Children: Tool Kit
 
Screening for Lead during the Domestic Medical Examination 
for Newly Arrived Refugees  
 
CDC Domestic Refugee Health Guidelines
  
  MDPH Office of HIV/AIDS  
Massachusetts Department of Public Health 
617-624-5300 
800-443-2437 
 
AIDS Action Committee HIV-AIDS Hotline
800-235-2331  
 
                                                 
65 Eisenberg KW, van Wijngaarden E, Fisher SG, Korfmacher KS, Campbell JR, Fernandez ID, Cochran J, Geltman PL. Blood 
lead levels of refugee children resettled in Massachusetts, 2000 to 2007.Am J Public Health. 2011 Jan;101(1):48-54. Epub 
2010 Nov 18. 
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Division of HIV/AIDS Prevention
U.S. Centers for Disease Control and Prevention 
1-800-CDC-INFO (1-800-232-4636) (assistance regarding personal risk)  
1-800-HIV-0440 (1-800-448-0440) (assistance regarding clinical care) 
1-800-458-5231 (National Prevention Information Network, assistance 
regarding information distribution) 
 
 
The Massachusetts HIV/AIDS Services and Resource Guide 
was updated in 2012 and provides extensive information on 
services and resources.  
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3.11 OTHER DIAGNOSES / MEDICATIONS / REFERRALS  
 
      
 
 
PURPOSE    To record abnormal or significant findings and diagnoses, 
medications prescribed, referrals for primary care and other 
appointments, and health education content 
 
 
DOCUMENTATION  Record diagnoses other than those listed elsewhere 
 OTHER DIAGNOSES in the health assessment form under “Other Diagnoses”. 
 
 
Do not record normal findings or non-specific symptoms 
which do not strongly suggest a significant clinical 
diagnosis. 
 
 
Record the diagnosis (as opposed to the symptoms which led 
to the diagnosis) and any appropriate referrals, follow-up, or 
interventions needed; i.e., record your assessment and plan 
and not your subjective and objective findings.  Examples: 
1) Record “Probable peptic ulcer disease” rather than 
“chronic epigastric pain, dyspepsia, nocturnal 
exacerbation;”   
2) Record “Upper respiratory infection” rather than “3 day 
history of clear rhinorrhea and occasional cough.”   
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An exception to recording symptoms would be a symptom that 
is considered a diagnosis by itself.  An example of this is 
“headaches.”  Even in this case, however, it is preferable to 
use a more specific diagnosis, such as “migraine headaches.”  
 
MEDICATIONS   Record medications that are prescribed or dispensed 
PRESCRIBED  for the treatment of parasitic infections and other conditions.  
For example, if a clinician diagnoses otitis media and 
prescribes amoxicillin, he/she should record the dose, 
frequency, and duration of treatment on the core form.  
Treatment for conditions identified through targeted tests are 
recorded on the Targeted Test Form. 
 
Whenever possible, all prescriptions reimbursed by the RHAP 
should be pre-filled and available at the second visit for review 
with the health assessment patient.  This is required for anti-
parasitic medications prescribed to treat pathological parasites 
identified in the O & P.  It is recommended that, as 
appropriate, the first dose be taken during the second visit. 
 
COMMENTS/REFERRALS 
 
Primary Care Referral All refugees should be referred to a primary care provider. 
 
All providers should schedule a primary care appointment for 
refugees with their consent either at the RHAP site or 
elsewhere.  Record the name of the primary care provider 
(and/or clinic site), the date, and the time of the appointment 
on the health assessment form. 
 
Many refugees with chronic conditions are likely to be aware 
that they have a health problem or even have had it diagnosed 
or treated in the past.  Refugees will often be relieved to 
receive medical care for conditions which they have neglected, 
often knowingly because of the disruption to their lives which 
caused them to flee their home countries. 
 
The U.S. Citizenship and Immigration Services (USCIS) 
requires immunization documentation with applications for 
legal permanent residence.  All refugees will need to have 
documentation of completed primary series’ for all vaccines 
currently recommended in the United States.  In addition to 
initiating vaccination during the health assessment, all 
refugees are likely to need follow-up for vaccination which can 
be completed by primary care providers.  Community Health 
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Workers with the MDPH Division of Global Populations and 
Infectious Disease Prevention also provide refugees with 
information on the importance of primary care and other 
referral appointments.   
 
Other Referrals  Make referrals, as appropriate, for urgent matters.  
 
Record referral information on the health assessment form. 
 
The decision to make a referral is up to the RHAP provider.  
Providers must use their judgment as to what constitutes an 
“urgent” or “emergent” matter.  For medical conditions, 
referrals should be made if the condition poses a threat to life 
or a serious health risk which could result in permanent 
damage.  For example, it is common to encounter refugees 
with chronic ear infections and perforated tympanic 
membranes.  Given the risks of suppurative complications, 
especially in younger children, and hearing impairment, it 
would be appropriate to begin a course of antibiotics and refer 
the patient to an otolaryngologist for evaluation rather than 
leave the referral up to the primary care physician, a decision 
which could add up to several months to the process, an 
unacceptable delay for a child in a developmental phase of 
rapid language acquisition or entering school, or an adult 
trying to learn English and enter the job market.   
 
Make referrals, as appropriate, for other medical, dental and 
support services. 
 
Instruct and refer refugees as appropriate to the following 
services: 
 
• Dental care services  
• Appropriate medical sub-specialty referrals for initiation or 
continuation of care of identified medical conditions 
• Local community resources, such as WIC, the Special 
Supplemental Nutrition Program for Women, Infants, and 
Children 
• Educational evaluations: Early Intervention Programs for 
children with, or at risk of, developmental delay, up to age 
2 years and 9 months, after which age, a referral should be 
made to local public schools for a Chapter 766/CORE 
evaluation for special educational services  
• Mental health services 
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NOTE:  
All refugees who are pregnant or lactating women or 
children age 5 years or less will generally be eligible for 
WIC and should be referred, if not already referred by the 
resettlement agency.  MDPH Community Health Workers 
and resettlement case managers may be able to assist 
with such referrals. 
 
 
In considering child development issues, the RHAP 
encourages providers to be aggressive.  While a refugee 
child’s culture may play a great role in determining 
developmental stage, it must be remembered that the child will 
now be measured against and expected to meet 
developmental standards of the US.  For example, it would be 
appropriate in the case of a 24 month old who is not talking to 
refer the child for audiologic testing and an Early Intervention 
program.  Refugee children are at increased risk of school 
failure and mental health issues; therefore, interventions 
aimed at expediting child development or educational 
interventions to maximize school readiness and addressing 
mental health issues should be prioritized. 
 
MassHealth   Most refugees will have their MassHealth cards by the time 
of a referral appointment, and concerns about coverage 
should not prevent referrals. 
 
Refugees who have not received their MassHealth cards 
should be eligible for MassHealth either retroactively to the 
date of application (usually within the first week of 
resettlement) or through a temporary number.   
 
 
Mental Health  Providers can obtain information about multicultural mental 
health services, particularly for immigrants and refugees, from 
the Massachusetts Department of Mental Health. The Office of 
Refugee Resettlement provides funding for a comprehensive 
program of support for survivors of torture living in the United 
States. Grantees in Massachusetts include: 
 
Boston Center for Refugee Health and Human Rights 
Boston Medical Center 
http://www.bcrhhr.org/
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Harvard Program in Refugee Trauma 
Massachusetts General Hospital 
http://www.hprt-cambridge.org/
  
In addition to providing direct services, clinicians with these 
programs are available for training and technical assistance to 
RHAP providers relative to serving torture survivors. 
 
 
Health Education  Detailed information on health education that is considered  
integral to the health assessment is found in Section 3.10. 
 
Record (by check-off) topics that are reviewed with refugee 
patients. 
 
 
RESOURCES  Massachusetts Women, Infant and Children (WIC) Nutrition  
Program
 
Early Intervention Program
Massachusetts Department of Public Health 
 
Massachusetts Department of Mental Health
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Links to Online Resources 
 
 
Massachusetts Government Commonwealth of Massachusetts
 
     Department of Public Health
      MDPH list of Reportable Diseases
       Immunization Guidelines and Schedules
       Sexually Transmitted Disease Clinics
       Tuberculosis Clinics
       WIC
Office of Health Equity
 
Office for Refugees and Immigrants
 
Federal Government   Centers for Disease Control & Prevention (CDC)
Updates on the medical examination of aliens 
(refugees and immigrants)
Division of Global Migration and Quarantine
       
Growth charts
 
Childhood immunization schedule
National Immunization Program
Immunization questions by email
 
      Emerging Infectious Diseases
      Division of Sexually Transmitted Diseases
Division of Tuberculosis Elimination
HIV/AIDS Information
 
Travelers Information
 
      Malaria Treatment guidelines
       Treatment Table
       Reporting
 
MMWR journal
 
Department of State, Bureau of Population, Refugees, and 
Migration     
 
Bureau of Citizenship and Immigration Services
  Civil surgeon locator
 
National Institutes of Health
  
Guide to Clinical Preventive Services, 2nd ed.
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Health Information Page, NIH
 
NLM Medline and PubMed
 
Office of Civil Rights 
  Limited English Proficiency federal interagency workgroup
 
Office of Minority Health     
 
Office of Refugee Resettlement (ORR)
 
SAMHSA Refugee Mental Health Program
 
 
International Agencies  United Nations High Commission for Refugees (UNHCR)
 
United Nations Children’s Fund (UNICEF)
 
World Health Organization
 
Pan American Health Organization
 
Weekly Epidemiological Record  
 
International Organization for Migration
 
 
Non-Governmental   Bridging Refugee Youth & Children’s Services
Organizations 
Cultural Orientation Resource Center, Center for Applied 
Linguistics
 
Diversity Rx
  
Ethnomed
 
Ethnologue
 
Hablamos Juntos
 
Healthy Roads Media
 
Immunization Action/Hep. B Coalition
 
InterAction
 
International Comm. of the Red Cross (English site)
 
Migration Policy Institute
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Modern Language Association Language Map 
 
National Coalition of State Legislatures- Immigrant Policy Project
 
National Council on Interpreting in Health Care (NCIHC)
 
Physicians for Human Rights
 
Refugee Council USA
 
Refugee Health Information Network
 
Relief Web
 
TB Education and Training Resources
 
Think Cultural Health
 
U.S. Committee for Refugees and Immigrants
 
 
National Voluntary   Church World Service (CWS) 
Agencies    
Episcopal Migration Ministries (EMM)
 
Ethiopian Community Development Council (ECDC)  
 
Hebrew Immigrant Aid Society (JFS)  
 
Immigration & Refugee Services of America (USCRI, Int’I. Inst.)
  
International Rescue Committee (IRC)  
 
Lutheran Immigration & Refugee Service (LSS)  
 
US Catholic Conference (USCC)  
 
World Relief (WR)  
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6.1 MDPH Refugee Health Assessment Program:  Protocol Summary 
 
 Children <7 yrs Children >7 yrs and 
Adults 
CORE ELEMENTS 
Review overseas documents X X 
Complete history and physical X X 
PPD / TB Clinic referral X X 
Hepatitis B (HBsAb/HBsAg) X X 
Varicella (Ab)  7 – 59 years only 
Immunizations X X 
Ova & Parasites – single stool sample X X 
Giardia/Cryptosp. by Fluor. Ab Stain X X 
CBC with differential X X 
Vitamin D level (25-OH Vit. D) X X 
Urinalysis dipstick X X 
Pb (blood lead) X 7-16 years 
recommended 
Vision screening X X 
Dental screening X X 
Hearing screening X X 
Health education X X 
Medical interpreter X X 
TARGETED ELEMENTS 
Gonorrhea probe/culture/LCR 
Syphilis serology 
Chlamydia probe/LCR 
RPR 
Strongyloides serology 
Schistosoma serology 
Filaria serology 
Total Immunoglobulin levels 
Plasmodium serology 
Stool O&P (up to 2 additional) 
Malaria smears 
HIV 
Streptococcus rapid direct/culture 
Urine culture and sensitivities 
Pregnancy test 
TSH 
ECG 
FS blood glucose 
MEDICATIONS 
Medications for parasitic infections 
Medications for acute infections 
Iron supplements for iron deficiency 
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Adjustment of Status – procedure allowing certain aliens already in the U.S. to apply for 
immigrant status (Lawful Permanent Resident); a medical examination performed by an 
approved civil surgeon is required as part of the application process; refugees are required to 
apply for adjustment of status one year after arrival in the U.S. 
Administration for Children and Families (ACF) - the HHS agency responsible for federal 
programs that promote the economic and social well-being of families, children, individuals, and 
communities; ORR is part of ACF. 
Website:  www.acf.hhs.gov
Affidavit of Relationship (AOR) - a form filed with the U.S. Refugee Admissions Program by 
refugees, permanent residents, or American citizens to enable persons in countries of first 
asylum to establish a claim to a relative in the U.S. This form is not used in the application 
process for an immigrant visa. 
Alien – a person who is not a citizen or national of the U.S.; term includes Legal Permanent 
Resident (LPR). 
Amerasian – refers to certain Amerasians from Vietnam who are admitted to the U.S. as 
immigrants pursuant to Sec. 584 of the Foreign Operations, Export Financing, and Related 
Programs Appropriations Act, 1988 (as contained in Sec. 101(e) of Public Law 100-202 and 
amended by the 9th proviso under Migration and Refugee Assistance in title II of the Foreign 
Operations, Export Financing, and Related Programs Appropriations Act, 1989 (Public Law 100-
461 as amended) and “was born in Vietnam after January 1, 1962 and before January 1, 1976 
and was fathered by a citizen of the United States.”  Amerasians are admitted to the U.S. as 
immigrants, rather than refugees. They and their immediate relatives are entitled to ORR-
funded refugee services and benefits to the same extent as refugees. 
American Council of Voluntary Agencies (ACVA) form - refers to a form sent by the U.S. 
Public Health Service quarantine station to the state health department  The ACVA contains 
demographic and medical information on individual refugees.   
Arrival Paper – the notification form provided by the U.S. Public Health Service quarantine 
station to the state health department from; also called the ACVA form, Orderly Departure Form, 
Non-Indochinese Refugee Notification, or Reception and Placement Assurance Form; form 
contains demographic and medical information on individual refugee arrivals. 
Association of Refugee Health Coordinators (ARHC) - a national membership organization 
for state and local Refugee Health Coordinators. 
Asylee - an alien already in the U.S. or at a port of entry who is found to be unable or unwilling 
to return to his or her country of nationality, or unable to seek the protection of that country 
because of persecution or a well-founded fear of persecution because of the alien’s race, 
religion, nationality, membership in a particular social group, or political opinion.  An asylee has 
made a formal application for asylum and has been granted asylum by the USCIS or by an 
Immigration Judge of the Executive Office of Immigration Review of the U.S. Department of 
Justice.  Asylees may also petition for immediate family members who are outside of the U.S. to 
join them in the U.S.  If the petition is approved, their family members are granted derivative 
asylee status and may join the asylee in the U.S.  Asylees are eligible for ORR-funded refugee 
benefits and assistance beginning on the date of their final grant of asylum. 
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Asylum Corps – corps in USCIS of professional asylum officers who receive special training in 
international human rights law, conditions in countries of origin, and other relevant national and 
international refugee law. 
Case Management Agency - agency under contract to the Massachusetts Office for Refugees 
and Immigrants to perform certain functions under the Massachusetts Refugee Resettlement 
Program (MRRP) including, but not limited to, (1) working with refugees and employment 
services agencies to develop a Family Employment Plan designed to employ at least one adult 
in the shortest possible times and lead to self-sufficiency for the family; (2) tracking the progress 
of the Family Employment Plan; (3) linking refugees with appropriate services and programs; (4) 
determining initial and ongoing eligibility for Transitional Cash and Medical Assistance. 
Center for Applied Linguistics (CAL) - private, non-profit organization, based in Washington 
DC, working to improve communication through better understanding of language and culture.   
The Cultural Orientation Resource (COR) Center is housed at CAL and works closely with the 
U.S. government, international organizations, refugee resettlement agencies in the United 
States, and their representatives overseas to develop and distribute resources about refugee 
training and resettlement, provide technical assistance regarding refugees' native cultures, 
languages, and orientation needs, and develop a network of refugee providers who exchange 
refugee orientation information, concerns, and best practices. 
Website: www.cal.org
Centers for Disease Control and Prevention (CDC) - the federal agency responsible for 
promoting health and quality of life by preventing and controlling disease, injury, and disability.   
Website: www.cdc.gov  
Centers for Medicaid and Medicare Services (CMS) – the HHS agency responsible for health 
insurance programs for older persons, persons with low income, and all qualified children. 
Website: www.cms.gov
Church World Service (CWS) – a national voluntary agency. 
Website:  http://www.churchworldservice.org/Immigration/index.html
Civil Surgeon - a physician in the U.S. approved by the USCIS to conduct the medical 
examination of applicants seeking to adjust status to Lawful Permanent Resident (the 
terminology for this role when performed abroad is Panel Physician). 
Civil Surgeon Locator: 
https://egov.uscis.gov/crisgwi/go?action=offices.type&OfficeLocator.office_type=CIV
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Class A Condition - a medical condition that renders the alien inadmissible to the U.S. under 
the INA.  From  Title 42--Public Health, Chapter I--Public Health Service, Department of Health 
and Human Services, Part 34--Medical Examination of Aliens--Table of Contents 
Sec. 34.4 Medical notifications. 
    (a) Medical examiners shall issue medical notifications of their findings of the presence or 
absence of Class A or Class B medical conditions. The presence of such condition must 
have been clearly established. 
    (b) Class A medical notifications. (1) The medical examiner shall report his/her findings to the 
consular officer or the INS by Class A medical notification which lists the specific 
condition for which the alien may be excluded, if an alien is found to have: 
(i) A communicable disease of public health significance; 
    (ii)(A) A physical or mental disorder, and behavior associated with the disorder that may 
pose, or has posed, a threat to the property, safety, or welfare of the alien or others;  
or 
         (B) A history of a physical or mental disorder and behavior associated with the 
disorder, which behavior has posed a threat to the property, safety, or welfare of 
the alien or others and which behavior is likely to recur or lead to other harmful 
behavior; 
    (iii) Drug abuse or addition; 
and diagnosed in a refugee during the overseas medical examination. Class A conditions 
require approved waivers for entry to the U.S. and require follow-up upon arrival by appropriate 
medical personnel. 
Class B Condition - a physical or mental abnormality, disease, or disability serious in degree 
or permanent in nature amounting to a substantial departure from normal well-being diagnosed 
during the overseas medical examination; Class B designations indicate a need for follow-up 
soon after arrival in the U.S. by appropriate medical personnel but are not grounds for 
inadmissibility to the U.S. under the INA. 
Code of Federal Regulations (CFR) – compilation of federal rules and regulations. 
Search the CFR on the web:  http://www.gpoaccess.gov/cfr/index.html
Community-Based Organization (CBO) – a non-profit organization that serves needs of the 
community within which it is located 
Cuban/Haitian Entrant - refers to (a) Any individual granted parole status as a Cuban/Haitian 
Entrant (Status Pending) or granted any other special status subsequently established under 
the immigration laws for nationals of Cuba or Haiti, regardless of the status of the individual at 
the time assistance or services are provided; and (b) Any other national of Cuba or Haiti (1) 
Who: (i) Was paroled into the United States and has not acquired any other status under the 
Immigration and Nationality Act; (ii) Is the subject of exclusion or deportation proceedings under 
the Immigration and Nationality Act; or (iii) Has an application for asylum pending with the 
Immigration and Naturalization Service; and (2) With respect to whom a final, non-appealable, 
and legally enforceable order of deportation or exclusion has not been entered. (Refugee 
Education Assistance Act of 1980, Pub. L. No. 96-422). 
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Cultural Orientation (CO) - overseas CO helps refugees develop realistic expectations about 
life in the United States; the overseas CO program is funded by the Department of State, 
Bureau of Populations, Refugees, and Migration. CO is not required for admission to the U.S. 
as a refugee.  
Website:  www.cal.org/co/overseas/
Customs and Border Protection (CBP) – agency within DHS responsible for enforcement of 
immigration and customs laws at the air, land, and sea ports of entry to the U.S.; CBP can 
exclude from the U.S. those aliens found to be inadmissible upon inspection at the port of entry 
or within 100 miles of the border. 
Date of Entry - a term for the date on which individuals become eligible for benefits and 
services. For refugees this is their date of arrival in the U.S. (as recorded on the Form I-94 
Arrival/Departure Record). For Cuban/Haitian Entrants this is the date they were granted 
Cuban/Haitian Entrant status, which is typically the date of their parole into the U.S.  For 
asylees this is the date of final grant of asylum (as noted on the approval letter or immigration 
court order). For victims of a severe form of trafficking it is the date of certification or eligibility 
(as noted on the certification or eligibility letter), or date they were granted a T visa. 
Division of Global Migration and Quarantine (DGMQ or DQ) – the CDC division responsible 
for reducing morbidity and mortality due to infectious diseases among immigrants, refugees, 
international travelers, and other mobile populations that cross international borders. In addition, 
DGMQ is committed to promoting border health and preventing the introduction of infectious 
agents into the U.S. DGMQ is responsible for 20 Quarantine Stations at U.S. ports of entry and 
land-border crossings. 
Website:  www.cdc.gov/ncidod/dq
Department of Homeland Security (DHS) – the federal agency tasked with leading the unified 
national effort to secure America; charged with protecting the United States from threats and 
hazards;  also responsible for ensuring safe and secure borders, enforcing the INA, welcoming 
lawful immigrants and visitors, and promoting the free-flow of commerce.  USCIS, ICE and CBP 
are part of DHS.  
Website:  www.dhs.gov
Department of Justice (DOJ) – the federal agency that enforces federal laws 
Website:  www.justice.gov
Department of State (DOS) – the federal agency with principal responsibility for the foreign 
policy and international relations of the U.S., including non-military programs and activities of 
the U.S. Government abroad, and the visa function. 
Website:  www.state.gov
Division of Tuberculosis Elimination (DTBE) – the CDC Division responsible for prevention 
and control of TB in the U.S. 
Website:  http://www.cdc.gov/tb
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DS-2053 - a Department of State form required for medical examination of applicants overseas 
for U.S. visas; this form is in the possession of the refugee on his/her arrival in the U.S. and 
contains all findings from the overseas medical examination. 
Website:  http://www.cdc.gov/ncidod/dq/dsforms/2053.htm
Electronic Disease Notification (EDN) –  a web-based system that automates the process by 
which states or local health officials are notified of the arrival of immigrants with medical or 
health conditions and refugees.  EDN provides relevant overseas medical screening and 
treatment information for stateside follow-up; EDN is administered by the CDC Division of 
Global Migration and Quarantine. 
Employment Authorization Document (EAD) – document issued by USCIS to the alien 
granting him/her authorization to work in the U.S., or evidence of employment authorization 
incident to the alien’s immigration status. 
Episcopal Migration Ministries (EMM) – a national voluntary agency. 
Website:  http://www.episcopalchurch.org/emm.htm
Ethiopian Community Development Council (ECDC) – a national voluntary agency. 
Website:  www.ecdcinternational.org/
Health and Human Services (HHS) – the federal agency that administers federal health and 
social services programs 
Website:  www.hhs.gov
Health Assessment (aka “Domestic Health Exam” or “Health Screening” or “Medical 
Screening”) - the comprehensive assessment of newly arrived refugees; it should include a 
follow-up of conditions identified overseas; and evaluation and diagnostic services to determine 
health status and identify health problems; referral for follow-up of identified health problems; 
education/orientation to local health care services; and linkage with primary health care 
services.  The process varies depending on the state.  ORR uses the term “Medical Screening” 
in the regulations. 
Health Assessment Provider - the provider contracted by the Massachusetts Department of 
Public Health to deliver health assessment services. 
Hebrew Immigrant Aid Society (HIAS) – a national voluntary agency. 
Website:  www.hias.org
I-94 - the immigration document that records each alien’s arrival and departure from the U.S.  It 
identifies the period of time for which the alien is admitted and the alien’s immigrant status 
Immigrant - a person who is not a U.S. citizen or national who enters the U.S. with the intent to 
remain for an indefinite period of time or, once in the U.S., is granted permission to do so (see 
Adjustment of Status). 
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Immigration and Customs Enforcement (ICE) – the agency within the Department of 
Homeland Security that is responsible for enforcement of the immigration laws; ICE detects, 
detains, and removes from the U.S. aliens unlawfully present in the U.S. and aliens who have 
otherwise violated the immigration laws. 
Website:  www.ice.gov
Immigration Status - the status under the INA under which an alien is allowed to enter and 
remain in the U.S., and which determines the activities he/she is permitted to engage in while in 
the U.S.   Examples of immigration status include Lawful Permanent Resident, refugee, 
Cuban/Haitian Entrant, visitor for business or pleasure, student, exchange visitor, specialized 
worker, temporary agricultural worker, crewmember, and parolee.  Aliens physically in the U.S. 
who lack an immigration status, who violate the terms of their visas, or who overstay their visas 
are considered unlawfully present 
Immigration and Nationality Act (INA) of 1952 – the Act that, along with other immigration 
laws, treaties, and conventions of the United States, relates to the immigration, temporary 
admission, naturalization, or removal of aliens 
Website: 
http://www.uscis.gov/propub/ProPubVAP.jsp?dockey=cb90c19a50729fb47fb0686648558dbe
Information on Migrant Populations (IMP) – a CDC data notification system for all refugees 
and immigrants with Class A/B TB conditions (being replaced with EDN in 2007-08) 
Internally Displaced Persons (IDP) –  persons who have been forced to flee their homes for 
the same reasons as refugees, but who have not left their own countries and are therefore not 
considered "refugees" under the UNHCR Statute (General Assembly res. 428 (v)) or under 
relevant international or regional instruments. 
International Committee of the Red Cross (ICRC) - intergovernmental agency with a 
permanent mandate founded in international law, on a worldwide basis to help victims of 
conflicts and internal violence, whoever they may be. 
Website:  www.icrc.org
International Organization for Migration (IOM) - the intergovernmental organization that 
arranges refugee travel and travel loan to the U.S.; provides cultural orientation briefings and/or 
medical screenings in some locations. 
Website:  www.iom.int
IOM Bag - the large white plastic bag issued to refugees at the time of travel to the U.S. in order 
to carry medical and other documents, including the OF-157, immunization records, and 
overseas chest X rays. 
International Rescue Committee (IRC) – a national voluntary agency.  
Website:  www.theirc.org
Joint Voluntary Agency (JVA) (now OPE) – see Overseas Processing Entity; former term for 
this function.   
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Lawful Permanent Resident (also called Permanent Resident) (LPR) – an alien granted 
permission by DHS/USCIS to remain permanently in the U.S., evidenced by I-551 (green card).  
After one year in the U.S., refugees must apply for adjustment of status to LPR.  After one year 
in the U.S., asylees are permitted to, but are not required to, apply for adjustment of status to 
LPR.  After five years in LPR status (four years for refugees), the LPR may file an application for 
naturalization to become a U.S. citizen.  LPRs who obtained LPR status by marriage to a U.S. 
citizen are eligible to apply for naturalization in three years. 
Lutheran Immigration and Refugee Service (LIRS) – a national voluntary agency. 
Website:  www.lirs.org
Massachusetts Refugee Resettlement Program (MRRP) - the refugee resettlement program 
administered by the Massachusetts Office for Refugees and Immigrants.  The primary purpose 
of the MRRP is to assist refugees to achieve durable economic self-sufficiency.  It seeks to 
accomplish this purpose by emphasizing coordination of services, early employment and post-
placement services. 
MassHealth - the combined Medicaid program (Title XIX) and Children’s Health Insurance 
Program (CHIP) in Massachusetts.  MassHealth is administered by the Office of Medicaid. 
Match Grant Program – the ORR discretionary grant program that provides grants to VOLAGs 
to resettle newly arriving refugees and assist them in becoming economically self-sufficient 
within the first 4-6 months in the U.S. without access to public assistance. The Matching Grant 
Program requires a match from private funds or donated goods and services to partner with 
monies provided by ORR. 
Website:   http://www.acf.hhs.gov/programs/orr/programs/match_grant_prg.htm
Medicaid - a state administered program, jointly funded by the states and federal government, 
that provides medical coverage to eligible persons based on age, income, and/or disability 
status. Eligible groups include children, adults with dependent minors, and SSI recipients. Each 
state sets its own guidelines regarding eligibility and services. 
Migrant - generally understood to be an economic migrant who has been “engaged in a 
remunerated activity in a state of which he or she is not a national”; the term also encompasses 
undocumented migrants.  The term “migrant” should be understood to include cases where the 
decision to migrate has been taken freely, for “personal convenience,” without any external 
compelling factors such as ethnic or civil strife or any environmental destruction. 
Mutual Assistance Association (MAA) – a non-profit, community-based organization 
promoting successful refugee resettlement comprised of refugee populations. Generally, MAAs 
are small grass-roots organizations that work in specific communities and geographic areas. 
ORR encourages states to give special consideration to MAAs in contracting refugee services. 
Non-immigrant – a foreign national who seeks temporary entry to the U.S. for a specific 
purpose (e.g., persons on student, business or tourist visas). 
Office for Refugees and Immigrants (ORI) – the state agency that oversees refugee 
resettlement in Massachusetts. 
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Office of Global Health Affairs (OGHA) – the HHS Office responsible for promoting the health 
of people worldwide by advancing HHS' global strategies and partnerships. 
Website:  www.globalhealth.gov/globalhealth/refugee/index.html  
Office of Refugee Resettlement (ORR) - the HHS agency responsible for the domestic 
refugee resettlement program, refugees, asylees, Amerasians, Cuban/Haitian Entrants, victims 
of trafficking, survivors of torture, unaccompanied alien children, Lawful Permanent Residents 
who have held one of these statuses in the past and Iraqi and Afghan Special Immigrant Visa 
holders, as well as the repatriation of U.S. citizens. 
Website:  www.acf.hhs.gov/programs/orr/
Optional Form 157 (OF-157) (replaced by DS-2053) – the DOS form for medical examination 
of applicants overseas for U.S. visas. No longer in use; the DS-2053 replaced the OF-157. 
Orderly Departure Program (ODP) – the program between the United Nations High 
Commissioner for Refugees (UNHCR) and Vietnam that established a legal emigration program 
for those seeking family reunification, or those of special interest to resettlement countries (e.g., 
former political detainees, Amerasians); program was established to provide an alternative to 
the dangerous boat departures. 
Overseas Processing Entity (OPE) – funded by DOS/PRM to prepare the necessary 
casework for persons eligible for consideration by the USCIS under the U.S. Refugee 
Admissions Program and, for those approved, to provide assistance in completing the additional 
requirements for refugee admission under Section 207 of the INA. In addition, the OPE forwards 
the necessary data on all DHS-approved cases to the Refugee Processing Center (RPC) for 
distribution to Reception and Placement agencies according to procedures established by PRM. 
Many also provide cultural orientation. 
Panel Physician – a physician, appointed by the U.S. Consul and per the INA, who conducts 
the medical examination of the alien overseas (the terminology for this role when performed in 
the U.S. is Civil Surgeon) 
Parolee – an alien who has been given permission to enter the U.S. under emergency or 
humanitarian conditions or when that alien’s entry is considered to be in the public interest or for 
significant public benefit. Parole does not constitute a formal admission to the U.S. and confers 
temporary status only. Absent a change in or adjustment of status, parolees must depart the 
U.S. when the conditions supporting their parole cease to exist. There are several types of 
parole, including parole authorized as part of an overseas parole program (such as the U.S. has 
with Cuba), port-of-entry parole, deferred inspection parole, advance parole, humanitarian 
parole, or public interest parole.   
Under the INA a parole is not an admission to the U.S. 
Permanent Resident – see Lawful Permanent Resident 
Port of Entry – any location in the U.S. or its territories that is designated as a port of entry for 
aliens and U.S. citizens;  refugees are generally limited to entering the country through those 
ports of entry with staffed Quarantine Stations 
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Population, Refugees, and Migration [Bureau of] (PRM) – the Department of State bureau 
responsible for formulating policies on population, refugees, and migration, and for 
administering U.S. refugee assistance and admissions programs. 
Website:  www.state.gov/g/prm/
Public-Private Partnership (PPP) Program – ORR program under which states have the 
option of entering into a partnership agreement with local resettlement agencies for the 
operation of a public/private refugee cash assistance (RCA) program.  The partnerships 
facilitate the successful resettlement of refugee by integrating cash assistance with resettlement 
services and ongoing case management. Through these public/private RCA programs, States 
are permitted to include employment incentives that support the refugee program’s goal of 
family self-sufficiency and social adjustment in the shortest possible time after arrival. 
Quarantine Station (Q-Station) - the station at a major port of entry charged with preventing 
the importation and spread of communicable disease into the U.S.; quarantine officers inspect 
arriving aliens and review medical documents, copies of which are forwarded to appropriate 
health authorities in the resettlement location. 
Website:  http://www.cdc.gov/ncidod/dq/quarantine_stations.htm
Reception and Placement (R&P) - the initial resettlement services provided by voluntary 
agencies (VOLAGs) and their affiliates through cooperative agreements with the Department of 
State, to refugees upon their arrival in the U.S. These initial services cover basic food, clothing, 
shelter, orientation, referral, and other services for the first 90 days after the refugee’s arrival in 
the U.S. 
Refugee - any person who is outside any country of such person's nationality or, in the case of 
a person having no nationality, is outside any country in which such person last habitually 
resided, and who is unable or unwilling to return to, and is unable or unwilling to avail himself or 
herself of the protection of that country because of persecution or a well-founded fear of 
persecution on account of race, religion, nationality, membership in a particular social group, or 
political opinion. The term “refugee” is distinguished from “asylee” in that “refugee” refers to 
individuals admitted into the U.S. under Section 207 of the INA and determined to be refugees 
before arriving in the U.S., while asylees are aliens in the U.S. who are determined to meet the 
legal definition of “refugee” in Section 101 (a) 42 of the Immigration and Nationality Act and are 
granted asylum in the U.S. 
Note:  For the purposes of the Refugee Health Program, the term “refugee” is generally 
inclusive of all persons eligible for ORR-funded refugee benefits and assistance, including 
asylees, victims of trafficking, and Cuban/Haitian entrants. 
Refugee Act of 1980 - Public Law 96-212, enacted in 1980; established a comprehensive 
refugee resettlement and assistance policy.  It provides mechanisms for setting annual level of 
admissions to the United States, authorizing refugee admissions in emergency situations, and 
authorized, for the first time, federal assistance to resettle refugees in the United States on a 
uniform basis, regardless of their country of origin. 
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Refugee Cash Assistance (RCA) - temporary cash assistance provided by ORR to needy 
refugees who arrive in the U.S. with no financial resources and are not eligible for other 
assistance programs such as Temporary Assistance to Needy Families (TANF), Supplemental 
Security Income (SSI); this cash assistance is paid entirely from federal funds and is available 
only for eight months following arrival in the U.S. 
Website:  www.acf.hhs.gov/programs/orr/benefits/cma.htm
Refugee Corps - corps in USCIS of officers dedicated to the adjudication of refugee 
applications at overseas locations; Refugee Corps officers are based in Washington, DC, but 
travel overseas for 50% of the year. 
Refugee Council USA (RCUSA) - coalition of U.S. non-governmental organizations focused on 
refugee protection. 
Website:  www.rcusa.org
Refugee Health Assessment Program (RHAP) – the Massachusetts preferred provider 
system through which comprehensive assessments of newly arrived refugees are delivered; 
organized and overseen by the Massachusetts Department of Public Health, through an 
Interdepartmental Service Agreement with the Massachusetts Office for Refugees and 
Immigrants. 
Refugee Health Coordinator (RHC) – state or local person responsible for administration of 
refugee health programs and services within their jurisdiction. 
Refugee Medical Assistance (RMA) – funding for temporary medical assistance provided by 
ORR to needy refugees who arrive in the U.S. with no financial resources and are not eligible 
for other assistance programs such as Temporary Assistance to Needy Families (TANF), 
Supplemental Security Income (SSI), or Medicaid;  this medical assistance is paid for entirely 
from federal funds and is available only for eight months following arrival in the U.S. 
Refugee Processing Center (RPC) – center operated by the U.S Department of State Bureau 
of Population, Refugees, and Migration. The RPC mission is to provide the necessary technical, 
data and refugee processing support to assist DOS/PRM in achieving its annual U.S. Refugee 
Admissions Program objectives. At the RPC and at Overseas Processing Entities (OPEs), an 
interactive computer system called the Worldwide Refugee Admissions Processing System 
(WRAPS) is used to process and track the movement of refugees from various countries around 
the world to the U.S. for resettlement under the U.S. Refugee Admissions Program. 
Website:  www.wrapsnet.org/  
Refugee Resettlement Program - federally-funded program for the resettlement in the U.S. of 
refugees, asylees, Cuban/Haitian Entrants, Amerasians, and Victims of Trafficking, LPRs who 
have held one of these statuses, and Unaccompanied Alien Children, administered by the 
Office of Refugee Resettlement. 
Website:  http://www.acf.hhs.gov/programs/orr/about/divisions.htm
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Refugee Social Services (RSS) – intensive social services provided to help refugees obtain 
employment, achieve economic self-sufficiency, and realize social adjustment.  Programs that 
administer RSS services are funded through ORR, which provides both state grants and direct-
service grants. The programs provide employability and other services which may include 
employment assistance, job training, English language training, and social adjustment.  
Refugees and other ORR eligible populations are only eligible for this program for the first 60 
months from their date of entry. 
Request for Evidence (RFE) – upon application by alien to DHS/USCIS for an immigration 
benefit, request by USCIS for additional or missing evidence such as medical information. 
Resettlement Agency (VOLAG) – see Voluntary Resettlement Agency. 
Returnees - refugees or internally displaced persons who have returned to their place of origin. 
Secondary Migrant - refugee who initially resettles elsewhere in the United States and 
subsequently moves to Massachusetts. 
Special Immigrant (Iraqi and Afghani)  - refers to Iraqi and Afghan aliens granted special 
immigrant status under section 101(a)(27) of the Immigration and Nationality Act (INA) who are 
eligible for resettlement assistance, entitlement programs, and other benefits available to 
refugees admitted under section 207 of such Act for a limited period. 
Sponsor – the person or organization that assists an applicant in their admission to the U.S. 
The term "sponsor" in the immigration sense often means to bring to the U.S. or "petition for". In 
the U.S. Refugee Admissions Program the voluntary agencies that have cooperative 
agreements with the Department of State are the sponsors of the refugees they resettle. 
State Coordinators of Refugee Resettlement (SCORR) – national membership organization 
for State Refugee Coordinators. 
State Letter – a letter to provide policy guidance to the field on a specific subject; issued by the 
director of the Office of Refugee Resettlement; most recent state letters may be found on the 
ORR website. 
Website:  www.acf.hhs.gov/programs/orr/policy/orr_policy.htm
State Refugee Coordinator (SRC) – person designated as responsible for administration of 
ORR programs within a state 
Substance Abuse and Mental Health Services Administration (SAMHSA) – the federal 
agency, which is comprised of three centers, that carry out the agency’s mission of providing 
substance abuse and mental health services; the Refugee Mental Health Program (RMHP) is 
within the Center for Mental Health Services. 
Website:   http://mentalhealth.samhsa.gov/cmhs/SpecialPopulations/refugmhnew.asp
Supplemental Security Income (SSI) - federally-administered program that provides 
assistance for individuals who are aged, blind, or disabled and have limited income and 
resources as established under title XVI of the Social Security Act. 
Website:   http://www.ssa.gov/ssi/
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Temporary Assistance for Needy Families (TANF) - state-administered program, jointly 
funded by the states and federal government, that provides cash assistance and work 
opportunities to needy families with dependent children. States are granted wide flexibility to 
develop and implement their own welfare programs. 
Website:   http://www.acf.hhs.gov/programs/ofa/
Trafficking Victim (Victim of a Severe Form of Trafficking in persons) - individual who is 
subjected to (1) Sex Trafficking, which is the recruitment, harboring, transportation, provision, or 
obtaining of a person for the purpose of a commercial sex act [any sex act, on account of which 
anything of value is given to or received by any person], in which a commercial sex act is 
induced by force, fraud, or coercion, or in which the person forced to perform such an act is 
under the age of 18 years; or (2) Labor Trafficking, which is the recruitment, harboring, 
transportation, provision, or obtaining of a person for labor or services, through the use of force, 
fraud or coercion for the purpose of subjection to involuntary servitude, peonage, debt bondage 
or slavery. Victims of trafficking are eligible for ORR benefits and services and other federal 
benefits provided they have been certified as a victim of trafficking by ORR. 
Website:   http://www.acf.hhs.gov/programs/orr/programs/anti_trafficking.htm#_ftn1
Unaccompanied Alien Children (UAC) – refers to unaccompanied minors placed into ORR 
custody until his/her reunification with family members or sponsors in the U.S. or until he/she is 
removed to his/her home country by DHS immigration officials. 
Website:   http://www.acf.hhs.gov/programs/orr/programs/unaccompanied_alien_children.htm
Unaccompanied Refugee Minors Program (URMP) - assists unaccompanied minor refugees 
and entrants in developing appropriate skills to enter adulthood and to achieve economic and 
social self-sufficiency; administered by the Office of Refugee Resettlement. 
Website:   http://www.acf.hhs.gov/programs/orr/programs/unaccompanied_refugee_minors.htm
Undocumented Immigrant (or Undocumented Alien) - a person who is not a U.S. citizen or 
national, who has entered the U.S. (or has remained in the U.S.) and is not in a legal 
immigration status under the INA and lacks proper immigration documentation. 
United Nations High Commission for Refugees (UNHCR) – international organization, 
headquartered in Geneva that, with host country authorization, provides services (directly or 
indirectly) in refugee camps including protection, assistance, medical services, registration of 
camp population, and referral for possible resettlement in the U.S. or other refugee-receiving 
country. 
Website:  www.unhcr.org
United States Conference of Catholic Bishops (USCCB) – a national voluntary agency. 
Website:  http://www.usccb.org/mrs/refugeeprograms.shtml
U.S. Citizenship and Immigration Services (USCIS, formerly INS) - agency within the 
Department of Homeland Security that  adjudicates applications for immigration benefits under 
the INA including employment authorization, refugee travel document and advance parole, 
adjustment of status, and naturalization.  
Website:  www.uscis.gov
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U.S. Committee for Refugees and Immigrants (USCRI) – a national voluntary agency. 
Website:  www.refugees.org    
Unlawfully Present Alien – includes undocumented aliens, aliens who violate the terms of their 
visas, and visa overstays. 
Victim of a Severe Form of Trafficking – see Trafficking Victim.  
Visa Medical Examination – also called overseas medical examination; the physical and 
mental examination the immigrants and refugees coming to the U.S. complete as part of the 
visa application process to identify the presence or absence of certain disorders that could 
result in exclusion from the U.S. under provisions of the INA. 
Website:   http://www.cdc.gov/ncidod/dq/health.htm
Voluntary Resettlement Agency (VOLAG) – (aka “Resettlement Agency”) Public or private 
agencies that provide initial reception and placement services to newly-arriving refugees under 
cooperative agreements with the Department of State. Currently, the Department of State has 
such agreements with nine national agencies and one state government agency (Iowa). Local 
affiliates of these national agencies may be referred to as VOLAGs and are responsible for 
providing initial R&P services covering basic food, clothing, shelter, orientation, referral, and 
other services for the first 90 days after arrival for refugees. They often serve as providers of 
other services, including RSS, TAG or Matching Grant.  
Web resource:  http://www.acf.hhs.gov/programs/orr/partners/voluntary_agencies.htm
Wilson/Fish Alternative - an alternative to traditional publicly-administered programs or 
public/private partnerships for providing assistance to refugees; this program is delivered 
through public or private nonprofit agencies and provides integrated services and cash 
assistance such as interim financial assistance, case management, social services and may 
include medical assistance to refugees and eligible populations. The Wilson/Fish Projects 
provide such integrated services and cash assistance to refugees to increase their prospects for 
early employment and self-sufficiency, and to reduce their level of welfare dependence.  States 
that determine that a public/private RCA program or publicly-administered program modeled 
after its TANF program is not the best approach for the state, may choose instead to establish 
an alternative approach under the Wilson/Fish program. If a state withdraws from all or part of 
the refugee resettlement program, a public or private nonprofit organization may apply to 
operate refugee programs in the state under the Wilson/Fish program. 
World Health Organization (WHO) – directing and coordinating authority for health within the 
United Nations system; responsible for providing leadership on global health matters, shaping 
the health research agenda, setting norms and standards, articulating evidence-based policy 
options, providing technical support to countries and monitoring and assessing health trends. 
Website:  http://www.who.int/en/
World Relief (WR) – a national voluntary agency. 
Website:  www.wr.org
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Worldwide Refugee Admission Processing System (WRAPS) – the Department of State’s 
interactive computer system used to process and track the movement of refugees from various 
countries around the world to the U.S. for resettlement under the U.S. Refugee Admissions 
Program. 
Website:  www.wrapsnet.org/  
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APPENDIX 6.5: PROGRAM CONTACT INFORMATION 
 
 
REFUGEE AND IMMIGRANT HEALTH PROGRAM 
BUREAU OF COMMUNICABLE DISEASE CONTROL 
DEPARTMENT OF PUBLIC HEALTH 
Program Contact Information: September 2008 
 
Central Office: 
Refugee and Immigrant Health Program 
State Laboratory Institute 
305 South Street 
Jamaica Plain, MA 02130 
Tel: 617-983-6590 
Fax: 617-983-6597 
 
Greater Boston Regional Office: 
Area includes Metropolitan Boston, North Shore and South Shore 
Refugee and Immigrant Health Program 
State Laboratory Institute 
305 South Street 
Jamaica Plain, MA 02130 
Tel: 617-983-6594 or 617-983-6587 
Fax: 617-983-6597 
 
Northeast/Central Regional Office: 
Area includes Merrimack Valley and Worcester County  
Refugee and Immigrant Health Program 
DPH Regional Office 
Tewksbury Hospital 
365 East Street 
Tewksbury, MA 01876 
Tel: 978-851-7261 x4033 
Fax: 978-640-1027 
 
Western Regional Office: 
Area includes Hampden, Hampshire, Franklin and Berkshire Counties  
Refugee and Immigrant Health Program 
DPH Regional Office 
23 Service Center 
Northampton, MA 01060 
Tel: 413-586-7525 x1141 
Fax: 413-784-1037 
 
